Prospective observational study to find correlation between non-invasive ultrasound based shear wave velocity by acoustic radiation force impulse ARFI and semiquantitative

histopathological renal fibrosis scoring among patients

undergoing diagnostic renal biopsy in native kidneys. by Sudhakar, G
Prospective observational study to find correlation between non-invasive 
ultrasound based shear wave velocity by acoustic radiation force impulse 
ARFI and semi-quantitative histopathological renal fibrosis scoring among 
patients undergoing diagnostic renal biopsy in native kidneys 
 
A dissertation submitted to the Tamilnadu  
Dr. M.G.R. Medical University in partial fulfillment of 
the University regulations for the award of D . M .  
( B r a n c h  –  I I I )  ( N e p h r o l o g y ) .  
 
 
 
 
 
 
 
AUGUST 2014 
 
BONAFIDE CERTIFICATE 
 
 
 
 
This is to certify that the work presented in this dissertation titled “Prospective 
observational study to find correlation between non-invasive ultrasound 
based shear wave velocity by acoustic radiation force impulse ARFI and semi-
quantitative histopathological renal fibrosis scoring among patients 
undergoing diagnostic renal biopsy in native kidneys” done towards 
fulfillment of the requirements of the Tamilnadu Dr. M.G.R. Medical 
University, Chennai for the D.M. (Branch–III) (Nephrology) exams to be 
conducted in August 2014, is a bonafide work of the candidate Dr. Sudhakar G, 
Senior Post-graduate student in the Department of Nephrology, Christian 
Medical College, Vellore under my guidance and supervision.  This dissertation 
has not been submitted, fully or in part to any other board or University. 
 
Guide & Head of Department 
 
Dr. V Tamilarasi M.D., D.C.H, D.M.,  
Professor and Head, 
Department of Nephrology, 
Christian Medical College, 
Vellore – 632004 
Acknowledgement 
 
First and foremost I thank the Lord God Almighty for providing me the opportunity and 
grace to conduct this dissertation.  
This dissertation would not have been possible without the support, encouragement, timely 
help and advice from many people. 
I am greatly indebted to Prof. Dr. V. Tamilarasi, Professor and Head, Department of 
Nephrology, Christian Medical College, Vellore for being instrumental in initiating this 
research venture, for her valuable inputs into the study, and guidance throughout the study. 
I owe a deep sense of gratitude to Prof. Dr. C.K. Jacob for his valuable inputs and 
encouragement in fulfilling the dissertation. 
I extend my gratitude to my mentor Dr. Basu Gopal for his valuable suggestions and 
guidance throughout the study and immense help in data analysis, write-up of the dissertation 
and moral support.  
I extend my sincere thanks to Dr. Anila Korula,Dr.Kavitha,  Dr.Rayani Palak  
Department of Pathology  for their valuable inputs and guidance and help. 
I extend my sincere thanks to Dr. Anuradha, Dr.Pushpa, Dr.Praharsha Department of 
Radiology for their valuable inputs and guidance and help. 
It gives me great pleasure to place on record my obligation to Dr.Santhosh Varughese 
Dr.Anjali Mohapatra for ther interest and unstinted support.  
I extend my sincere thanks to Dr. Suceena Alexander, Dr.Shibu jacob, Dr.Anna valson for 
their guidance and help. 
My special thanks to Mrs. Grace Rebakah for her dedication work in helping in statistics to 
complete my thesis. 
I am very much grateful to all the faculties and office staff for their timely help and support. 
I am very much thankful to my wife, Dr.B.Archana, my son, Mihir Srinivas and my 
parents  for their inspiration and support towards the smooth completion of the dissertation.  
I express my sincere gratitude to all the patients who were part of the study.  
I would like to thank my colleagues for their help and support. 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONTENTS 
 
FRONT MATTER  PAGE NO 
Abbreviations    
List of Tables  
List of Figures  
PART I   
Introduction       1 
Review of Literature 2 
PART II  
Aim and Objective   36 
Materials and Methods 37 
Observation and results 45 
Discussion 68 
Conclusions 74 
ANNEXURES  
Bibliography 75 
Pro forma  
List of patient’s  
  
                                                                                  
 
 
 
 
 
 
 
 
 
ABBREVIATIONS 
CKD-chronic kidney disease 
NKF –K/DOQI- National Kidney Foundation-kidney Disease Outcome Quality Initiative  
GFR-Glomerular filtration rate 
eGFR- estimated Glomerular filtration rate 
KDIGO Kidney Diseases: Improving Global Outcomes  
CGA-cause, GFR albuminuria  
AER- Albumin excretion rate 
ARFI- Acoustic radiation force impulse 
ECM- Extra Cellular Matrix  
EMT- Epithelial mesenchymal Transition 
α-SMA- Smooth Muscle Acting 
MCP- Membrane Cofactor Protein 
RANTES- Regulated on Activation, Normal T cell Expressed and Secreted 
PDGF-Platelet Derived growth factor 
EGF-Epithelial Growth Factor 
TGF-β-Tissue Growth Factor- β 
MMP-Matrix metalloproteinase 
tPA- Tissue plasminogen activator 
AngII- Angiotensinogen II 
CNI- Calcineurin inhibitors 
TA -Tubular Atrophy 
IF- Interstitial Fibrosis 
US – Ultrasound 
B- Brightness Mode 
PRF- Pulse repetition frequency 
CT- Computer Tomography 
MRI – Magnetic Resonance Imaging 
RF-Radiofrequency 
EI-Ealastography 
SWEI-Shear Wave Elasticity Imaging 
SSI-Supersonic shear imaging 
VA-Vibro acoustography 
SDUV-Shear wave Dispersionultrasound vibrometry 
MRE-Magnetic resonance Imaging 
MI-Mechanical Imaging 
  
LIST OF TABLES 
Table No. Title Page 
No 
Table 1.  Definition of Chronic Kidney disease 2 
Table 2  Source of error in GFR estimating using creatinine 5 
Table 3 Banff Criteria for Interstitial Fibrosis 17 
Table 4 Acoustic impedance of different body tissues and organs 24 
Table 5 Comparison of different shear wave-based elasticity 
measurement and imaging methods. 
32 
Table 6  Sample size calculation for study  44 
Table 7 Baseline characteristics of study population 46 
Table 8 The baseline demographic data of the study population 
with CKD staging as defining character  
47 
Table 9 Frequency in the IF classes i1,i2 and i3 and Tubular aatrophy 
grades  
49 
Table 10  Mean eGFR and mean shear wave velocities according to 
the CKD staging 
51 
Table  11a   Univariate analysis for association of Mean SWV with 
clinical features. 
51 
Table  11b Univariate analysis for association of Mean SWV with 
clinical features 
52 
Table 12  Showing mean ARFI SWVs in the IF groups  54 
Table 13  Mean ARFI SWV values in the tubular atrophy groups 55 
Table  14 Independent t test for mean and median SWV with realigned IF 
groups 
56 
Table 15  
 
One way ANOVA for Mean and Median SWV in CKD 
staging 
58 
Table 16 
  
Independent t test with Mean SWV in Realigned CKD 
Groups 
58 
Table 17 
 
Shear wave velocity (SWV) Correlation between in same 
kidney in same patient 
59 
Similarity matrix 
Table 18 Clinical predictors of interstitial fibrosis 60 
Table  19 Correlation of Continuous variables with IF scoring 60 
Table 20 Linear regression model for interstitial fibrosis 62 
Table 21  Univariate analysis for clinical predictors of  interstitial 
fibrosis grades 
63 
Table 22 Multiple Logistic Regression Model For Clinical And 
Radiological Predictors Of Interstitial Fibrosis 
64 
 
 
  
LIST OF FIGURES 
Figure 
Number 
Title Page no 
Figure 1   Classification of CKD and the prognosis by GFR and Albuminuria 4 
Figure 2  Molecular mechanisms and key cytokines in the interstitial fibrosis 
 
9 
Figure 3 Lazzaro Spallanzani 19 
Figure 4  Attenuation of ultrasound waves and its relationship to wave frequency 22 
Figure  5  Comparative resolution and penetration of different ultrasound 
transducer frequencies 
23 
Figure 6  Schematic representation of ultrasound pulse generation 23 
Figure 7  various modalities of tissue elasticity imaging 31 
Figure 8 Study Design of present study 38 
Figure 9  Measurement of Shear wave velocity by the ultrasound probe in prone 
position 
40 
Figure 10  
 
Data of Shear wave velocity in the pro forma Liver segment 1represents 
the right kidney and the liver segment 2 represent left kidney 
40 
Figure 11  Data recording on the electronic medical records 41 
Figure 12 Picture of region of interest (ROI) in the lower pole of 1 cm x0.6 cm 41 
Figure 13 Hamotoxycillin and eosin stains showing different grades of fibrosis 
and Masson trichrome stain for assessing the renal interstitial fibrosis 
43 
Figure 14  Diagram representing the study descriptive algorithm 45 
Figure 15 age distribution in the study population 46 
Figure 16  Bar diagram representing the clinical characteristics of the study 
population 
48 
Figure 17  distribution of clinical renal syndrome in the study population 48 
Figure 18 representing distribution of final diagnosis in the study population 49 
Figure 19  Pie diagram representing the distribution of the tubular atrophy 50 
Figure 20 Histogram withnormal distribution in study distribution 50 
Figure 21  Box and whisker plot of mean SWV in CKD stages 52 
Figure 22 Correlation of eGFR(CKD EPI) with the MEAN SWV 53 
Figure 23 Correlation of eGFR (MDRD) with the MEAN SWV 53 
Figure 24 The mean SWV in the three IF groups 54 
Figure 25 Scatter plot represent the correlation between the SWV and IF 54 
Figure 26 Mean ARFI SWV values in tubular atrophy groups 55 
Figure 27 Box whisker plot of mean ARFI SWV values IF groups 57 
Figure 28 Box Plot depicting Mean SWV in realigned CKD 58 
Figure 29 Scatter plot eGFR(MDRD)Vs IF showing a negative correlation 61 
Figure 30 Scatter plot eGFR(CKDEPI) Vs IF with negative correlation 61 
Figure 31 Correlation of BMI with IF scoring 65 
Figure 32  Correlation of Haemoglobin with IF scoring 65 
Figure 33 Correlation of serum albumin with IF scoring 66 
Figure 34. Box whisker plot for the grades of the echogenicity with Mean SWV 66 
Figure 35 Correlation of systolic blood pressure with IF scoring 67 
Figure 36 Correlation of percentage glomerulosclerosis with IF scoring 67 
 
 
  
Abstract 
TITLE OF THE STUDY  :     Prospective observational study to find correlation  
   between non-invasive ultrasound based shear wave   
 velocity by acoustic radiation force impulse ARFI  
      and semi-quantitative histopathological renal          
      fibrosis scoring among patients undergoing  
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OBJECTIVE 
  To study the correlation between non-invasive ultrasound based shear wave velocity 
(SWV) by acoustic radiation force impulse ARFI and semi-quantitative histopathological renal 
interstitial fibrosis (IF) scoring among patients undergoing diagnostic renal biopsy. 
MATERIALS AND METHODS 
110 patients with renal disease advised for renal biopsy as part of the management by the treating 
nephrologist were enrolled in the study. Correlations between Shear Wave Velocity in the lower 
pole of the native kidneys measured by a pre biopsy ARFI and laboratory tests were analyzed in 
study population. Standard statistical analysis was used with SPSS 11.  
RESULTS 
 The study population (n=104) included 73.08% males  with a male to female ratio of 
2.7:1 with mean age for males and female participant being 41.41±13.8 and 32.07±13.59 
respectively.The mean height and weight of the study population was 162.14±7.94 cm and 
62.70±12.76 with a mean BMI of 23.83±4.3. The mean haemoglobin was 11.43±2.1, with a 
mean serum albumin level of 3.34±1.03. Nephritic syndrome (46.2%) was the most common 
presentation followed by nephrotic syndrome (33%) and chronic interstitial nephritis (17%). The 
most common diagnosis was the primary glomeruloneprhitis (75%) with IgA and proliferative 
GN being major contributors.The clinical and radiological characteristics were evaluated for the 
assessment of the prediction of the interstitial fibrosis. The mean e GFR (ml/min/1.73 m
2
) in the 
study population as a function of the CKD staging was 117.49±26.37 in stage 1, 75.68±8.69 in 
stage 2, 42.94±8.53 in stage 3, 23.21±4.71 in stage 4 and 6.96±2.57 in stage 5.The mean SWV 
velocity in the different CKD stages were 1.73±0.59, 1.78±0.34, 1.82±0.51, 1.94±0.86, 
1.80±0.53 in stage 1,2,3,4 and 5 respectively. There was no correlation between the Shear wave 
velocity (SWV) measured and the extent of IF and SWV was not helpful in prediction of the 
extent of fibrosis and there was good negative correlation between eGFR and the interstitial 
fibrosis. Smoking and hemoglobin were significant predictors of severe IF. The mean ARFI 
measured SWV in the realigned interstitial groups were 1.69±0.68 and 1.80±0.53 but these were 
not statistically significant between the early fibrosis and late fibrosis. 
CONCLUSION 
 There was no correlation in the non invasive ARFI measured mean as well as median 
SWV in the lower pole and the interstitial fibrosis in renal biopsy. The clinical predictors like 
eGFR, Systolic blood pressure, smoking, hemoglobin at presentation and echogenicity in kidneys 
were significant. The histological markers of tubular atrophy and the glomerulosclerosis had a 
good correlation with IF. The renal biopsy remains the gold standard for assessment of IF until 
further sensitive and valid methods are available. 
Keywords: ARFI, SWV, Interstitial fibrosis, biopsy, clinical predictors, grades of Interstitial 
fibrosis, eGFR. 
1 
 
 
Introduction 
Renal Interstitial Fibrosis, a non-specific manifestation of several renal diseases 
(especially glomerular diseases), that portends poor long term prognosis in terms of 
renal survival and reaching end stage renal disease. It forms an essential part of the 
final common pathway of progressive renal damage. In various diseases the degree of 
interstitial fibrosis has been correlated with poor long term outcomes of kidney 
disease. Currently assessment of renal interstitial fibrosis could be done reliably only 
by histological scoring in the renal biopsy. Ultrasound based ARFI shear wave 
velocity assessment has been shown to be of use in assessment of hepatic fibrosis. 
The current study is undertaken to evaluate if the ARFI assessment correlates well 
with renal interstitial fibrosis as assessed by histological scoring, thereby to ascertain 
its utility as a non-invasive surrogate of renal interstitial fibrosis.  
 
At Department of Nephrology, CMC Vellore, approximately 15-25 patients undergo 
diagnostic renal biopsy every week, for various clinical indications.  The purpose of 
this study is to evaluate correlation of Acoustic Radiation Force Impulse (ARFI) shear 
wave velocity with fibrosis measured in patients undergoing diagnostic renal biopsy 
and hence to look for the utility of this method of imaging for screening in patients 
with advance CKD and preclude a renal biopsy which is an invasive procedure 
associated with complications like bleeding and other associated complications. 
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Review of Literature 
Chronic Kidney Disease (CKD) as per the Kidney Diseases: Improving Global Outcomes 
(KDIGO) 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic 
Kidney Disease (KDIGO) guidelines 2012 is defined as ―abnormalities of kidney structure or 
function, present for more than 3 months, with implications for health and CKD is classified 
based on cause, Glomerular Filtration Rate (GFR) category, and albuminuria category (cause, 
GFR albuminuria CGA)‖ [1]. 
A lot of published data indicated the adverse consequences and outcomes in individuals with 
an albumin excretion rate (AER) >30 mg/24 hours and/or glomerular filtration rate (GFR) < 
60 ml/min/1.73 m
2
 (GFR categories G3a-G5), inconsequential of either aetiology or duration 
of reduced kidney function. This of the correlation between GFR, rate of albumin excretion 
and prognosis has appreciably enhanced the understanding of CKD in different populations. 
[2,3,4,5]
 
Table 1.Definition of Chronic Kidney disease 
 
Criteria for chronic kidney Disease (Either of the following present for >3 months)
[1]
 
 
Markers of kidney damage (One or More) Albuminuria(AER≥ 30mg/24 hr;ACR≥30 
mg/g (≥3 gm/mmol) 
 Urine sediment abnormalities 
Electrolyte and other abnormalities due to 
tubular disorders 
Abnormalities detected by histology 
Structure abnormalities detected by imaging 
History of Kidney transplantation 
Decrease GFR GFR< 60 ml/min/1.73 m
2
(GFR categories 
G3a-G5 
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Epidemiology of chronic kidney disease 
Ranked as 18th with an annual death rate 16·3 per 100,000 by Global Burden of Disease 
study 2010,  chronic kidney disease was only second to that for HIV and AIDS in terms of 
the rate of increase in deaths over the past two decades. In the order of leading causes for 
overall increase in years of life lost due to premature mortality chronic kidney disease was 
only behind HIV and AIDS (396%) and diabetes mellitus (93%) with 82 % premature 
mortality. 
[6]
 
 With respect to the developing world, the south Asia and Latin America in the globalisation 
has led to an emerging spectra of continued high prevalence of infectious diseases with rising 
prevalence and severity of lifestyle related disorders, such as diabetes and hypertension 
which has lead to an increase in the incidence and prevalence of the chronic kidney disease 
[7,8,9]
 
Although the need for treatment of chronic kidney failure with dialysis and/or kidney 
transplantation arises in only1% of people with CKD, it remains the most expensive of 
chronic diseases and reduces lifespan significantly. The costs of dialysis and transplantation 
consume disproportionate amounts within the health-care budgets in all jurisdictions (5% of 
annual budgets consumed by less than 1% of the population). Consequently, CKD has 
become an important public health problem in the global scenario, imposing an enormous 
socioeconomic burden on the affected communities at an individual level and on the society 
as well. As number of patients with diabetes mellitus and obesity continues to increase 
proportionally, the trend of increasing prevalence of CKD will not halt in the upcoming 
decades. 
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Figure 1.  Classification of CKD and the prognosis by GFR and Albuminuria
[1] 
Identification of people at earlier time points in the progression of CKD and with appropriate 
early management and referral of those who would benefit from nephrology services, should 
lead to more apt utilization of the limited medical and speciality services in the developing 
countries like India. 
The major limitation in the early identification and treatment of the chronic kidney disease 
irrespective of the aetiology is the inability of the current methods of diagnosis in accurately 
staging the extent of the chronic kidney disease in view of the inherent source of error in 
estimating the glomerular filtration rate which have been elucidated in the table 2.This 
emphasises that we understand the basic mechanism of progression of chronic kidney disease 
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and find out ways to estimated this rate of progression and time points where it may be 
fruitful to intervene to arrest this down slide of renal function. 
 
Table 2 Source of error in GFR estimating using creatinine
[1] 
Source of error Example  
Non-steady state Acute Kidney Injury (AKI) 
 
Non- GFR determinants of Scr that differ 
from study populations in which equations 
were developed 
Factors affecting creatinine generation 
 
 Race /ethnicity other than US and 
European black and white  
 Extremes of muscle mass 
 Extremes of body size 
 Diet and nutritional status 
o High protein diet 
o Creatine supplementation 
 Muscle wasting disease 
 Ingestion of cooked meat 
 Decrease by drug induced inhibition  
o Trimethoprim 
o Cimitidine 
o Fenofibrate 
 Dialysis 
 Decrease by inhibition of gut 
creatinase by antibiotics 
 Increased by large volume losses 
extracellular fluid 
 
Higher GFR Higher biological variability in non-GFR 
determinants relative to GFR 
 Higher measurement error in Scr and 
GFR 
Interference with creatinine assay  Spectral interferences (e.g., bilirubin, 
some drugs) 
 Chemical interferences (e.g., glucose,  
ketones, bilirubin, some drugs) 
Abbreviations AKI, Acute kidney injury, GFR, glomerular filtration rate Scr serum creatinine 
 
MECHANISM OF PROGRESSION OF CHRONIC KIDNEY DISESAE 
A varied spectra of insults which can be immunological, mechanical, metabolic and toxic 
insults can result in kidney disease. These predominantly affect the three disitictive and 
functional compartments of the kidney; the glomerulus ,vasculature, and tubulointerstitium. 
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Irrespective of cause,there  will be a  decline in renal function with time in all patients with 
chronic kidney disease
[10]
. This irrevocable progression  leading to stage 5 CKD, a condition 
that is unless supported by one of the modality of currently available renal replacement 
therapies i.e hemodialysis, periotneal dialysis or renal transplantation will invaraiablly 
progress to increased morbidity and inevitable mortality. Histologically endstage kidney 
disease manifests itself as fibrotic lesions affecting each compartment; glomerulosclerosis, 
vascularsclerosis and tubulointerstitial fibrosis. 
Of the three compartments the best correlate of the inexorable progreesion with declining 
renal function is with the tubulointerstitial fibrosis.This has been fluently shown more than 
half a centuary ago by Risdon 
[11]
 in patients with persistent glomerulonephritis and  
subsequently by several studies in chronic kidney disease with varied etiologies
[12,13,14]. 
In 
diabetes, there is a direct and inverse correlation betwen increase in interstitial fibrosis with 
the decrease in creatinine clearance 
[15]
. On the contrary, the extent of glomerular 
inflammation or sclerosis does not show a relationship with outcomes of kidney diseases
[11-
15]
. The explaination for this could be  that periglomerular fibrosis results in peritubular 
scarring with impairment  of flow into the proximal segment of the nephron.In this scenario 
the glomerulus may appear structurally normal but,functionally, is ―atubular.‖ It was well 
demonstration that the number of atubular glomeruli out number glomeruli with global 
sclerosis in the renal ablation model
[16]
. The above evidence provides a description for the 
credibility of utilising the tubulointerstitial scores over glomerular scores for predicting renal 
outcomes. Tubulointerstitial damage and reduction in glomerular filtration rate (GFR) are 
closely interlinked as the tubuloglomerular feedback would reduce GFR, if increased distal 
sodium delivery resulting from the defective proximal sodium reabsorption in the injured 
proximal tubule. The postglomerular ischemia which is a consequence of glomerular injury 
results in  tubulo interstitial hypoxia with reduced blood flow in the pritubular capillaries  and 
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unrestrained oxidative stress, resulting in tubular injury,concluding in loss of that 
nephron.This loss of individual nephrons would put an undue  hemodynamic stress over the  
remaining nephron units with increased nephron loss which initiates a vicious cycle of 
nephron loss and cumulative hemodynamic stress. 
Kriz et al 
[17,18]
 proposed and demonstrated other mechanisms of tubulointerstitial damage 
induced by glomerular injury. These are histologically represented by the degenerative and 
inflammatory lesions like capsular synechia, resulting in misdirection of the glomerular 
filtrate in to periglomerular region. This wrongly directed glomerular filtrate with all its 
proteins and cytokines, and the increase in tubular protein content will result in various 
inflammatory pathways in the tubules and interstitium, resulting interstitial inflammation and 
infiltration with infringement of the tubular architecture, resulting in the functional nephron 
loss secondary to the glomerular dysfunction and scarring. 
TUBULOINTERSTITIAL INJURY AND ITS PROGRESSION 
A number of factors play a major role in the progression of renal injury. Proteinuria may be a 
both a risk factor and a pointer of disease severity, but is a helpful therapeutic predictor in the 
enduring management of chronic kidney disease 
[19]
. An out of place activation of the 
alternative pathway of complement on the surface of  tubular cells may also play a role, 
through the terminal C5b-9 membrane attack complex 
[20,21]
. This activation of complement 
might be secondary to the cytokine stimulation as a result of the Proteinuria and the ammonia 
as result of its excessive production as a compensatory mechanism for the metabolic acidosis 
in the more advance stages of the chronic kidney disease .The inappropriate complement 
stimulation will result in oxidative stress which is both a cause and consequence of interstitial 
inflammation precipitating a vicious cycle. The structural changes will lead to tissue hypoxia 
at the microcirculation resulting from structural disruption of peritubular capillaries and or 
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angiotensin-induced vasoconstriction is a final common pathway in the development of 
tubulointerstitial fibrosis. Hypoxia results in activation of the fibroblasts, 
[22]
 stimulate the 
epithelial mesenchymal trans-differentiation (EMT) 
[23]
 and activate apoptotic pathways in 
tubular cell 
[24].
 
The cellular basis of fibrosis in all three anatomical compartments is associated with the 
mesenchyme derived cellular activity. The activated interstitial fibroblast and glomerular 
mesangial cell fibroblast cell on activation with by the inflammatory cytokines will acquire 
phenotypic features of smooth muscle 
[25,26,27]
. In addition to being the principal cell in each 
compartment producing extracellular matrix, the resident mesenchymal cell is the force for 
contraction and reorganisation of extracellular matrix, thus aggravating the density of the scar 
tissue 
[25]
. The renal interstitial fibroblast is typical of all three scenarios of tubulointerstitial 
fibrosis, glomerulosclerosis and vascular nephrosclerosis and has been the focus of our 
research in progressive tubulointerstitial fibrosis. De novo synthesis of a smooth muscle actin 
(α SMA), is a signature of the activated fibroblasts, so called myofibroblasts,  which 
accumulate and are characteristic feature of all forms  chronic and progressive renal disease 
[25,27]
. These signature cells probably have origin from different sources, including resident 
fibroblasts, also pericytes, hematopoietic precursors and transition of adjacent epithelial cells 
and endothelial cells, the relative importance of each being the subject of much debate in 
view of incomplete evidence 
[28]
. 
The unique architectural and evolutionary complexity of the kidney with twenty different 
type of cells in its architecture and terminal differentiated cell lines with poor ability of 
regeneration which under stress of the uremic milieu and the cytokine barrage as a 
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Figure 2 Molecular mechanisms and key cytokines in the interstitial fibrosis 
consequence of the Proteinuria and the increased susceptibility of the tissues to hypoxia in 
view of a high oxygen demand and the increased role of the rennin angiotensin aldosterone 
system in the day to day regulation of glomerular  hemodynamics and ability to promote 
fibrosis with the up regulation of the TGF-β  and subsequent downstream pathways, makes 
for a perfect recipe for the uninhibited progression of the inflammation to the fibrosis and 
scarring manifesting as contracted kidney a hall mark of the end stage kidney disease in many 
situations 
[29]
.   
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MOLECULAR PATHWAY IN RENAL FIBROGENESIS: [Fig2] 
Although many factors have been documented to have a role in fibrogensis, including 
cytokines and hormonal, metabolic, and hemodynamic factors, the key fibrogenic factor is 
transforming growth factor-β (TGF-β) and its effectors, Smad signalling pathway play an 
essential role
[30,31]
. 
Increased expression of TGF-β is a widespread in almost every CKD, both in animal models 
and in humans. Experimental studies in animals have shown that, TGF- β as a sole factor can 
stimulate mesenchyme derived cells and tubular epithelial cells to undergo myofibroblastic 
activation or transition.  An induced expression of TGF-β, via gene delivery in vivo or in 
transgenic mice, causes renal fibrosis. Conversely, neutralising TGF- β by multiple strategies 
will help prevent the renal fibrosis and thus progressive loss of kidney function 
[32]
.  
THE MOLECULAR MECHANISMS IN FIBROSIS  
The expression and synthesis of Extra Cellular Matrix (ECM) proteins by the interstitial 
fibroblast is regulated at the level of gene transcription secondary to various extracellular 
fibrogenic signals. The essential fibrogenic factors include Tissue growth factor(TGF-β1), 
platelet derived growth factor (PDGF), Fibroblast growth factor 2(FGF2), Connective Tissue 
Growth Factor(CTGF) and angiotensin II (AngII), whereas hepatocyte growth factor and 
bone morphogenetic protein 7 (BMP7) oppose the production of matrix components by 
opposing TGF-β1 action[33,34,35,36,37,38].Through their corresponding sensors and precise 
downstream intracellular signal cascades, the fibrogenic cytokines initiate a multitude of 
regulators that influence specific  elements in the promoter regions of the collagen and  
fibronectin genes to promote their transcription which is in turn regulated by an array  of 
microRNAs
[34-37]
. Many studies have provided significant insights into explaining regulation 
of matrix genes at the molecular level. But it still remains to be elucidated if these in vitro 
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studies reflect in vivo regulation of the fibrogenesis and how these fibroblasts in the pro 
fibrotic milieu with spectrum of cytokines which can promote and or oppose the fibrosis, 
react to these cytokines in a synchronized fashion. TGF-β induction also appears to be a point 
of convergence in the pathways that integrates either on its own or indirectly, through the 
upstream activation of TGF β inducers by factors such as angiotensin II and high glucose, or 
downstream effectors like the connective tissue growth factors. 
The TGF-β through transmembrane receptors type I and type II serine/threonine kinase 
receptor 
[33]
 activation unleashes the phosphorylation and stimulation of its downstream 
signalling messengers, Smad2 and Smad3. These downstream phosphorylated Smad2/3 bind 
to common partner Smad4, together are translocated into the nuclei, where they regulate 
TGF-β responsive gene transcription. The TGF-b/Smad signalling pathway is controlled at 
both pre receptor and post receptor level through several levels of regulation, which include 
the TGF-β gene expression, latent TGF-β activation, expression of its receptor and post 
receptor Smad signalling.  
In chronic inflamed renal tissue, there is a hyperactive TGF-β/Smad signalling with increased 
induction of TGF-expression. In addition to this there is an augmented post-translational 
activation of TGF-β protein and release from latent complexes. There is also an over 
expression of the TGF-β receptors in an inflamed kidney. The Smad signalling in kidney is 
strictly regulated by a family of repressors proteins known as Smad transcriptional co 
repressors, which include SnoN, Ski, and TGIF 
[32]
. Through multitude of mechanisms, these 
molecules antagonize the Smad-mediated gene transcription, thereby protecting the tissue 
from the uninhibited TGF-β response. These co-repressors expression is progressively 
decreased in the fibrotic kidney which results intensification of TGF-β signal [38]. 
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It is obvious that the TGF-β/Smad signalling in renal fibrosis is stimulated in such a way that 
is unrestrained, a scenario akin to tumour genesis. Remarkable efforts at inhibiting TGF-β 
action in an attempt to hinder the relentless progression of renal fibrosis have been attempted 
[32]
. Of late, many therapeutic interventions were tried, like antisense inhibition of TGF-β 
expression, antibody antagonizing of the TGF-β, soluble TGF-β receptor, or blockade of 
TGF- β activation by decorin [33,39,40] and receptor inhibitors, which resulted in a variable 
range of improvement of kidney structure and function in animal models. But these were not 
translated in to human studies as achieving a successful antisense inhibition of TGF-β 
expression in the human kidney using present techniques remains elusive. But more 
significantly, we unaware of the impact of prolonged inhibition of TGF-β as a therapeutic 
approach to renal fibrosis, particularly in relation to its established anti-inflammatory 
cytokine properties. As has been eluded earlier the inflammation presumably precedes the 
onset and progression of chronic kidney disease, we should be cautious, that prolonged 
inhibition of TGF-β in humans may enhance inflammation, implying unfavourable outcomes 
and a therapeutic dilemma. Over expression of TGF-β1 in transgenic mice is protective 
against renal fibrosis, principally through anti-inflammation activity 
[41]
 and mice with TGF-
β1 deficiency succumb to unregulated and excessive inflammation [32]. To circumvent this 
problem, several strategies at TGF-β downstream signalling pathways mediating fibro 
genesis were targeted which include the decreasing of connective tissue growth factor 
expression or activity or inhibition of Smad signalling through the delivery of inhibitory 
Smad7
[42]
 
MATRIX METALLOPROTEINASE (MMP) IN TISSUE REMODELLING IN 
RENAL FIBROSIS  
Matrix production and its degradation are a continuous process and the excessive matrix 
accumulation seen in fibrotic kidney results from both uninhibited production of matrix 
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components and ineffective destruction as a part of tissue remodelling. The plasminogen 
activator inhibitor-1 and tissue inhibitor of matrix metalloproteinase-1 are often up regulated 
in a diseased kidney. 
MMP historically are considered to reduce matrix accumulation and hence are assumed to 
reduce the renal fibrosis after injury. A contradictory picture has been proposed in recent 
literature regarding function of these proteins in relation to fibrotic lesions in vivo. Tissue 
plasminogen activator (tPA) though proteolytic can promote interstitial fibrosis through 
induction of MMP-9 gene expression, enhancing the tubular basement disruption and 
epithelial mesenchymal transition. 
ROLE OF TUBULAR ATROPHY IN INTERSTITIAL FIBROSIS 
Tubular atrophy and dilation were considered together with interstitial fibrosis en bloc as 
evidence of progression to end stage kidney disease 
[43,44]
. Nonetheless, which of these 
changes in these compartments are responsible for the progression and which specific 
changes interrelate causally is not well established. El Nahas has proposed that tubular 
atrophy is a manifestation of functional overload or a higher rate of metabolism in 
hypertrophic (dilated) tubules, thought conclusive evidence is lacking in favour of the above 
hypothesis
[44]
. 
Several previous studies have emphasised on the significance of injured tubules in initiation 
and augmentation of tubulointerstitial injury by increased expression of  various cytokines 
including growth factors
[45,46]
 and matrix proteins
[47,48]
. The trans-differentiation of tubular 
epithelial cells into phenotype myofibroblasts 
[49]
 and an increased index of proliferation 
among degenerating tubular cells have been documented in fibrotic kidneys 
[50]
. 
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The simultaneous origin of the pathological changes in tubules and interstitial fibrosis in most 
experimental models of renal disease makes it difficult to establish a causal relationship 
between these changes and to delineate the interacting mechanism.Tubular atrophy precedes 
glomerular alterations like hyalinosis and capsular synechia, which are thought to be induced 
by hyperfiltration, onset of severe proteinuria, hypertension, or hypercholesterolemia and are 
like to predate the development of the interstitial fibrosis. And the predominant insult in the 
origin of the tubular atrophy and probable subsequent interstitial fibrosis appears to be 
hypoxia 
[51]
. 
RENAL FIBROSIS: ROLE OF HYPOXIA AND MICROCIRCULATION 
Glomerular endothelial cells form the first line in the glomerular filtration barrier and any 
injury to endothelium will therefore result in the worsening of the renal function. The renal 
fibrosis which includes the interstitial fibrosis and tubular atrophy correlated more with the 
decline in the renal function than the glomerular sclerosis. The renal fibrosis has been 
postulated to have to originated out of several mechanism among which the most important 
paradigms has been the hemodynamic alterations and consequent increase of the intra-
glomerular pressure, nephrotoxic effects of the Proteinuria on the renal histological spectrum 
[52]
.The lineage tracing studies concluded pericytes as the major source of interstitial 
myofibroblasts in the renal fibrosis in a rodent model, throwing light at  refocusing research 
on renal on vascular injury as one of the primary mechanism as an initiating factor  for renal 
fibrosis
[53]
.  
The loss of renal microvasculature is a result of lack of the angiogenic responses resulting 
from either inadequate endothelial proliferation or from imbalance in the local milieu with 
respect to the angiogenesis promoting and inhibiting factors 
[54]
. Several animal studies 
showed that the decreased density of the peritubular capillaries correlates with interstitial 
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fibrosis but none of these studies demonstrated that it precedes the later. Current evidence in 
animal studies points to tubular hypoxia preceding the tubulointerstitial fibrosis 
[55,56]
. 
Steegh et al. showed that reduced peritubular capillaries (PTC) in protocol biopsies after 
kidney transplantation done at an interval of 3 months, correlated inversely with 
inflammation and predicted increased fibrosis/atrophy and decrease in e GFR at 12 month 
[57]
. 
In a similar study which looked at the angiogenesis in allograft recipient with acute rejection 
revealed an increase in the angiogenesis and increased PTC density and this angiogenic 
response correlated with more fibrosis in follow up biopsies
[58]
 which leads us to the query  as 
to which is first the fibrosis or the decrease in the PTC density. 
IMPACT OF INFLAMMATION AND FIBROSIS ON THE KIDNEY 
It is an established fact that CKD progression is proportional to increasing tubulointerstitial 
fibrosis, tubular atrophy and glomerulosclerosis with a complex interaction between several 
pathways that mediate transformation of persistent inflammation to fibrosis with increase in 
the synthesis of the collagen and decrease in its break down by the matrix metalloproteinases. 
The typical phenotype of renal fibrosis is the myofibroblast and in concurrence with other 
inflammatory cells results in the intricate network of events leading to impact on the renal 
parenchyma which are complex and specific for each stage of the CKD. 
DIAGNOSTIC AND QUANTITATIVE EVALUATION OF THE INTERSTITIAL 
FIBROSIS AND ITS CLINICAL SIGNIFICANCE: 
Evaluation of interstitial fibrosis conventionally has been done on the renal biopsy specimens 
in both the native kidneys and the allograft and it has been the gold standard for this 
evaluation. The qualitative patterns of interstitial fibrosis like the striped pattern in the 
Calcineurin (CNI) toxicity are not specific and may also been seen in the hypertensive 
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kidneys and hence are these may not have a single cause or consequence and are not very 
useful in the assessment of the fibrosis as a predictor of aetiology or prognostication of rate of 
decline of renal function. In addition these pattern are less common than the diffuse or the 
patchy interstitial fibrosis pattern as the aetiology associated with a specific patterns are 
usually present in combination with other factors which are either causal or associated with 
the renal disease. There are several studies which have demonstrated a positive correlation 
between the kidney function and the extent of the fibrosis 
[59]
. 
Tubular atrophy (TA) is described in renal tissues which show dilated tubules with thin or 
sparse lining epithelial cells with pale cytoplasm and functionally this is associated with loss 
of the tubular re-absorption and secretory function. The tubular atrophy is typically 
associated with interstitial fibrosis (IF) and are commonly described in combination as 
tubulointerstitial fibrosis or IFTA. The quantitative assessment of IF is useful in the 
prediction of the renal function both in the native kidneys as well as renal allograft 
[60,61,62,63,64]
.  
An objective and a quantitative assessment of IF measurement has application in a variety of 
areas like, research focused on therapeutic inhibition of IF, comparison of protocol biopsies 
in study of renal allografts, therapeutic 
[65,66,67,68]
 decisions regarding immunosuppression in 
primary glomeruloneprhitis and in avoiding subsequent biopsies in individuals with advance 
fibrosis in prior biopsy when they present with worsening of renal function. The last area is 
of particular interest because these are cases which have higher risk of complications 
associated with the renal biopsies. Fibrosis predisposes these kidneys for bleeds in view of 
abnormal vascular architecture and significant hypertension and a uremic environment which 
causes uremic platelet dysfunction further increasing the risk of a bleed.   The visual 
assessment of fibrosis on a Masson‘s trichrome-stained slide in renal biopsy specimen is 
often conventional practice in most institutions 
[69]
. However this practice had been shown to 
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have poor reproducibility 
 [70,71]
. According to Banff criteria
[72]
 trichrome is typically used 
since the recommendation for slide preparation is seven slides containing multiple sequential 
sections, 3 with Haematoxylin  and Eosin, 3 with Periodic Acid Schiff or silver stains, and 1 with 
a trichrome stain. Under Banff working classification of renal allograft pathology, fibrosis is 
scored as follows: 
Table 3 Banff Criteria for Interstitial Fibrosis 
 
Banff Quantitative Criteria for Interstitial Fibrosis ('ci')
[72]
 
ci0 Interstitial fibrosis in up to 5% of the cortical area 
ci1 Mild interstitial fibrosis in 6-25% of the cortical area 
ci2 Moderate interstitial fibrosis in 26-50% of the cortical area 
ci3 Severe interstitial fibrosis in > 50% of the cortical area 
 
Fibrosis can be important to assess in renal donor biopsies to predict subsequent allograft 
behaviour by the morphometric analysis 
[73]
  
 
In addition to the visual histological assessment, several morphometry techniques are being 
utilized as research tools to assess the IF. These include morphometry analysis of renal 
biopsy specimen slides stained with trichrome 
[74]
,Sirius Red, specific for collagen types I and 
III under polarized light and collagen immunohistochemistry, particularly type III 
collagen
[75]
. The Sirius Red dye molecule attaches to the tertiary groove in both types I and 
III collagen molecules and imparts a pink stain to the tissues when looked at in the white 
light. When observed under polarized light, collagen types I and III are strongly birefringent. 
Computer-assisted morphometry has shown good agreement with visual assessment methods 
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in the analysis of studies employing trichrome, Sirius Red, and collagen III 
immunohistochemistry. These studies have shown correlation of the morphometric 
assessment of interstitial fibrosis with glomerular filtration rate (GFR).  
 
The objective measurement of IF has intrinsic limitations which include the sampling error 
associated with a sample obtained from a renal biopsy and assuming that it would represent 
the functional and anatomical architecture of the entire kidney. For example, in one study in 
which an interstitial fibrosis scoring was attempted in repeated biopsies estimated that repeat 
biopsies show a decrease in scores in 12% of cases 
[76]
. The other inherent limitation of these 
methods is that they need an invasive procedure like renal biopsy to be performed to access a 
tissue for the assessment of the interstitial fibrosis 
.  
From the above we can infer that, there is no consensus regarding the best way to assess IF. 
There have been various studies attempting for a non invasive method for assessing the renal 
fibrosis. With the growing interest in the non invasive methods of assessment of the internal 
milieu of the human body there has been research in to the biomarkers in various body fluids 
for the predicting the extent and progression of the interstitial fibrosis of various organs. The 
most logical approach would be to look for the biomarkers in the urine for assessing the 
fibrosis in the kidney. Recent study to look at low molecular weight proteins as surrogate 
marker for the extent of interstitial fibrosis among which they found a significant correlation 
with urine retinol binding protein
[77]
. To bring this to practical utility will take further studies 
over a period of time for assessing its utility in routine evaluation and validation. 
Meanwhile radiological imaging has been well utilized in assessing the fibrosis in the internal 
organs and a special mention has to be made for the utilization of percutaneous elastography 
technique of Acoustic radiation force impulse imaging (ARFI) in the assessment of liver 
19 
 
fibrosis 
[78,79]
. This has been transformed in to a standard of care for the assessing the hepatic 
fibrosis and in many case acting as a screening tool before subjecting to an invasive 
procedure like liver biopsy. Before the proceeding to explore the utilization of these 
transcutaneous elastography techniques in the assessment of the interstitial fibrosis in the 
kidney we shall review the basic of ultrasound imaging and the various techniques of 
assessment of the tissue elasticity and their utility in the present era will be reviewed here. 
 
History of Ultrasound 
The earliest thought of ultrasound physics was given by Lazzaro Spallanzani from Italy
 [80]
. 
The question of how bats could navigate at night and catch insects as they flew lead him to 
experiment by blindfolding them. He noted that they could still manoeuvre very well but 
when he plugged their ears he noted that they bumped into obstacles. He inferred that their 
primary mode of navigation was through sensing the echoed ultrasound waves to determine 
distance and direction of objects. He also proposed that these waves were not audible to the 
humans. 
  
Figure 3. Lazzaro Spallanzani [picture downloaded from 
[80]
 
In 1826 Jean-Daniel Colladon introduced sonography with an underwater bell which was 
used to produce the sound waves. The subsequent development in the sonography technology 
was the introduction of Ultrasound transducers that use piezoelectric crystals which vibrate 
when stimulated with electricity 
[80]
. The piezoelectric effect was described as a vibration 
response generated from multiple piezoelectric crystals (quartz) electronically interconnected 
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in Ultrasound transducers (or probes) to an applied electric current. This phenomenon was 
originally described by the Curie brothers in 1880 when they subjected a cut piece of quartz 
to mechanical stress resulting in generation of an electric charge on the surface 
[81]
. The 
reverse piezoelectric effect is application of electricity to the quartz resulting in generation of 
the sound waves secondary to quartz vibration 
[82]
. This the principle used to generate the 
ultrasonic waves by the transducers used in the current devices. 
In the late 1930's an Austrian neurologist Dr. Karl Dussik, used the ultrasound pictures 
generated by the procedure called "hyperphonography" as a diagnostic tool to detect brain 
tumours. This was further improvised by Dr. George Luwig University of Pennsylvania in the 
late 1940's, who studied the difference in sound waves as they travelled through different 
tissues in animal studies 
[83]
.  
Scottish, Ian Donald, from University of Glasgow, invented the B-mode scanner 
[84]
. Later in 
1950‘s and 60's Douglas Howry and Joseph Holmes improved on the B-mode scanner by 
inventing a transducer that was put in direct contact with the patient.  
The sonographic imaging is free of radiation hazard, portable, without any teratogenic effects 
and relatively inexpensive when compared with other cross sectional imaging modalities, 
such as magnetic resonance and computed tomography. The images acquired in ―real time,‖ 
thus providing dynamic visual guidance for many   interventional procedures including renal 
biopsy. 
FUNDAMENTAL PRINCIPLES AND PHYSICS UNDERLYING ULTRASOUND   
TECHNOLOGY 
Medical UltraSonography (US) in principle uses a pulse-echo approach with a Brightness-
mode (B-mode) display 
[84]
. This involves transmission of small pulses of Ultrasonic waves 
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from a transducer into the body. These waves traverse body tissues of different acoustic 
impedances along the path of transmission, some are reflected back to the transducer (echo 
signals) and some continue to penetrate deeper. The echo signals  returned  from  many  
sequential  coplanar  pulses  are  processed  and  combined  to generate an image.  
The transducer functions as a source for wave generation as well as sensor for the echoed 
waves from the tissues. The direction of ultrasound propagation along the beam line is called 
the axial direction, and the direction in the image plane perpendicular to axial is called the 
lateral direction 
[84]
. These  mechanical sound waves create alternating areas of compression 
and rarefaction when propagating through body tissues. The physical attributes of the Sound 
waves are frequency, wavelength and amplitude measured as cycles per second or hertz, 
millimetre and decibel respectively. 
Ultrasound of high frequency has a short wavelength as the wavelength and frequency of US 
are inversely related. The human audible range is from 20 – 20000 Hz and the waves above 
this frequency are called as ultrasonic waves and the waves below this range are called as 
infrasonic waves.US waves have frequencies beyond  the upper limit for audible range for 
humans  i.e., greater than 20 kHz
[81]
. 
The sound waves utilized in Medical ultrasound devices are in the range of 1–20 MHz The 
transducer frequency is an important aspect for adequate image resolution in the radio -
diagnosis and for interventional guidance. High-frequency waves generate images of high 
axial resolution. The ability of the US to discriminate between two structures with good 
spatial and visual resolution will be enhanced by increasing frequency of the waves and in 
doing so increasing the number of cycles of compression and rarefaction of the waves for a 
given distance. On the other hand, the tissue attenuation of the high-frequency waves is more 
for a given distance making them appropriate for only imaging superficial structures 
[85] 
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On the contrary, lesser frequency wave put forward images of lower resolution but can go 
through to deeper structures due to less significant tissue attenuation. Thus in Nephrology 
higher frequencies are used for vascular interventions and relatively lower frequencies are 
used for abdominal cross sectional imaging. 
The transducer using the piezoelectric effects generates ultrasonic sound waves in pulses that 
commonly emanates two or three sound cycles of the same frequency (Figure 5). The 
number of pulses emitted by the transducer per unit of time is pulse repetition frequency 
(PRF).  The PRF should be such that there is enough time in between the sequential wave 
generation to allow the signal to reach the target of interest and sense the reflected echo 
before the next pulse is generated. The range of PRF for medical imaging devices is 1 to 10 
kHz.  
 
Figure 4: Attenuation of ultrasound waves and its relationship to wave frequency 
[86] 
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Figure  5: Comparative resolution and penetration of different ultrasound transducer 
frequencies 
 
 
Figure 6: Schematic representation of ultrasound pulse generation 
[86] 
 
The transmitted waves from the transducer with pass through tissues are in parts transmitted 
to deeper structures, scattered, or transformed to heat. Some of the waves are reflected back 
to the transducer as echoes, which are of interest for the imaging.  
Acoustic impedance a tissue property determines the amount of echo returned after hitting a 
tissue interface. This is an inherent property of a medium or tissue defined as‖ the density of 
the medium times the velocity of US wave propagation in the medium‖. Organs such as the 
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lung which have air filled in them have the least acoustic impedance, whereas organs such as 
bone vowing to their high density have very high-acoustic impedance.  
Table 4. Acoustic impedance of different body tissues and organs
[86]
 
Body tissue Acoustic impedance (10
6
Rayls) 
Air 0.0004 
Lung  0.18 
Fat  1.34 
Liver  1.65 
Blood  1.65 
Kidney 1.63 
Muscle 1.71 
Bone 7.8 
 
The difference in the acoustic impedance between two mediums is proportional to and will be 
reflected in terms of intensity of the image 
[87]
.
  
UTILITY OF ULTRASOUND IN NEPHROLOGY 
Ultrasound imaging has become vital to the management of renal disease. The predominant 
modality used is the brightness (B)mode .One of the basic utility is to rule out the obstructive 
causes of the renal dysfunction as the fluid is well visualised due to poor acoustic attenuation. 
The other most common use is measurement of renal size, though subjective to operator 
dependent variability still is a good and reliable guide. At the same time it gives a rough 
estimate of the evidence of renal parenchymal disease by providing the ability to demarcate 
the cortex and medulla and their relative acoustic impedance depending on the extent of the 
progression of the disease. 
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The current standard of care for performing the renal biopsy involves the use of the 
ultrasound guidance. The relative ease of use makes this as an essential part of management 
of renal diseases. On the other hand the disadvantages include the subjective nature of the 
imaging being operator dependent, acoustic interference from intervening structures between 
the tissue of interest and the probe and lack of proper  visualization for most of the ureter. 
In addition to the anatomical imaging which included the structural changes in the 
parenchyma as well as the renal collecting system including the ureter, over the last few 
decades the functional imaging with the use of the colour Doppler innovation in the 
ultrasound imaging has involved the evaluation of the renal vasculature and the implications 
of the ultra structural changes in the renal parenchymal disease on the vascular 
hemodynamics  were well studied and has been able to guide the further evaluation by the 
acting as effective screening investigation. Thus, US and Doppler techniques in addition to 
morphologic, information provide functional information on altered blood and in patients 
with renal diseases and the renal vascular anomalies. 
RECENT ADVANCES IN THE ULTRASOUND IMAGING TECHNOLOGY AND 
THEIR RELEVANCE TO THE NEPHROLOGY AND FUTURE IMPLICATIONS 
The past two decades witnessed considerable technical improvements within the equipment 
and new technologies in terms of transducer sensitivity, the beam formation, the speed of 
processing of imaging and the quality of the final image display which allowed ultrasound to 
penetrate every field of medicine. The equipment became smaller, power efficient with less 
heat generation. These advances, together with enhancements in image resolution, have 
turned it into the point-of-care investigation in most setting including emergency rooms, 
obstetric practices.  
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These advances have improved the image quality in B-mode imaging than what it was a 
decade ago. This has transformed in to Physicians visualising things that are smaller and a 
lot deeper than was earlier possible including the microvasculature of the organs of interest 
which lead to utilization of B mode imaging in interventional procedures being performed in 
real time.  
Volumetric Ultrasound  
Volumetric ultrasound has improved to the extent that multi-planar images are possible with 
current imaging with which we are able to acquire the volumes in real time. This multi-planar 
imaging also helps plan any intervention better with increased accuracy and help in reducing 
rate of complications. The volumetric assessment may also help in the monitoring the 
anatomical lesions for the rate of progression as in ADPKD 
[88]
 with cystic lesions and the 
longitudinal follow up of the complex cyst as assessed with anatomical attributes with a 
potential for transformation to malignancy.  
Newer Technology in the ultrasound imaging 
The recent innovations  that are set to change the perception of ultrasound practice include 
the sonoelastography, and contrast enhanced ultrasound  imaging .The sonoelastography has 
been in evaluation for almost two decades, utilizes the same machine that does B-mode 
ultrasound to measure tissue stiffness. The mechanical characteristics of tissues are estimated 
and are represented as an overlaid variable on the routine B-mode ultrasound image.  
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SONOELASTOGRAPHY – AN INNOVATIVE BRANCH OF NON INVASIVE 
IMAGING 
This technology is aimed at a virtual method as a substitute for the art of palpation in the 
clinical examination with the help of the ultrasound waves with increased sensitivity and 
specificity with an additional accuracy in delineation of the essential pathologies behind the 
altered tissue consistency. 
Quantitative assessment of the tissue elasticity has been practiced since ancient times with 
palpation of the tissues. Shear elasticity modulus of tissue is a physical property of a tissue 
which is very sensitive to structural changes secondary to normal physiological process such 
as aging and disease conditions. 
The earliest mention of  tissue elasticity as measure parameter was made in the In the book 
―Physical Principles of Medical Ultrasonics‖ published in 1986 [89] written by Kit Hill which 
has a  chapter titled ―Telehistology‖, where he described the ideas which are now forming the 
foundation of Elasticity Imaging.  
He defined ―telehistology‖ as ―the description of a defined region of a target tissue or organ 
in terms of ‗features‘…that can be quantified by remote means – in this case ultrasound[89].‖ 
Of many features described by Hill most relevant for the tissue elasticity was tissue motion. 
Hill accurately defined all primary techniques used in modes of elasticity imaging currently 
in practice for inducing the strain necessary for elasticity assessment. 
 He describes four types tissue movements:‖ primary (e.g. cardiac or foetal limb movement), 
secondary (e.g. movement of liver tissue in response to pulsation of a neighbouring major 
blood vessel), fluid flow (particularly blood flow), and externally induced movement.‖ 
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One of the methods for generating the stress for remote probing tissue elasticity was acoustic 
radiation force 
[90,91]. Acoustic radiation force is defined as the ―time-average force exerted on 
an object by an acoustic wave‖.  
BIOPHYSICS OF ELASTICITY IMAGING: INTERPLAY BETWEEN 
MECHANICAL CHARACTERISITICS AND CONSTITUTION OF SOFT TISSUE 
The mechanical tissue characteristics when viewed as a system consists of several parameters 
like shear and Young‘s moduli, bulk compressional modulus, Poisson‘s ratio, viscosity, 
nonlinearity poro-elastic parameters, anisotropy and heterogeneity indices, etc.  
In a gross simplification to say that among the many characteristics mentioned the one with 
most relevance for the medical use is the young modulus. It describes the tissue consistency 
with best correlation with the composition of the tissue and might be considered adequate to 
address most diagnostic tasks.  One should bear in mind that the level of appropriate 
simplification in characterizing a tissue biomechanics might be one of limitation for a total 
reliance of these imaging modalities in clinical diagnosis. 
 
The term ―elasticity‖ and ―stiffness‖ are the mechanical characters most closely correlating to 
a rigorous physical parameter – Young‘s modulus, E. Detection of heterogeneity of the organ 
consistency by manual palpation is based on sensing the distinction of the Young‘s modulus 
of tissue. 
Bulk compressibility and shear elasticity are dependent on different characteristics of tissue. 
Bulk compressibility modulus is defined mainly by tissue molecular composition and 
depends on short range molecular interactions and while shear elasticity is defined by 
structural uniqueness of tissue, its cellular and spatial design 
[92]
.  As water constitutes the 
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bulk of tissues, bulk modulus of tissues predominantly is contributed by the water content of 
the tissues, and the consequential interplay of atomic groups of organic substances with 
water. The range of diversity of structural features of tissues, such as geometrical parameters 
of the cellular architecture and anisotropy, are incomparably greater.  
Local viscoelastic properties of tissue may also be evaluated from the data on tissue motion 
induced by a radiation force impulse in the focal region of the focused ultrasound beam, 
which is the basis of Acoustic Radiation Force Impulse (ARFI) imaging. 
ELASTICITY IMAGING(EI) METHODS 
Almost all elasticity imaging methods encompass two essential components: the application 
of a stimulus and the measures to estimate a mechanical response consequent to it.The 
measure of mechanical response can be estimated  by using differing modes of imaging like, 
X-rays, Magnetic resonance imaging (MRI), ultrasound imaging.The follwing description 
deals with some of  modalities of the tissue imaging using the ultrasound imaging which has 
proven clinical use. 
ACOUSTIC RADIATION FORCE IMPULSE (ARFI) IMAGING 
The impulsive force stimulates  a focal dislocation of soft tissue.The tissue relaxes after 
cessation of the force  to its native configuration.This tissue dislacement  to the force can be 
characterised by many parameters, which include peak displacement, the time taken for peak 
displacement, and time for the recovery 
[93]
. There has been  good correlation  of peak 
displacement with the inverse of the modulus 
[94]
. These displacments are used to  construct  
images representative of tissue responses .The signals from  stimulation and detection are 
analysed  to build up images of the tissue response 
[95]
. This process can be done 
simultaneously to push and track the tissue alterations simultaneously 
[96]
.  
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TRANSIENT ELASTOGRAPHY (TE) 
In Transient Elastography (TE)  the source of stimulus is an external actuator to generate a 
single cycle of lowfrequency (50 Hz) and track the resulting motion. This type of stimulation 
leads to generation of  compressional wave and shear wave which  can be distinguished 
temporally because of relative difference in the  wave speeds as  longitudinal wave is faster 
than the shear wave 
[97]
. 
Motion estimation is performed using cross-correlation of  generated radiofrequency data 
which has been studied and optimized 
[98].
Early measurements of shear waves produced by 
mechanical actuation were reported by Dutt, et al 
[99]
. 
The other modalities of elastic imaging are Shear Wave Elasticity Imaging (SWEI)supersonic 
shear imaging (SSI),Vibro-acoustography (VA), Harmonic Motion Imaging (HMI), 
Shearwave Dispersion Ultrasound Vibrometry (SDUV), Magnetic Resonance Elastography 
(MRE), Endogenous Motion Imaging and Mechanical Imaging (MI) and these are in various 
stages of development of the clinical uitiltys. 
PROS AND CONS OF ELASTICITY BASED IMAGING METHODS 
These most  modalities of this imaging are designed to achieve the same objective of  
quantifying  the viscoelasticity of tissue ,each one of them has their individualised variations 
in techniques and as the elasticity properties of tissue are dependent on the  frequency  which 
it self  varies from nearly stastic to dynamic  with frequency  content (up100 KHz)  of the 
stimulating wave which when comparing quantitative variables generated by  various 
modalities warrants caution. 
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Figure 7. Various modalities of tissue elasticity imaging 
A comparitve of the excitation and measurement methods and some advantages of each 
elasticity imaging utilising the ultrasound method are listed in Table 4 
ARFI, SWEI, SSI, VA, HMI, and SDUV use ultrasound radiation force to  create 
displacement or shear waves. Only one ultrasound probe is necessary to create the vibration 
and assess  the resulting alteration of the viscoelastic properties  and wave propagation . 
However, because of limits on the intensity used to avoid both mechanical and thermal 
bioeffects 
[90,100], the resulting motion amplitude of the shear waves is usually below 20μm.  
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Table 5 .Comparisof of shear wave based ealsticity measurement and imaging methods 
Method Excitation 
Modality 
Routine 
Machine 
Advantage 
 Time 
Course 
Stimulus  
Elastography Quasistatic Mechanical US yes Full strain and 
modulus images 
estimates elastic 
nonlinearity 
ARFI Dynamic Radiation 
Force 
US yes Viscoelastic char 
acterisation 
HMI Dynamic Radiation 
Force 
US No Viscoelastic 
characterisation 
Endogenous 
Motion 
Imaging 
Dynamic Endogenous US No Mechanical Wave 
imaging 
TE Dynamic Radiation 
Force 
US No Simple,inexpensive 
Sono 
elastography 
Dynamic Radiation 
Force 
US yes Fulla elasticity 
images 
SWEI Dynamic Radiation 
Force 
US /MRI No Remaote palpation 
SSI Dynamic Radiation 
Force 
US No Full elasiticity 
images 
SDU Dynamic Radiation 
Force 
US No Viscoelastic 
characterisation 
 
A  major limitation  of radiation force methods is inability to produce the stimulus  to 
generate sufficient displacement beyond depth of  6 cm with current imaging systems.The 
shear wave attenuation generated by the ultrasound  imaging  is very high so the waves will 
not  transmit very far form the region of interest which is  an gain interms of speicificity as 
the shear waves generated are less susceptible to artifacts from other tissue boundaries 
[90]
 
ensuring  a  more localized elasticity measurements.  
However the  desirable  features of imaging such as  enhanced resolution, least bias and 
variance errors and realtime  image formation are always in the wishlist of the tactile imaging 
techniques which would require further reseach in to this feild of tissue dynamics. 
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CLINICAL APPLICATIONS 
From largely research tool the elastography imaging,  with a wide spread availability  in the 
new machines of ultrasound imaging has transformed in to an experimental   and in some of 
the clinical situation as an effective screening tool  as exemplified by the  use of ARFI in 
heaptic fibrosis assessment . 
The vast accessibility of Elastography has increased interest in  large numbers of researchers 
to try it on different  tissues and lesions that were not initially thought as candidates for 
elasticity imaging. A search of the current literature shows that EI is tried in most of the 
tissue which are accessible to the ultrasound imaging and some of the deeper tissues have 
also been evaluated with the help of ultrasound waves with more tissue penetration or other 
modalities of imaging like Magnetic resonance. Most of the experimental applications are 
still in the early stages of research, but a few are making  foray in to common applications in 
clinical practice. 
BREAST: 
This was the first tissue to be studied systemically with elasticity imaging . studies 
demonstrated an area under the receiver operating characteristic(ROC) curve (Az) values 
ranging from 0.89 to 0.95 for distinguishing  non malignant from malignant lesions
 [101]
.  
LIVER 
The widespread application of elasticity imaging is for the assessing the  of hepatic fibrosis as 
a mraker of the advanced chronic liver disease
[102]
. FibroScan® from Echosens is most 
commonly employed for assessing the heaptic fibrosis. With the area under the ROC  of 
0.84—0.89 for heaptic fibrosis with the good  correlation with moderate to severe 
fibrosis.This has lead its inclusion in to routine evaluation of chronic liver disease.   
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PROSTATE 
The elasitiy technique which can guide at targeting the foci for tissue sampling in prostate 
biopsy
[103]
. The second application with probable clinical use is the post ablation monitoring 
of malignant lesions 
[104]
.  
GRAFT REJECTION: 
The allograft rejection in most of the solid organ transplants involves inflammation and 
fibrotic change, which together increase tissue stiffness. Hence imaging targeted at evaluation 
of the tissue elasticity is a reasonable diagnostic modality to assess the tissue architecture of 
renal and other solid organ transplants. Liver transplant fibrosis seems to correlate with 
fibrosis scores using the FibroScan® device 
[105]
. This scan was used to evaluate kidneys in 
transplant recipients with a clinical success rate (96.5%) with a positive relation of stiffness 
with increased interstitial fibrosis. It demonstrated marked distinction in elasticity 
measurement values in patients with low estimated (GFR) in distinction to those with GFR 
values more than 50 ml/min 
[106]
. The literature generated with regard to utilization of 
elasticity imaging of kidney allograft recipients are being published more frequently. Though 
the initial results were not promising
 [107,108]
 the subsequent studies have shown positive 
results emphasising the need for larger studies. 
NATIVE KIDNEYS 
Taking a lead from the renal allograft studies 
[109,110]
, ARFI, has been performed to assess the 
tubulointerstitial fibrosis in the native kidneys. These studies have shown a significant 
correlation between the tissue shear wave velocity and the level of fibrosis in the renal 
biopsies. 
Elasticity imaging methods are promising as commercial applications, a true witness to the 
progress of the field in medical arena. The ARFI imaging has been implemented as the 
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Virtual Touch imaging and Tissue Quantification, respectively, in the Siemens S2000 (Berlin, 
Germany) ultrasound scanner.  
In summary, the viscoelastic tissue properties of can be used as signature for characterisation 
of the tissues using the elasticity imaging methods.  This would help in evaluation of various 
disease states which modify viscoelastic properties of a normal to a distinct phenotype in 
diseased states from various aetiologies. The application of this imaging modality holds a lot 
of promise as a non invasive and easily repeatable modality in identification of disease and 
their severity. 
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AIMS AND OBJECTIVES 
  
Primary objective: 
To study the correlation between non-invasive ultrasound based shear wave velocity (SWV) 
by acoustic radiation force impulse (ARFI) and semi-quantitative histopathological renal 
fibrosis scoring among patients undergoing diagnostic renal biopsy of native kidneys.  
Secondary objectives:  
 To identify clinical predictors of the degree of interstitial fibrosis in renal tissue 
 To ascertain the  correlation between the radiological  parameters of the kidney  and  
extent of interstitial fibrosis in renal tissue 
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Materials and Methods 
Type of study: Prospective observational cohort study approved by the Institutional review board 
Setting and location: Department of Nephrology, Radiology and Pathology, Christian Medical 
College, Vellore-632004. 
Participants: Consecutive consenting patient who are planned and willing to undergo a 
diagnostic renal biopsy as per treating nephrologists‘ advice in Department of Nephrology, 
Christian Medical college, hospital  during a period of august 2013 to January 2014. 
Inclusion criteria 
Consecutive consenting patients who had been advised a renal biopsy by the treating 
Nephrologists and willing to give consent for their participation in the study. 
Exclusion criteria 
Age <15 and >75 yrs 
Prior history of any urological intervention on the native kidneys  
Data Sources/measurement:  
 
History and treatment details (current and past) are noted from the chart records. 
Blood pressure, height, weight, BMI, age, gender and other demographic details are noted 
from the chart records.  
Serum creatinine, albumin, uric acid, cholesterol, LFT, Urine analysis & microscopy, 24 hour 
urine protein, USG parenchymal echogenicity and other investigations are noted from clinical 
work station.GFR is calculated with use of creatinine from lab reports, age and sex  
Shear wave velocity to be assessed by ARFI scan 
38 
 
Fibrosis scoring and histological diagnosis from the pathology biopsy reports on clinical 
work station 
Study algorithm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.  Study design 
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Prior history of any urological 
intervention on the native kidneys  
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39 
 
Methods and Definitions used in the study: 
1. Estimated glomerular filtration rate (eGFR) was calculated with abbreviated 
Modification of Diet in Renal Disease (MDRD) equation: 
eGFR (mL/min/1:73m
2
) =186xserum creatinine (mg/dL)
-1.234
 x age (years)
-0.179
X (0:79if female) 
2. Routine evaluation which included a urine analysis, renal function test and other 
relevant serum chemistry test and the immunological investigation as indicated by the 
clinical presentation. The measurement of the renal sizes in the longitudinal axis and a 
documentation of the echogenicity were done with as part of routine evaluation. 
3. Shear wave velocity measured by Radiologist using the US Acuson S2000 ultrasound 
system (Siemens Medical Solutions), ARFI technology incorporated in to it. The 
SWV are generated by with patient in prone positions and focussing the region of 
interest box over the lower pole of the kidney. Five valid measurements of the 
quantitative variable for the SWV are generated on either kidney or a mean SWV is 
calculated by the virtual touch tissue quantification by the ultrasound machine. The 
radiologist was  blinded to the initial diagnosis and the renal functions of the 
participants 
The measurements are taken with patient holding the breath at the time of acquisition 
of the shear wave velocity. The sound beam was maintained as perpendicular as 
possible. A total of five values for each kidney lower pole were obtained and the 
mean and the median ARFI values and the standard deviation were also obtained and 
recorded. The inter-quartile range was also obtained to assess the variation of the 
measurements obtained during the imaging. 
These were recorded in predetermined pro forma used for the assessment of the liver fibrosis 
with the ―Liver segment 1‖ measurements representative of the right kidney and the ―Liver 
segment 2‖ measurements representing the left kidney. The measurement were localised to 
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the lower pole as the renal biopsy is almost always done in the lower pole 
 
 
Figure 9 Measurement of Shear wave velocity by the ultrasound probe in prone position
 
Figure 10. Data of Shear wave velocity in the pro forma “Liver segment 1”represents the 
right kidney and the “Liver segment 2” represent left kidney 
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Figure 11. Data recording on the electronic medical records 
 
Figure 12. Depicting the region of interest (ROI) in the lower pole of 1 cm x0.6 CM in 
the left Kidney Labelled as “Liver segment 2” 
 
Left Kidney 
Represented as 
“Liver Segment 2” 
42 
 
RENAL BIOPSY 
Once SWV are obtained has been completed the patients were taken up for renal biopsy after 
obtaining a separate consent for the renal biopsy as part of the routine protocol of the hospital 
before any invasive procedure. The participants were thoroughly acquainted with the 
procedure, the local anaesthesia used for the procedure and the associated risk of renal biopsy 
procedure is explained. After the participant has understood the complications involved in the 
procedure they were subjected to the renal biopsy. 
 
INTERSTITIAL FIBROSIS SCORING 
Interstitial fibrosis scoring was used for assessment of the fibrosis on the renal biopsy 
specimen using trichrome staining for the collagen. The fibrosis scoring was done by the 
pathologist and it was scoring percentage of the medulla with fibrosis and participants were 
grouped in to three class based on the scores of fibrosis which were i1 (<25%), i2 25-50%and 
i3>50% .The pathologist was blinded to the clinical data of the participants. 
The samples for routine histopathological assessment were sent in a formalin bottle for 
fixation and the samples for the immunofluorescence are sent in saline as a preservative. The 
formalin fixed samples are subjected to the procedure like fixing and slicing and then are 
stained as per protocol with the haematoxylin and eosin stain for assessment of the cellular 
architecture and, PAS for the tissue architecture and the extracellular matrix. Special stains 
like the Masson‘s trichrome for the assessment of the collagen content of the specimen and 
Jones methanamine silver for assessment of the basement structures of the glomerulus and 
the tubules. 
43 
 
 
Figure 13.Hamotoxycillin and eosin stains showing different grades of fibrosis and 
Masson trichrome stain for assessing the renal interstitial fibrosis 
The renal biopsy specimen slides are assessed by the pathologist and a scoring are uploaded 
on the electronic medical records. The pathologist was kept blinded to the ARFI scores and 
the clinical data.   
Methods to minimize bias:   
 Cases were indicated with unique protocol ID and not with patient‘s name or hospital number. 
Radiologist assessing the ARFI score is blinded to the renal function and Proteinuria of the 
patients. Pathologist scoring, the renal fibrosis were blinded to the ARFI score and renal 
imaging. 
STATISTICAL ANALYSIS 
Sample size calculation was done assuming a difference of 0.5 in ARFI between the grade i1, 
i2 and i2 with 5% α-error with 90% power with sample size of 30 in each arm. 
i1 
i2 
i3 
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Table 6.  Sample size calculation for study 
  Grade 2 Vs 
3_diff=0.5 
Grade 2 Vs 
3_diff=0.3 
Standard deviation in group  I 0.53 0.53 
Standard deviation in group  II 0.66 0.66 
Mean difference 0.5 0.3 
Effect size 0.840 0.504 
Alpha error (%) 5 5 
Power (1- beta) % 90 80 
1 or 2 sided 2 2 
Required sample size per group 30 63 
 
Statistical analysis was done with the SPSS version 11.0 software .The continuous variables 
were expressed as mean±SD .The Pearson‘s correlation was used to look for relation between 
the clinical and radiological characteristics which were thought to have an influence on the 
structure and the composition of the kidneys. Correlation between SWV and variables (such 
as eGFR, creatinine) were analyzed with Pearson‘s correlation. 
One-way analysis of variance (ANOVA) test was used to look for utility of the SWV to 
differentiate between different stages of CKD in the study. An independent t-test was used to 
analyze the differences in SWV between two different groups. The P value, 0.05 was taken as 
statistically significant. For the assessing the clinical predictors of interstitial fibrosis 
independent t test and Pearson correlation were used. 
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OBSERVATIONS AND RESULTS 
Study descriptive algorithm 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Study Algorithm 
Study population: The study population (n=104) included 73.08% males  with a male to 
female ratio of 2.7:1 with mean age for males and female participant being 41.41±13.8 and 
32.07±13.59respectively. The mean height and weight of the study population was 
162.14±7.94 cm and 62.70±12.76 with a mean BMI of 23.83±4.3. The mean haemoglobin 
and 24 hr urine protein were 11.43±2.1 and 3265 mg respectively with a mean serum albumin 
level of 3.34±1.03.The mean size of the kidneys were 9.99±1.1 cm on the right side and 
10.23±1.23 cm on the left side.  
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Table 7.Baseline characteristics of study population 
Characteristics Mean Std. Deviation 
eGFR*(MDRD) 57.31 40.06 
eGFR *(CKDEPI) 57.62 39.57 
SCr (mg/dl) 2.49 2.61 
Age(yrs) 38.50 14.26 
Height(cm) 162.14 7.94 
Weight(Kg) 62.70 12.76 
BMI 23.83 4.31 
Haemoglobin(mg/dl) 11.43 2.12 
24hrUP(mg/day) 3265.12 3540.71 
Sr.albumin(gm/dl) 3.34 1.03 
US size Rt(cm) 9.99 1.10 
US size Lt(cm) 10.23 1.23 
SBP(mm of Hg) 130.40 11.86 
DBP (mm of Hg) 90.69 71.50 
%Glomerulosclerosis 26.08 29.84 
Tubular Atrophy 
scoring# 
1.23 0.91 
Interstitial fibrosis 
scoring 
45.86 22.96 
*ml/min/1.73 m
2
,#T0 25, T1<25-50%, T250-75, T3>75 
 
Figure 15. Bar chart showing age distribution in the study population 
 
Baseline characteristics according to stage of CKD: The mean e GFR (ml/min/1.73 m
2
) in 
the study population as a function of the CKD staging was 117.49±26.37 in stage 1, 
75.68±8.69 in stage 2, 42.94±8.53 in stage 3, 23.21±4.71 in stage 4 and 6.96±2.57 in stage 5 
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Table 8.Baseline characteristics according to CKD stages 
Characteristic 
Mean ±SD 
CKD 1 
N=23 
CKD 2 
N=17 
CKD 3 
N=33 
CKD 4 
N=21 
CKD 5 
N=10 
Age(yrs) 27.52±15.3 42.81±12.4 49.9±12.8 38.66±10.5 40.9±14.3 
Females (%) 43.5 17.6 21.2 23.8 30 
Height(cm) 158.96±8.2 162.19±7.2 162.00±6.7 163.67±8.3 163.90±9.4 
Weight(Kg) 54.82±13.4 63.18±10.0 62.00±10. 70.18±14. 66.52±7.0 
BMI 21.76±5.4 23.95±3.1 26.14±4.4 26.14±4.4 25.05±3.2 
MDRD eGFR*  
 
117.49±26.37 75.68±8.69 43.00±8.55 22.97±4.68 6.96±2.57 
CKDEPI eGFR*  116.23±18.75 80.61±12.7 43.30±8.3 21.75±4.3 4.31±2.34 
HTN (%) 43.5 47.1 84.8 90.5 100 
DM (%) 8.7 11.8 27.3 14.3 20 
Edema (%) 78.3 76.5 45.5 47.6 90 
Hematuria (%) 34.8 29.4 36.4 33.3 60 
Creatinine  (mg/dl) 0.79±0.16 1.08±0.17 1.81±0.3 3.25±0.69 9.27±3.36 
Urea(mg/dl) 27±30.1 23.7±6.0 40.81±15.6 70.5±23.05 150.2±51 
Haemoglobin(gm/dl) 12.8±1.9 11.3±1.8 11.75±2.1 10.7±1.4 9.0±1.03 
Serum Albumin(gm/dl) 2.36±0.98 3.00±1.02 3.80±0.84 3.78±0.69 3.57±0.53 
Right Kidney (cm) 10.5±0.8 10.4±0.6 9.54±1.2 9.73±1.1 9.58±0.5 
Left Kidney (cm) 10.86±0.88 10.49±0.9 9.86±1.2 9.8±1.3 10.03±1.2 
* In (ml/min/1.73 m2) HTN Hypertension, DM Diabetes mellitus 
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Figure 16.Bar diagram representing the clinical characteristics of the study population 
Comorbidites like Hypertension and Diabetes were present in 72.1 % and 17.3 % of the 
participants. Only 7 among the study population gave a history of smoking. 61.5% of the 
participant has renal dysfunction defined as eGFR < 60 ml/min/1.73 m
2
 was the most 
common presenting symptom followed by the oedema (62.5%) and hematuria (36.5%). There 
were 3.63% participants with prior exposure to calcineurin inhibitors. 25 % had prior 
exposure to immunosuppressive medication and predominantly received steroids.  
PREBIOPSY RENAL SYNDROMES 
 
Figure 17. Clinical renal syndrome in the study population 
Nephritic syndrome (46.2%) was the most common presentation followed by nephrotic 
syndrome (33%) and chronic interstitial nephritis (17%). Diabetic nephropathy was only 
suspected in 1 % of the population.. 
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Distribution of the final diagnoses in the study population: 
The most common diagnosis was the primary glomeruloneprhitis (75%) with IgA and 
proliferative GN being major contributors. Diabetic Nephropathy was seen in 7.7% cases.  
 
Figure 18. Final diagnosis in the study population 
 
HISTOLOGICAL CHARACTERISTICS 
The mean interstitial fibrosis scoring was 45.85±22.9 with 85% in the i2 and the i3 .The t1, t2 
and t3 groups outnumbered t0. Overall the study population had a higher proportion of the 
interstitial fibrosis and tubular atrophy. 
 
Table  9. Frequency in the IF classes i1,i2 and i3 and Tubular aatrophy grades 
Interstitial Fibrosis Scoring Tubular Atrophy scoring 
Groups Frequency percent Groups Frequency percent 
i1 ,<25% 19 18.27 T0,<25% 27 26.0 
i2, 25-5% 40 38.46 T1,25-50% 32 30.8 
i3, >50% 45 43.27 T2,50-75% 39 37.5 
   
T3, >75% 6 5.8 
CGN
2%
CIN
6%
DN
8%
FSGS
5%
HTN 
nephroscler
osis
17%
IgAN
17%
LN
10%
MN
11%
PGN
21%
Primary 
amyloidosis
1%
Vasculitis 
2%
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Figure 19. Distribution of the tubular atrophy 
Radiological characteristics in the study population 
Correlation of ARFI with interstitial fibrosis (IF) 
The mean SWV were distributed normally in the study population 
 
Figure 20.Histogram representing the normal distribution in study distribution 
 
The mean and the median Shear wave velocity (SWV) in CKD stages is represented in 
following table    
 
T0,<25%, 27
T1,25-50%, 32
T2,50-75%, 39
T3>,75%, 6
1.00 1.50 2.00 2.50 3.00
MEAN SWV
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o
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n
t
ARFI DISTRIBUTION IN THE STUDY POPULATION
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Table 10. Mean eGFR and mean shear wave velocities according to the CKD staging 
STAGE eGFR 
ml/min/1.73 m2±SD 
Mean  SWV±SD Median 
SWV±SD 
1 117.49±26.37 1.73±0.59 1.67±0.64 
2 75.68±8.69 1.78±0.34 1.73±0.39 
3 42.94±8.53 1.82±0.51 1.73±0.51 
4 23.21±4.71 1.94±0.86 1.77±0.97 
5 6.96±2.57 1.80±0.53 1.74±0.57 
 
Table  11a Univariate analysis for association of Mean SWV with clinical features. 
CHARACTERISTICS 
SWV  (Mean ±SD) 
P value 
YES NO 
Sex(F) 2.073±0.64 1.707±0.45 0.009 
Smoking 1.631±0.28 1.818±0.54 0.157 
Hypertension 1.771±0.56 1.896±0.44 0.157 
Diabetes 1.733±0.45 1.821±0.54 0.527 
Hematuria 1.896±0.57 1.754±0.50 0.192 
Edema  1.879±0.60 1.683±0.36 0.412 
CKD Stage 3,4,5 1.852±0.55 1.725±0.49 0.368 
CKD Stage,4,5 1.875±0.63 1.776±0.48 0.368 
TA (T0,T,1Vs T2,T3) 1.8063±0.53 1.8056±.52 0.995 
IF grades(i1+i2)Vs i3 1.805±0.53 1.807±0.54 0.938 
  
The female gender and right kidney size were associated with Mean SWV in the study 
population as represented in the Univariate analysis for  demographic features with ARFI 
measured Shear Wave Velocity.  
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Table 11 b. Univariate analysis of correlations with Mean SWV 
Charactersitic  
Pearson  
Correlation  
p  
Age (yrs) -0.09  0.364  
eGFR(ml/min/1.73 m
2
) -0.02  0.810  
BMI  0.15  0.133  
Haemoglobin(gm/dl) -0.06  0.529  
24 hour urine 
protein(mg/day) 
0.16  0.113  
S. Albumin(gm/dl) -0.10  0.308  
Rt Kidney Size (cm) 0.29  0.002  
Lt Kidney Size (cm) 0.18  0.064  
Echogencity  0.05  0.640  
SBP (mm of Hg) -0.08  0.396  
DBP (mm of Hg) -0.02  0.847  
% glomerulosclerosis  -0.11  0.272  
Means SWV in the chronic Kidney disease stages were overlapping in the CKD stages as 
represented below 
 
Figure 21.Box and whisker plot of mean SWV in CKD stages  
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Correlation of ARFI with the demographic data: 
There was no correlation between the mean SWV measured by the ARFI in the lower pole of 
the native kidneys with demographic data variables like age, weight, BMI as well as with 
eGFR (R
2
=0.002) 
 
Figure  22. Correlation of eGFR (CKD EPI) with the MEAN SWV 
 
Figure  23. Correlation of eGFR (MDRD) with the MEAN SWV 
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ARFI WITH INTERSTITIAL FIBROSIS 
The mean SWV values for IF were grouped in to three groups of <25%, 25-50% and >50% 
are represented in the following table 
Table 12. Showing mean ARFI SWVs in the IF groups  
Fibrosis scoring  groups with respective  mean 
SWV(m/sec) 
Groups Mean±SD N 
<25% 1.92±0.55 18 
25-50% 1.75±0.51 39 
>50% 1.80±0.54 47 
Total 1.80±0.53 104 
 
Figure 24. The mean SWV in the three IF groups 
No obvious relation was seen between Mean SWV or Median SWV and IF (R
2
=0.02).  
 
Figure 25.Scatter plot represent the correlation between the SWV and IF  
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There was a considerable overlap of SWV values and the fibrosis scores (R
2
 was 0.00).No 
pattern of relation between the Mean SWV tubular atrophy grouped in to t0<25, t1>25-50%, 
t2>50-75%, t3>75% was observed and a similar trend noticed with the median SWV. There 
was a significant overlap without any distinction between the groups 
Table 13. Mean ARFI SWV values in the tubular atrophy groups 
Group Mean±SD N 
T0 (<25%) 1.80±0.52 27 
T1, (25-50%) 1.82±0.53 32 
T2, (50-75%) 1.76±0.51 39 
T3, (>75%) 1.98±0.71 6 
Total 1.80±0.53 104 
 
The box whisker plot representing the mean ARFI SWV values are depicted in the tubular 
atrophy groups demonstrating significant overlap of the ARFI score in different tubular 
atrophy groups.  
 
Figure 26.Box whisker plot of mean ARFI SWV values the tubular atrophy groups 
1.98 
1.80 
1.76 1.82 
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In view of poor correlation with the ARFI values and the IF and tubular atrophy scores the 
groups were realigned  in to mild and moderate fibrosis grouped together against the severe 
fibrosis to look for any correlation with SWV and its predictability to distinguish the groups. 
The correlation was done with independent t test for the realigned groups‘ i1and i2 together as 
a single group and i3 in the other. 
There was no correlation and the mean ARFI measured SWV in these group were not 
significantly different. 
Table 14.Independent t test for mean and median SWV with realigned IF groups 
IF groups 
Mean 
SVW 
Mean±SD 
 
Median 
SWV 
Mean±SD 
P value 
i1+ i2 1.69±0.68 1.64±0.80 0.43 
i3 1.82±0.51 1.76±0.55 0.49 
The mean ARFI measured SWV in the realigned group were 1.69±0.68 and 1.80±0.53 but 
these were not statistically significant in differentiating the two groups from each other and 
the median SWV was also looked at for any correlation and for any significant difference 
between the two group with the paired t test. This analysis was also showed that median 
SWV value does not represent a distinguishing factor between the moderate fibrosis from 
severe fibrosis. 
The independent t test was performed to look for mean SWV as factor for differentiating the 
early fibrosis from the advance fibrosis showed a p value of 0.49 for the median SWV and a 
p value of 0.43 for the mean SWV. 
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Figure 27. Box whisker plot of Mean SWV values IF groups 
  
MEAN ARFI WITH CKD STAGING 
As there was correlation between the Mean ARFI SWV and the IF we looked at comparison 
of the mean and median SWV in participants with different CKD stages using One Way 
ANOVA which also showed that there was no significance and SWV was also was not able 
to distinguish between CKD stags. Comparison of the Mean and Median SWV between the 
realigned groups based on CKD staging with stage1 and 2 realigned as group 1 and the stage 
3, 4, and 5 as group two using independent sample t test. There was a overlap in the values of 
SWV for in these groups and the test was not able to distinguish between the early CKD and 
the late CKD 
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Table 15. One way ANOVA for Mean and Median SWV in CKD staging 
MEAN SWV in different CKD stages 
Stage Mean±SD  p value 
1 1.73±0.59  0.887 
2 1.78±0.35  
3 1.79±0.48  
4 1.82±0.51  
5 1.94±0.86  
Median SWV 
Stage Mean±SD  p value 
1 1.67±0.64  0.923 
2 1.73±0.39  
3 1.73±0.51  
4 1.83±0.53  
5 1.77±0.97  
Table16. Independent t test with Mean SWV in Realigned CKD Groups 
SWV Realigned Group Mean±SD Sig. (2-
tailed) 
Median SWV CKD stage 1+2 1.67±0.54 
0.29 
 CKD stage 3-5 1.79±0.60 
Mean SWV CKD stage 1+2 1.73±0.49 
0.28 
 CKD stage 3-5 1.84±0.55 
The distribution if the mean SWV in the two groups has been represented in the box plot as 
below.  
 
 
Figure28 .Box Plot depicting Mean SWV in realigned CKD groups. 
59 
 
 
To assess the consistency of the values of the mean SWV a correlation of for all five values 
measured in each kidney were assessed. 
Table 17.Shear wave velocity (SWV) Correlation between in same kidney in same 
patient 
Similarity matrix 
Right side Rt. SWV 
1 
Rt. 
SWV2 
Rt. SWV 
3 
Rt. SWV 
4 
Rt. SWV 
5 
Rt.SWV 1 1.000 0.529 0.421 0.554 0.464 
Rt.SWV 2 0.529 1.000 0.375 0.529 0.453 
Rt.SWV 3 0.421 0.375 1.000 0.609 0.555 
Rt.SWV 4 0.554 0.529 0.609 1.000 0.688 
Rt.SWV 5 0.464 0.453 0.555 0.688 1.000 
Left side Lt.SWV 
1 
Lt.SWV 
2 
Lt.SWV 
3 
Lt.SWV 
4 
Lt.SWV 
5 
Lt.SWV 1 1.000 0.415 0.566 0.330 0.490 
Lt.SWV 2 0.415 1.000 0.459 0.603 0.420 
Lt.SWV 3 0.566 0.459 1.000 0.446 0.385 
Lt.SWV 4 0.330 0.603 0.446 1.000 0.449 
Lt.SWV5 0.490 0.420 0.385 0.449 1.000 
 
The correlation index between the mean SWV velocity of the right and left kidney 
correlations was only 0.561 and there was a wide variability in the measurement between 
SWV in same kidney and between two kidney in the same individual.  
  
Clinical and Radiological predictors of IF: 
The clinical parameters were looked for correlation with the interstitial fibrosis scoring as a 
continuous variable. 
 
Univariate analysis has shown that hypertension at presentation and the renal dysfunction as 
defined by the CKD staging was showing a significant association with the interstitial 
fibrosis. The tubular atrophy was also significantly associated with a p value of <0.000. 
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Table 18.Clinical predictors of interstitial fibrosis 
characteristics Fibrosis % score (Mean ±SD) P value 
YES NO 
Sex(F) 43.64±26.42 46.67±21.68 0.553 
Smoking 43.57±18.41 46.02±23.32 0.787 
Hypertension 51.05±21.92 32.42±20.24 0.000 
Diabetes 48.72±23.67 45.25±22.90 0.563 
Hematuria 48.02±22.97 44.60±23.03 0.467 
Edema  44.26±24.11 48.51±20.90 0.363 
CKD Stage 3,4,5 56.50±19.82 27.36±14.90 0.000 
CKD Stage,4,5 65.32±14.94 37.58±20.70 0.000 
TA (T1,T2,T3) 51.05±21.92 32.41±20.22 0.000 
The clinical predictors which were continuous variables were looked for strength of 
correlation with Pearson‘s correlation. This showed a significant correlation of eGFR, BMI, 
Haemoglobin, albumin, echogenicity, systolic blood pressure at presentation and percentage 
of glomerulosclerosis with interstitial Fibrosis 
 
Table 19.Correlation of Continuous variables with IF scoring 
Characteristic Pearson Correlation Sig. (2-tailed) 
Age(yrs) 0.171 0.082 
eGFR(ml/min/1.73m
2
) -0.711 0.000 
BMI 0.221 0.024 
Haemoglobin( mg/dl) -0.499 0.000 
24 hour urine protein(mg/day) -.117 0.239 
Albumin(gm/dl) 0.330 0.001 
Size of Rt kidney(Cm) -0.171 0.083 
Size of Lt kidney (Cm) -0.149 0.132 
Echogenicity 0.335 0.000 
Systolic BP (mm of hg) 0.323 0.001 
Diastolic BP (mm of hg) 0.203 0.039 
% Glomerulosclerosis 0.516 0.000 
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Figure 29.Scatter plot between the eGFR (MDRD) and IF showing a negative 
correlation 
 
Figure 30.Scatter plot between the eGFR (CKDEPI) and IF showing a negative 
correlation 
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The above scatter plots represent a good negative correlation with interstitial fibrosis ad the 
R
2
=0.52 
Table20. Linear regression model for interstitial fibrosis 
Variables B Sig. 
95% Confidence Interval 
Lower bound Upper 
bound 
eGFR (ml/min/1.73 m2) -.414 0.000 -.510 -.317 
Haemoglobin(mg/dl) 1.842 0.027 -3.467 -.217 
24hr urine protein(gm/day) 0.001 0.049 .000 .000 
Age(yrs) -.188 0.98 -.412 .035 
Dependent variable Interstitial fibrosis  
 
To look for the independent predictability a linear regression analysis for interstitial fibrosis 
was done with the clinical and radiological predictors. Using this model eGFR and 
haemoglobin and 24 hr urine protein were found to be significant independent predictors. The 
cumulative predictive power of the model was 76%.The variable entered at the begin of the 
linear regression model done by the backward method were e GFR, Haemoglobin,24 hr urine 
protein, systolic blood pressure at presentation, age, BMI, albumin and echogenicity of the 
kidneys 
Clinical and Radiological predictors for grades of IF 
We analysed the clinical predictors for the interstitial fibrosis grades with Univariate analysis  
Showed that hypertension pressure at presentation, Haemoglobin was showing a significant 
association. Radiological echogenicity of the kidney on ultrasound was also associated with a 
p value of 0.005.Histological markers of tubular atrophy was showing a p value of <0.0001 
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Table 21. Univariate analysis for clinical predictors of  interstitial fibrosis 
grades 
Clinical predictors Fibrosis  
Grade (I1+I2) 
n(%) or Mean ±SD 
N=57 
Fibrosis  
Grade (I3) 
n(%) or Mean ±SD 
N=47 
P value 
Age (years) 38.1±14.9 39.0±13.5 0.758 
Sex(F) 17(29.8) 11(23.4) 0.463 
BMI 23.06±4.4 24.7±4.03 0.444 
Smoking,n(%)  6 (10.5) 1(2.1) 0.125 
Diabetes n(%) 10 (17.5) 8( 17) 1.000 
Edema n(%) 37( 64.9) 28 (59.6) 0.685 
Hematuria n(%) 18 (35.1) 20 (38.3) 0.833 
SBP(mm of Hg) 127.71±1.09 133.65±12.20 0.010 
DBP (mm of Hg) 82.89±5.47 84.61±7.14 0.167 
Haemoglobin(gm/dl) 12.04±1.95 10.7±2.1 0.001 
24 hr Ur. 
Protein(mg/day) 
3351.78±3.477.57 3160±3650.74 0.785 
Sr. Albumin(gm/dl) 3.81±1.1 3.5±0.8 0.078 
US size Rt(cm) 10.13±1.1 9.81±1.17 0.133 
US size Lt (cm) 10.35±1.10 10.07±1.36 0.250 
Echogenicity(grade) 0.96±0.86 1.44±0.85 0.005 
Tubular Atrophy 30(52.6) 25(95.7) <0.0001 
%glomerulosclerosis 14.68±22.7 40.25±3.71 0.167 
CKD Stage 3,4,5 23(40.4) 43(91.5) <0.0001 
CKD Stage 4,5 6(10.5) 25(53.2) <0.0001 
 
. 
 
 
64 
 
 
Table 22.Multiple Logistic Regression Model For Clinical And Radiological Predictors Of 
Interstitial Fibrosis 
Characteristics Sig. Exp(B) Confidence interval 
Lower bound Upper 
bound 
Smoking 0.019 0.044 .003 .593 
Systolic BP(mm of Hg) 0.243 1.028 .981 1.077 
Haemoglobin(gm/dl) 0.036 0.736 .592 .982 
urineprotin24hr(mg/day) 0.278 1.000 1.000 1.000 
Sr. Albumin (gm/dl) 0.454 1.293 .660 2.530 
Echogenicity 0.564 1.208 .635 2.301 
CKD Stage4,5 0.004 6.788 1.853 24.860 
 Enter method  Variable entered at step one Smoking Systolic Blood pressure at presentation 24 hr urine 
protein serum albumin, kidney echogenicity, CKD stage 4+5, and haemoglobin 
 
The interstitial fibrosis scoring was realigned into 2 groups with the first group representing i0 
and i1 and the second group consisting of the i3 and a binary regression model for the 
predicting the interstitial fibrosis grades was created . And using this model, different clinical 
and radiological variable was analysed and it was shown that eGFR by the CKD Stage 4and 
5, smoking, Hemoglobin were the independent predictor of grades of interstitial fibrosis and 
are helpful in distinguishing the early fibrosis from the advanced fibrosis with p value of <0.05. 
The following scatter plot represents the correlation of interstitial fibrosis scoring and other 
variable in the study population  
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Figure  31. Correlation of BMI with IF scoring 
 
Figure  32. Correlation of Haemoglobin with IF scoring 
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Figure  33. Correlation of serum albumin with IF scoring 
 
Figure  34. Box whisker plot for the grades of the echogenicity with Mean SWV  
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Figure  35. Correlation of systolic blood pressure with IF scoring  
 
Figure  36. Correlation of percentage glomerulosclerosis with IF scoring 
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Discussion 
An important step in effective management of CKD is to diagnose the chronic kidney disease 
at an early stage. The gold standard to know the extent of the fibrosis in renal tissue is biopsy 
with several validated methods for assessment. Interstitial fibrosis on the renal biopsy has 
been shown to be the best prognostic indicator for the decline in renal function in many 
numbers of studies 
Renal biopsy is invasive and associated with potentially serious and sometimes even life 
threatening adverse effects. The current focus of the health care industry towards more and 
more non invasive methods for diagnosis and therapy we looked at ways for assessing the 
renal interstitial fibrosis non-invasively. 
ARFI has been well established in the field of hepatology where it has become a routine tool 
for non invasive assessment of the fibrosis in the liver. The important attribute to the AFRI is 
that it measures the tissue elasticity quantitatively. There has been very limited literature 
about the use of this modality in assessment of interstitial fibrosis. A practical application of 
the ARFI in the assessment of renal allograft fibrosis and in native kidney   was evaluated in 
the recent studies with mixed results 
[107,108]
. 
In our study we have evaluated the utility of the ARFI generated mean SWV velocity in the 
predicting the renal interstitial fibrosis in native kidneys. The lack of abundant data regarding 
the utilisation of the ARFI in native kidneys is indicated by the absence of a population based 
mean SWV.   
Baseline Characteristics of the study population 
The demographic characteristics of the study cohort were representative of the population 
that seeks nephrology consultation. The baseline characteristics were comparable to the 
population in general with kidney disease indicating the applicability of the study results.The 
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kidney sizes were in the normal range in all five stages of CKD. This could be because these 
are patients who were advised for a renal biopsy by the treating physician and a biopsy is 
unlikely to be advised if the kidneys are of small size. 
The predominant pre-biopsy syndrome diagnosis was nephritis. The final diagnosis was 
predominantly an IgA nephropathy and other primary glomeruloneprhitis in whom the 
interstitial fibrosis is more closely associated with the worsening renal function. The mean 
interstitial fibrosis in the study population was 45.85±22.9% with 85% in the i1 and i2 groups. 
As expected, a similar distribution was seen with tubular atrophy scores. 
 
ARFI measured SWV in relation to IF and CKD Staging 
The ARFI was done prior to the biopsy and the SWV velocity has a normal distribution in the 
study population. There was a considerable variability in the values obtained both within the 
same kidney and between the two kidneys in the same individual. There was no correlation of 
ARFI measured SWV with the age, BMI or eGFR. There was no correlation with interstitial 
fibrosis scoring and even after the realignment of fibrosis scores to compare the ability to 
predict the moderate fibrosis from severe fibrosis the mean SWV failed to show any 
distinction and similar results was also seen with the Median SWV. The significant 
variability in the SWV values within the kidney and between the kidneys in the same 
individual, show that the assessment is not consistent despite standard procedure followed for 
the kidneys. The considerable overlap in the SWV in relation to both the degree of interstitial 
fibrosis and the CKD staging shows that test has a poor ability in distinguishing the renal 
fibrosis. 
The study from the Guo L-H et.al [109] has shown a good correlation with the age in 327 
healthy individuals and there was a higher SWV in the general population than the CKD 
patients. There was a significant difference in males and females in the healthy subjects as 
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well as the CKD patients. In contrast to our study it was only correlating with gender but not 
with age. The Guo L-H et.al said that in their study the Mean SWV was not correlated with 
the Wt, BMI, and size of the kidney and the depth of SWV measurement in a small subgroup 
of their study population. The mean SWV was value of the  CKD patient was 1.69±0.42 
m/sec in comparison with the normal population 2.15±0.51 m/sec and in CKD and they 
proposed a cut off value of 1.88 m/sec with 71.87% sensitivity and  69.69%, specificity for 
identifying CKD . There study also showed that there was a significant overlap in the SWV 
in the various stages of CKD and was not able to differentiate the stages of CKD and there 
was no correlation with the any laboratory parameter in the chronic kidney disease except the 
eGFR and its determinants creatinine and the urea. For the assessment of interstitial fibrosis a 
study from Guanghe Cui et al 110 showed that in 76 patient of chronic kidney disease 
showed a difference of Shear wave velocity in the mild group to the moderate group with a 
mean value of 1.67 m/sec. The significance of IF in the moderate to the late fibrosis in 
predicting the benefit of therapeutic intervention and it would be best to have a marker which 
can predict between the moderate to sever fibrosis and with that regard the SWV by the ARFI 
was not useful. 
 
We are looking for a marker for predicting early fibrosis from late fibrosis and it is futile to 
try look for differentiating CKD from the general population with a test that has a sensitivity 
of around 70% .We have more cost effective investigations for diagnosing CKD. The need of 
the hour is for a predictor which will differentiate between the fibrosis occurring in the 
different stages of CKD and help us plan therapeutic intervention accordingly. 
With reference to this aim the ARFI measured SWV in our study were not correlating with 
CKD staging. And when we looked for the predictability of this test in prediction of early Vs 
late CKD it was not able to distinguish and there was a considerable overlap. 
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 This could be because of unique architecture of kidney with predominantly fluid filled 
compartment which would negate the ability of ARFI to diagnose fibrosis. Also the amount 
of fibrosis that occurs in the kidney to cause clinical implication may be relatively less 
compared to the liver where this technique has been helpful in diagnosing fibrosis. The 
current method of ARFI is not standardised for individual organs and this might played a role 
in the negative correlation in our study. Though this test is considered to be quantitative 
assessment there are several factors which will influence SWV measurement. The important 
factors to be considered include the operator‘s choice of the area of interest, the ability to 
hold the breath by the patient and to focus the ROI box exactly over the lower pole, the depth 
of the kidney which markedly varies in individuals, and the experience of the operator in 
measurement and consideration of possible outlier measures. This proves that there is a 
significant scope for subjective errors in this methodology and effort to standardize and 
probably a more organ specific and sensitive measurement taking in to account physical 
characters of individual organs is required to improve this percutaneous technique.  
Size of the kidneys was not correlating in our study, but the echogenicity of kidney assessed 
at the time of diagnostic Ultrasound was correlating the degree of interstitial fibrosis. This 
reflected the change in the physical attributes of the kidney tissue with increased tissue 
causing acoustic impedance. As this is reported with US machine, standardized objective 
assessment of echogenicity for me further evaluated which would lead to more effective 
utilization of a conventional instrument that ARFI based SWV measurement. 
Clinical Predictors of interstitial Fibrosis 
The clinical predictors of interstitial fibrosis the eGFR had a good negative correlation with 
the interstitial fibrosis. The hypertension and more specifically the systolic blood pressure at 
the presentation of >130 mm of Hg at presentation and eGFR and stage of CKD, 
haemoglobin, interestingly the echogenicity of kidneys were associated with interstitial 
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fibrosis on univariate analysis. The other association were the tubular atrophy and the 
percentage glomerulosclerosis. On linear regression analysis with interstitial fibrosis as a 
continuous and   dependent variable has shown that eGFR, haemoglobin, 24 hr urine protein 
were independent predictors of interstitial fibrosis.  
 
When these predictors were looked at predictive ability to differentiate early fibrosis from 
late fibrosis was the systolic blood pressure of >130 mm of Hg, haemoglobin and 
echogenicity along with stage of CKD were showing a significant correlation with the 
grading of the interstitial fibrosis in to moderate and severe grades. Advanced CKD stage 
(4&5), haemoglobin at presentation and anaemia were independent predictors helpful in 
differentiating the moderate from severe fibrosis. 
It was interesting to know that the echogenicity was an independent predictor of the degree of 
fibrosis measured by the radiologist and it may due to the different physical attributes of the 
fibrotic renal tissue which are measure by the ultrasound waves. The echogenicity detects the 
ability to reflect the waves which increase as the solid component of the tissue increases , 
where as the ARFI looks for displacement of the tissue for generation of shear wave  and the 
amount of fibrosis in the kidney may not be sufficient enough to produce a shear wave 
sufficient enough to be accurately distinguish the various grades of interstitial fibrosis with 
clinical implications and also the fact that the fluid content of the kidney may be related to 
hydration the might likely interfere with the SWV measurement. These require further studies 
to establish this modality in the field of Nephrology.  
Finally the important correlation with the interstitial fibrosis clinical predictors like eGFR, 
haemoglobin, systolic blood pressure at the time of presentation, echogenicity of kidney on 
ultrasound and the histological predictors like tubular atrophy and glomerulosclerosis with 
interstitial fibrosis proves the role of control of anaemia and the blood pressure to <130 mm 
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of Hg in retarding the progression of interstitial fibrosis. The CKD staging for management 
of renal disease also reiterated the fact that the e GFR is was an independent predictor for the 
IF. The important message that the IF well correlated with by the grades of Tubular atrophy 
and the glomerulosclerosis emphasizes the fact that the renal histology is the best modality to 
assess the IF and its severity and hence remains the gold standard for assessing the IF. 
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Conclusions 
1. There was no correlation between the non-invasive Acoustic Radiation Force Impulse 
imaging (ARFI) measured mean & median Shear Wave Velocity SWV in the lower 
pole and the interstitial fibrosis in renal biopsy specimens from the lower pole biopsy. 
2. The Modified Diet Renal Disease estimated Glomerular Filtration Rate (eGFR), 
Hypertension and specifically the systolic blood pressure, and haemoglobin at 
presentation were significant clinical predictors of interstitial fibrosis(IF) 
3. Semi-quantitative assessment of renal cortical echogenicity by ultrasound 
significantly correlated with degree of renal interstitial fibrosis. This prediction was 
much superior to that by Acoustic Radiation Force Impulse imaging measured Shear 
Wave Velocity (SWV) 
4. The histological markers of tubular atrophy and the glomerulosclerosis had a good 
correlation with interstitial fibrosis(IF) 
5. Along with clinical features of estimated Glomerular Filtration Rate (eGFR), and 
hypertension, the renal biopsy with semiquantitative assessment of renal fibrosis 
remains the gold standard for assessment of interstitial fibrosis until further sensitive 
and valid methods of non-invasive assessment of interstitial fibrosis are available. 
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71.84 24.60 0.00 1.00 1.00 1.00 0.00 1.00 0.00 0.00 1.00
54.30 25.10 0.00 1.00 1.00 1.00 0.00 1.00 0.00 1.00 1.00
70.80 25.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00
60.10 20.80 1.00 0.00 0.00 1.00 0.00 1.00 0.00 1.00 0.00
44.42 16.30 0.00 0.00 0.00 1.00 0.00 0.00 0.00 1.00 0.00
44.60 18.10 0.00 0.00 0.00 1.00 0.00 0.00 0.00 1.00 1.00
66.00 25.10 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00
63.52 23.90 0.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
52.60 20.00 1.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00
48.64 20.20 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
42.64 16.70 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
66.12 22.60 0.00 1.00 1.00 1.00 0.00 1.00 1.00 1.00 1.00
39.70 18.40 0.00 0.00 1.00 1.00 0.00 1.00 0.00 1.00 1.00
59.30 21.30 1.00 0.00 1.00 1.00 0.00 1.00 0.00 1.00 1.00
63.40 24.80 0.00 0.00 0.00 1.00 0.00 1.00 0.00 0.00 0.00
66.96 24.30 0.00 0.00 0.00 1.00 0.00 1.00 1.00 1.00 1.00
63.20 21.90 1.00 0.00 1.00 1.00 0.00 0.00 0.00 1.00 1.00
57.44 23.30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00
57.42 22.40 0.00 0.00 1.00 0.00 0.00 1.00 0.00 0.00 1.00
54.40 20.20 0.00 0.00 0.00 0.00 0.00 1.00 0.00 1.00 0.00
72.48 26.30 0.00 0.00 1.00 1.00 0.00 1.00 0.00 1.00 1.00
61.96 23.30 0.00 0.00 1.00 1.00 0.00 1.00 0.00 1.00 0.00
38.36 16.60 0.00 0.00 0.00 1.00 0.00 1.00 0.00 0.00 0.00
61.90 23.60 0.00 0.00 1.00 1.00 0.00 1.00 0.00 0.00 1.00
63.40 23.60 0.00 0.00 0.00 1.00 0.00 1.00 0.00 1.00 0.00
73.08 27.80 1.00 0.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
58.24 23.60 0.00 0.00 1.00 1.00 0.00 1.00 0.00 0.00 1.00
95.72 32.70 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00
87.50 32.10 0.00 0.00 1.00 1.00 0.00 1.00 0.00 0.00 1.00
57.20 19.80 1.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00
86.24 30.60 0.00 0.00 1.00 1.00 0.00 1.00 0.00 1.00 0.00
63.50 25.80 0.00 1.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00
64.54 24.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00
62.40 21.30 0.00 0.00 1.00 1.00 0.00 1.00 0.00 1.00 1.00
60.20 22.10 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 1.00
51.60 21.80 0.00 0.00 1.00 1.00 0.00 1.00 0.00 1.00 0.00
47.90 20.70 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00
64.16 26.70 0.00 0.00 1.00 1.00 0.00 1.00 0.00 1.00 1.00
80.30 24.80 0.00 0.00 1.00 1.00 0.00 1.00 0.00 1.00 1.00
61.90 22.70 0.00 0.00 1.00 1.00 0.00 1.00 0.00 1.00 1.00
45.90 18.90 0.00 0.00 0.00 1.00 0.00 1.00 1.00 1.00 1.00
77.86 26.30 0.00 0.00 0.00 1.00 0.00 1.00 0.00 0.00 1.00
59.30 21.80 0.00 0.00 0.00 1.00 0.00 1.00 0.00 0.00 1.00
64.76 20.90 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00
70.00 31.10 0.00 1.00 1.00 1.00 0.00 1.00 0.00 1.00 1.00
64.60 23.70 0.00 0.00 1.00 1.00 0.00 1.00 0.00 1.00 1.00
55.96 19.10 0.00 0.00 1.00 1.00 0.00 1.00 0.00 1.00 1.00
70.26 22.90 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00
41.00 16.80 0.00 0.00 0.00 1.00 0.00 1.00 0.00 1.00 1.00
61.92 26.50 0.00 0.00 0.00 1.00 0.00 1.00 0.00 1.00 1.00
67.06 25.60 0.00 0.00 1.00 1.00 0.00 1.00 0.00 0.00 1.00
59.14 22.50 0.00 0.00 1.00 1.00 0.00 1.00 0.00 1.00 1.00
61.36 21.70 0.00 0.00 0.00 1.00 0.00 1.00 0.00 0.00 1.00
82.96 28.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00
60.60 21.50 0.00 0.00 1.00 1.00 0.00 1.00 1.00 1.00 1.00
54.56 21.30 0.00 0.00 1.00 1.00 0.00 1.00 0.00 0.00 1.00
61.74 29.00 0.00 1.00 1.00 1.00 0.00 1.00 1.00 1.00 1.00
72.02 27.60 0.00 0.00 1.00 1.00 0.00 1.00 0.00 1.00 1.00
53.84 24.60 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00
64.22 23.30 0.00 0.00 1.00 1.00 0.00 1.00 0.00 1.00 1.00
75.36 27.70 0.00 0.00 0.00 1.00 0.00 1.00 0.00 0.00 1.00
73.02 25.30 0.00 1.00 1.00 1.00 0.00 1.00 0.00 0.00 1.00
72.56 26.00 0.00 0.00 1.00 1.00 0.00 1.00 0.00 1.00 1.00
63.46 26.40 0.00 0.00 0.00 1.00 0.00 1.00 0.00 1.00 1.00
65.82 22.50 0.00 1.00 1.00 1.00 0.00 1.00 0.00 1.00 1.00
58.88 26.20 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00
74.92 30.80 0.00 0.00 1.00 1.00 0.00 1.00 0.00 1.00 1.00
67.06 25.20 0.00 1.00 1.00 1.00 0.00 1.00 1.00 0.00 1.00
67.84 23.80 0.00 0.00 1.00 1.00 0.00 1.00 0.00 0.00 1.00
69.70 26.20 0.00 0.00 0.00 1.00 0.00 1.00 0.00 0.00 1.00
47.28 18.50 0.00 0.00 1.00 1.00 0.00 1.00 0.00 0.00 1.00
59.38 21.00 0.00 0.00 1.00 1.00 0.00 1.00 0.00 0.00 1.00
69.18 23.40 0.00 0.00 0.00 1.00 0.00 1.00 0.00 0.00 1.00
70.60 33.60 0.00 0.00 0.00 1.00 0.00 1.00 0.00 1.00 1.00
46.76 17.70 0.00 0.00 1.00 1.00 0.00 1.00 0.00 1.00 1.00
64.39 26.50 0.00 0.00 1.00 1.00 0.00 1.00 0.00 1.00 1.00
70.64 25.90 0.00 0.00 1.00 1.00 0.00 1.00 0.00 0.00 1.00
110.26 35.60 1.00 1.00 0.00 1.00 0.00 1.00 0.00 1.00 1.00
69.30 29.10 0.00 0.00 1.00 1.00 0.00 1.00 0.00 1.00 1.00
59.08 24.30 0.00 0.00 0.00 1.00 0.00 1.00 0.00 0.00 1.00
57.58 21.10 0.00 0.00 1.00 1.00 0.00 1.00 0.00 1.00 1.00
78.82 27.90 0.00 0.00 1.00 1.00 0.00 1.00 0.00 1.00 1.00
hematuria RBC comodm comoHTN ComoCAD maligancy priorkdsisease VAR00004 prebxdiag hb platelet
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 MGN 8.50 145,000.00
0.00 0.00 0.00 0.00 0.00 0.00 1.00 1.00 Mes PGN 13.20 262,000.00
1.00 2.00 0.00 0.00 0.00 0.00 0.00 0.00 MCD 11.70 242,000.00
1.00 1.00 0.00 0.00 0.00 0.00 0.00 1.00 LN 9.80 556,000.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 MGN 12.30 192,000.00
1.00 2.00 0.00 0.00 0.00 0.00 0.00 1.00 CGN 13.40 194,000.00
1.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 MGN 12.60 134,000.00
1.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 MGN 13.00 179,000.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 FSGS 14.60 287,000.00
1.00 2.00 0.00 0.00 0.00 0.00 0.00 1.00 IGA 12.70 170,000.00
0.00 0.00 1.00 1.00 1.00 0.00 0.00 1.00 IGA 16.80 198,000.00
0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 MCD 14.50 392,000.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 MCD 13.70 245,000.00
0.00 0.00 1.00 0.00 0.00 0.00 0.00 2.00 CIN 12.70 147,000.00
0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 MGN 12.00 206,000.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 LN 13.80 310,000.00
0.00 0.00 0.00 0.00 0.00 0.00 1.00 1.00 Mes PGN 13.80 245,000.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 MGN 13.80 301,000.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 MCD 14.80 339,000.00
1.00 1.00 0.00 0.00 0.00 0.00 0.00 1.00 IGA 11.30 277,000.00
1.00 1.00 1.00 1.00 0.00 0.00 0.00 4.00 HTN NS 13.30 154,000.00
0.00 0.00 0.00 1.00 0.00 0.00 0.00 2.00 CIN 12.30 186,000.00
1.00 2.00 0.00 1.00 0.00 0.00 0.00 1.00 RPGN 12.00 450,000.00
1.00 2.00 1.00 1.00 0.00 0.00 0.00 1.00 IGA 9.90 113,000.00
0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 MGN 15.30 325,000.00
0.00 0.00 1.00 1.00 0.00 0.00 0.00 0.00 DN 11.90 229,000.00
0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 MCD 14.60 281,000.00
1.00 2.00 0.00 0.00 0.00 0.00 0.00 1.00 PIGN 8.90 380,000.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 LN 11.50 269,000.00
0.00 0.00 1.00 1.00 1.00 0.00 0.00 2.00 AIN 11.00 185,000.00
0.00 0.00 1.00 0.00 1.00 0.00 0.00 1.00 NDRD 11.40 111,000.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 LN 8.30 394,000.00
1.00 2.00 0.00 0.00 0.00 0.00 0.00 1.00 LN 11.50 184,000.00
0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 DN 10.00 171,000.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 RPGN 9.80 278,000.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 IGA 10.10 122,000.00
0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 NDRD 13.70 213,000.00
0.00 0.00 1.00 1.00 0.00 0.00 0.00 2.00 CIN 12.30 187,000.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.00 CIN 8.50 171,000.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 MGN 14.80 246,000.00
0.00 0.00 0.00 1.00 0.00 0.00 0.00 2.00 CIN 9.20 227,000.00
1.00 2.00 0.00 0.00 0.00 0.00 0.00 1.00 LN 10.00 131,000.00
0.00 0.00 0.00 1.00 0.00 0.00 0.00 1.00 IGA 14.50 229,000.00
1.00 1.00 0.00 0.00 0.00 0.00 0.00 1.00 MPGN 10.60 193,000.00
0.00 0.00 0.00 0.00 0.00 0.00 1.00 1.00 LN 13.60 188,000.00
0.00 0.00 0.00 1.00 0.00 0.00 0.00 4.00 HTN NS 13.70 186,000.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 FSGS 11.90 122,000.00
1.00 2.00 0.00 1.00 1.00 0.00 0.00 1.00 CGN 10.10 116,000.00
0.00 0.00 0.00 1.00 0.00 0.00 0.00 1.00 IGA 14.70 275,000.00
1.00 1.00 0.00 0.00 0.00 0.00 0.00 1.00 PIGN 10.00 303,000.00
1.00 1.00 0.00 0.00 0.00 0.00 0.00 1.00 CGN 11.00 398,000.00
1.00 1.00 0.00 0.00 0.00 0.00 0.00 1.00 IGA 14.00 157,000.00
0.00 0.00 0.00 1.00 0.00 0.00 1.00 0.00 FSGS 13.20 110,000.00
0.00 0.00 1.00 0.00 0.00 1.00 1.00 0.00 MYELOMA 11.40 369,000.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 MGN 11.00 307,000.00
1.00 1.00 0.00 1.00 0.00 0.00 0.00 1.00 RPGN 10.40 152,000.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.00 CIN 9.60 273,000.00
1.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 MGN 12.10 359,000.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 FSGS 15.60 290,000.00
0.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 FSGS 8.70 169,000.00
1.00 1.00 0.00 0.00 0.00 0.00 0.00 1.00 CGN 8.90 188,000.00
0.00 0.00 0.00 1.00 0.00 0.00 0.00 1.00 IGA 8.30 284,000.00
0.00 0.00 0.00 1.00 0.00 0.00 1.00 1.00 PIGN 9.60 133,000.00
1.00 1.00 0.00 1.00 0.00 0.00 0.00 1.00 RPGN 14.00 495,000.00
0.00 0.00 0.00 1.00 0.00 0.00 0.00 2.00 CIN 16.10 223,000.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.00 AIN 10.00 141,000.00
0.00 0.00 1.00 1.00 0.00 0.00 1.00 0.00 DN 9.10 280,000.00
0.00 0.00 0.00 1.00 0.00 0.00 0.00 1.00 CGN 10.00 166,000.00
1.00 1.00 0.00 0.00 0.00 0.00 0.00 1.00 RPGN 8.40 120,000.00
1.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00 MGN 8.60 127,000.00
0.00 0.00 0.00 1.00 0.00 0.00 0.00 1.00 CGN 10.00 201,000.00
0.00 0.00 0.00 0.00 0.00 0.00 1.00 1.00 LN 11.50 122,000.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.00 CIN 11.80 255,000.00
0.00 0.00 1.00 1.00 0.00 0.00 1.00 0.00 DN 11.20 203,000.00
1.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 IGA 11.70 138,000.00
1.00 1.00 0.00 0.00 0.00 0.00 0.00 3.00 CIN 10.20 301,000.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 DN 8.00 172,000.00
1.00 1.00 0.00 0.00 0.00 0.00 0.00 1.00 IGA 10.70 206,000.00
1.00 2.00 1.00 1.00 0.00 0.00 0.00 0.00 DN 8.20 153,000.00
1.00 0.00 0.00 1.00 0.00 0.00 0.00 1.00 IGA 8.90 191,000.00
1.00 2.00 0.00 0.00 0.00 0.00 0.00 0.00 MCD 10.10 261,000.00
0.00 0.00 1.00 1.00 1.00 0.00 0.00 2.00 CIN 12.40 116,000.00
0.00 0.00 0.00 1.00 0.00 0.00 0.00 2.00 AIN 12.30 259,000.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.00 HTN NS 11.00 239,000.00
0.00 0.00 0.00 1.00 0.00 0.00 0.00 2.00 CIN 10.00 169,000.00
0.00 0.00 0.00 1.00 0.00 0.00 0.00 2.00 CIN 10.60 160,000.00
0.00 0.00 1.00 1.00 0.00 0.00 0.00 0.00 DN 9.20 236,000.00
1.00 1.00 0.00 0.00 0.00 0.00 0.00 2.00 CIN 8.60 214,000.00
1.00 1.00 0.00 1.00 0.00 0.00 0.00 2.00 CIN 8.20 218,000.00
0.00 0.00 0.00 1.00 0.00 0.00 0.00 1.00 RPGN 11.80 120,000.00
1.00 2.00 0.00 1.00 0.00 0.00 0.00 1.00 RPGN 9.30 272,000.00
0.00 0.00 0.00 1.00 0.00 0.00 0.00 2.00 CIN 11.00 274,000.00
0.00 1.00 0.00 0.00 0.00 0.00 0.00 1.00 IGA 9.80 181,000.00
1.00 2.00 0.00 0.00 0.00 0.00 0.00 1.00 IGA 11.90 168,000.00
1.00 1.00 0.00 1.00 0.00 0.00 1.00 1.00 IGA 15.10 240,000.00
0.00 0.00 0.00 1.00 0.00 0.00 1.00 0.00 MCD 12.60 275,000.00
0.00 0.00 1.00 1.00 0.00 0.00 0.00 1.00 NDRD 10.40 207,000.00
0.00 0.00 0.00 1.00 0.00 0.00 0.00 1.00 CGN 8.80 423,000.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 CGN 9.40 169,000.00
0.00 0.00 1.00 1.00 0.00 0.00 0.00 0.00 DN 10.00 441,000.00
1.00 2.00 0.00 0.00 0.00 0.00 0.00 0.00 MGN 15.10 162,000.00
0.00 0.00 1.00 1.00 0.00 0.00 0.00 2.00 CIN 11.10 113,000.00
1.00 2.00 0.00 1.00 0.00 0.00 0.00 1.00 IGA 9.80 170,000.00
1.00 2.00 0.00 1.00 0.00 0.00 0.00 1.00 IGA 10.10 150,000.00
ptINR Aptt HIV HBsAg HCV urineanalysis WBC CASTS CRYstals Blood protein
10.00 28.10 0.00 0.00 0.00 1.00 0.00 0.00 0.00 1.00 3.00
10.80 28.70 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 2.00
9.80 25.70 0.00 0.00 0.00 1.00 2.00 0.00 0.00 3.00 2.00
11.20 28.40 0.00 0.00 0.00 1.00 1.00 4.00 0.00 0.00 2.00
10.30 30.40 0.00 0.00 0.00 1.00 1.00 4.00 0.00 2.00 3.00
10.50 29.00 0.00 0.00 0.00 1.00 1.00 0.00 0.00 3.00 3.00
10.60 36.50 0.00 0.00 0.00 1.00 0.00 0.00 0.00 2.00 2.00
9.80 35.60 0.00 0.00 0.00 1.00 0.00 0.00 0.00 1.00 3.00
10.70 35.70 0.00 0.00 0.00 1.00 0.00 0.00 0.00 1.00 2.00
11.90 31.70 0.00 0.00 0.00 1.00 1.00 4.00 0.00 3.00 1.00
11.40 29.40 0.00 0.00 0.00 1.00 0.00 4.00 0.00 1.00 2.00
11.40 42.30 0.00 0.00 0.00 1.00 0.00 4.00 0.00 1.00 3.00
12.40 44.30 0.00 0.00 0.00 1.00 0.00 4.00 0.00 1.00 2.00
12.50 30.30 0.00 0.00 0.00 1.00 0.00 4.00 0.00 0.00 2.00
10.60 33.00 0.00 0.00 0.00 1.00 0.00 4.00 0.00 2.00 3.00
10.30 32.80 0.00 0.00 0.00 1.00 0.00 4.00 0.00 1.00 3.00
11.80 28.40 0.00 0.00 0.00 1.00 0.00 0.00 0.00 2.00 3.00
10.40 33.50 0.00 0.00 0.00 1.00 0.00 4.00 0.00 2.00 3.00
10.50 32.00 0.00 0.00 0.00 1.00 0.00 4.00 0.00 2.00 3.00
10.30 33.20 0.00 0.00 0.00 1.00 1.00 0.00 0.00 2.00 3.00
11.10 29.50 0.00 0.00 0.00 1.00 0.00 0.00 0.00 2.00 1.00
10.50 29.20 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 1.00
11.40 27.90 0.00 0.00 0.00 1.00 0.00 1.00 0.00 3.00 2.00
10.70 25.70 0.00 0.00 0.00 1.00 0.00 4.00 0.00 3.00 2.00
10.30 24.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 1.00 3.00
11.00 33.70 0.00 0.00 0.00 1.00 0.00 3.00 0.00 2.00 3.00
10.90 34.10 0.00 0.00 0.00 1.00 0.00 0.00 1.00 0.00 2.00
11.90 32.20 0.00 0.00 0.00 1.00 1.00 4.00 0.00 3.00 1.00
10.60 31.70 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 2.00
10.90 29.50 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 1.00
10.90 30.10 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00
11.70 33.60 0.00 0.00 0.00 1.00 0.00 0.00 0.00 1.00 0.00
9.70 35.00 0.00 0.00 0.00 1.00 0.00 4.00 0.00 2.00 3.00
9.90 25.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 1.00 3.00
11.10 35.30 0.00 0.00 0.00 1.00 1.00 4.00 0.00 2.00 3.00
10.30 31.60 0.00 0.00 0.00 1.00 1.00 4.00 0.00 3.00 2.00
10.30 25.50 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 1.00
10.70 31.60 0.00 0.00 0.00 1.00 0.00 0.00 0.00 2.00 1.00
11.90 28.10 0.00 0.00 0.00 1.00 0.00 4.00 0.00 2.00 1.00
9.80 28.10 0.00 0.00 0.00 1.00 1.00 0.00 0.00 2.00 3.00
10.70 27.10 0.00 0.00 0.00 1.00 1.00 4.00 0.00 0.00 0.00
10.40 28.20 0.00 0.00 0.00 1.00 1.00 4.00 0.00 3.00 2.00
11.40 27.30 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 1.00
10.30 33.80 0.00 0.00 0.00 1.00 1.00 4.00 0.00 2.00 4.00
10.00 34.10 0.00 0.00 0.00 1.00 1.00 4.00 0.00 1.00 3.00
10.60 26.20 0.00 0.00 0.00 1.00 0.00 4.00 0.00 1.00 2.00
11.40 34.10 0.00 0.00 0.00 1.00 0.00 4.00 0.00 1.00 3.00
11.50 32.70 0.00 0.00 0.00 1.00 1.00 4.00 0.00 2.00 3.00
11.30 25.20 0.00 0.00 0.00 1.00 0.00 0.00 0.00 1.00 1.00
10.90 32.00 0.00 0.00 0.00 1.00 1.00 4.00 0.00 2.00 3.00
11.40 36.30 0.00 0.00 0.00 1.00 0.00 0.00 0.00 3.00 1.00
10.80 28.70 0.00 0.00 0.00 1.00 0.00 0.00 0.00 2.00 0.00
10.50 28.90 0.00 0.00 0.00 1.00 0.00 4.00 0.00 0.00 1.00
9.80 27.00 0.00 0.00 0.00 1.00 0.00 4.00 0.00 1.00 3.00
10.80 28.10 0.00 0.00 0.00 1.00 0.00 0.00 0.00 2.00 3.00
12.20 29.00 0.00 0.00 0.00 1.00 2.00 4.00 0.00 0.00 1.00
10.70 34.80 0.00 0.00 0.00 1.00 0.00 3.00 0.00 0.00 0.00
10.50 35.30 0.00 0.00 0.00 1.00 2.00 0.00 0.00 0.00 3.00
10.40 33.60 0.00 0.00 0.00 1.00 1.00 4.00 0.00 0.00 3.00
10.10 26.70 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 2.00
11.30 29.10 0.00 0.00 0.00 1.00 0.00 4.00 0.00 3.00 3.00
11.00 33.20 0.00 0.00 0.00 1.00 0.00 4.00 0.00 0.00 1.00
9.70 33.10 0.00 0.00 0.00 1.00 0.00 0.00 0.00 2.00 2.00
11.90 34.50 0.00 0.00 0.00 1.00 1.00 4.00 0.00 3.00 2.00
13.20 29.60 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00
11.90 32.30 0.00 0.00 0.00 1.00 1.00 0.00 0.00 0.00 0.00
10.50 35.40 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 1.00
11.90 29.20 0.00 0.00 0.00 1.00 0.00 0.00 0.00 1.00 3.00
11.10 43.50 0.00 0.00 0.00 1.00 0.00 4.00 0.00 2.00 3.00
10.80 32.10 0.00 0.00 0.00 1.00 0.00 0.00 0.00 2.00 3.00
#NULL! #NULL! 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 2.00
11.10 31.60 0.00 0.00 0.00 1.00 0.00 0.00 0.00 1.00 2.00
11.80 32.00 0.00 0.00 0.00 1.00 0.00 4.00 0.00 0.00 2.00
10.90 30.10 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 2.00
11.90 30.70 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 1.00
10.90 31.70 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00
11.90 32.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 2.00 2.00
10.60 28.70 0.00 0.00 0.00 1.00 0.00 0.00 0.00 2.00 2.00
11.30 37.60 0.00 0.00 0.00 1.00 1.00 0.00 0.00 2.00 4.00
10.00 26.20 0.00 0.00 0.00 1.00 0.00 4.00 0.00 2.00 3.00
9.50 34.50 0.00 0.00 0.00 1.00 2.00 0.00 0.00 3.00 4.00
10.60 26.50 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00
9.60 26.30 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 1.00
11.10 33.40 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 1.00
9.70 24.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 2.00 1.00
10.20 24.20 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 2.00
10.30 29.50 0.00 0.00 0.00 1.00 0.00 4.00 0.00 2.00 3.00
10.20 35.10 0.00 0.00 0.00 1.00 0.00 4.00 0.00 3.00 1.00
10.50 30.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 1.00 2.00
11.30 28.40 0.00 0.00 0.00 1.00 0.00 4.00 0.00 0.00 2.00
11.70 32.50 0.00 0.00 0.00 1.00 0.00 0.00 0.00 2.00 2.00
11.00 27.70 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00
10.40 34.30 0.00 0.00 0.00 1.00 0.00 4.00 0.00 1.00 3.00
11.30 42.80 0.00 0.00 0.00 1.00 0.00 0.00 0.00 2.00 3.00
10.30 30.00 0.00 0.00 0.00 1.00 0.00 4.00 0.00 3.00 2.00
10.80 31.80 0.00 0.00 0.00 1.00 0.00 0.00 0.00 2.00 2.00
10.00 35.50 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 4.00
10.60 27.20 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 2.00
10.60 28.00 0.00 0.00 0.00 1.00 0.00 4.00 0.00 1.00 3.00
10.20 31.00 0.00 0.00 0.00 1.00 0.00 4.00 0.00 1.00 3.00
11.70 37.50 0.00 1.00 0.00 1.00 0.00 0.00 0.00 2.00 0.00
10.30 32.30 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 1.00
10.20 33.70 0.00 0.00 0.00 1.00 1.00 0.00 0.00 2.00 4.00
11.90 32.40 0.00 0.00 0.00 1.00 2.00 0.00 0.00 3.00 3.00
urineprotin24hr UP_UC urea totalprotein albumin TC TG HDL LDL c3 c4
1,500.00 15.59 29.00 3.80 1.30 219 180.00 31.00 155.00 48.40 21.10
161.00 0.51 11.00 4.40 1.90 493 244.00 112.00 347.00 129.00 17.30
3,500.00 #NULL! 22.00 4.80 2.30 #NULL! #NULL! #NULL! #NULL! 135.00 28.90
139.00 #NULL! 16.00 7.50 3.10 #NULL! #NULL! #NULL! #NULL! 65.30 6.61
6,600.00 20.44 16.00 3.90 1.50 507 134.00 53.00 431.00 111.00 29.50
5,800.00 #NULL! 21.00 4.90 2.90 250 159.00 45.00 182.00 113.00 21.70
3,100.00 2.71 16.00 7.30 4.00 146 286.00 32.00 72.00 128.00 19.00
3,000.00 4.43 38.00 4.60 2.80 254 128.00 60.00 168.00 130.00 45.80
10,000.00 #NULL! 22.00 5.00 1.70 352 199.00 55.00 267.00 126.00 29.60
163.00 #NULL! 24.00 #NULL! #NULL! 124 95.00 30.00 84.00 96.20 23.50
1,300.00 #NULL! 22.00 7.10 4.70 106 62.00 42.00 50.00 #NULL! #NULL!
3,200.00 #NULL! 14.00 3.90 1.50 484 769.00 31.00 351.00 #NULL! #NULL!
7,790.00 7.79 14.00 3.90 1.80 372 409.00 42.00 277.00 #NULL! #NULL!
743.00 3.60 11.00 6.80 3.80 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
10,900.00 #NULL! 21.00 6.50 2.70 237 494.00 38.00 118.00 214.00 52.40
7,900.00 #NULL! 10.00 4.90 2.10 255 131.00 56.00 165.00 163.00 36.30
8,100.00 #NULL! 31.00 4.20 2.00 #NULL! #NULL! #NULL! #NULL! 132.00 34.40
4,200.00 #NULL! 36.00 5.00 1.20 #NULL! #NULL! #NULL! #NULL! 138.00 60.10
5,500.00 7.82 24.00 4.70 2.60 353 103.00 54.00 271.00 125.00 31.60
2,100.00 #NULL! 15.00 5.30 2.90 308 62.00 117.00 200.00 106.00 18.50
100.00 0.09 47.00 8.10 4.70 118 117.00 26.00 78.00 107.00 24.70
979.00 #NULL! 36.00 7.00 4.50 121 283.00 27.00 54.00 113.00 32.90
510.00 #NULL! 34.00 #NULL! #NULL! 162 210.00 22.00 109.00 159.00 17.90
1,200.00 #NULL! 47.00 6.90 3.90 178 380.00 38.00 92.00 117.00 26.80
9,200.00 #NULL! 28.00 4.90 2.60 430 270.00 72.00 313.00 193.00 54.80
6,500.00 #NULL! 12.00 5.40 2.40 #NULL! #NULL! #NULL! #NULL! 137.00 33.80
2,700.00 #NULL! 12.00 4.50 1.20 318 97.00 29.00 259.00 136.00 86.40
1,200.00 #NULL! 27.00 7.20 4.10 #NULL! #NULL! #NULL! #NULL! 41.00 21.10
329.00 1.07 23.00 7.50 4.30 #NULL! #NULL! #NULL! #NULL! 126.00 20.20
113.00 0.24 41.00 8.00 4.60 157 136.00 26.00 105.00 143.00 38.90
238.00 #NULL! 33.00 6.50 4.10 178 79.00 69.00 96.00 #NULL! #NULL!
207.00 #NULL! 20.00 7.30 2.70 #NULL! #NULL! #NULL! #NULL! 39.80 5.42
4,700.00 6.64 12.00 4.70 2.50 #NULL! #NULL! #NULL! #NULL! 49.80 10.50
5,000.00 5.24 26.00 7.80 3.80 202 312.00 42.00 123.00 #NULL! #NULL!
13,840.00 13.84 156.00 6.00 2.70 3 117.00 55.00 226.00 110.00 46.70
1,540.00 1.54 73.00 5.10 2.90 208 158.00 52.00 139.00 #NULL! #NULL!
1,500.00 #NULL! 17.00 6.60 4.40 128 91.00 32.00 86.00 0.00 0.00
476.00 #NULL! 21.00 7.90 4.60 #NULL! #NULL! #NULL! #NULL! 119.00 25.50
1,300.00 #NULL! 80.00 7.70 4.20 #NULL! #NULL! #NULL! #NULL! 96.80 42.30
10,400.00 #NULL! 18.00 3.90 1.70 624 343.00 45.00 533.00 156.00 50.20
99.00 #NULL! 70.00 8.20 4.70 250 231.00 42.00 167.00 131.00 37.40
2,000.00 #NULL! 25.00 6.00 3.10 140 169.00 24.00 90.00 21.40 5.42
866.00 #NULL! 50.00 7.70 4.80 132 165.00 32.00 76.00 122.00 36.30
4,700.00 #NULL! 26.00 4.50 2.10 302 118.00 82.00 194.00 95.30 23.80
3,100.00 #NULL! 16.00 4.70 2.00 #NULL! #NULL! #NULL! #NULL! 114.00 52.80
506.00 #NULL! 24.00 7.60 4.50 143 98.00 48.00 83.00 #NULL! #NULL!
4,300.00 #NULL! 20.00 4.80 2.10 291 148.00 72.00 213.00 #NULL! #NULL!
3,500.00 #NULL! 47.00 6.40 3.60 141 93.00 19.00 117.00 128.00 34.50
81.00 0.20 36.00 7.90 5.10 198 152.00 38.00 143.00 117.00 26.00
6,500.00 5.28 96.00 7.00 3.60 #NULL! #NULL! #NULL! #NULL! 18.40 12.00
815.00 0.65 51.00 7.40 3.90 156 145.00 36.00 82.00 187.00 60.60
50.00 0.05 21.00 7.40 4.70 #NULL! #NULL! #NULL! #NULL! 107.00 34.40
1,800.00 1.74 26.00 6.50 4.30 #NULL! #NULL! #NULL! #NULL! 157.00 48.60
3,200.00 #NULL! 18.00 7.40 4.00 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
10,900.00 #NULL! 22.00 4.60 1.90 367 414.00 40.00 283.00 86.90 45.40
499.00 #NULL! 136.00 7.30 3.40 #NULL! #NULL! #NULL! #NULL! 110.00 26.50
408.00 #NULL! 36.00 7.60 4.20 114 174.00 22.00 68.00 #NULL! #NULL!
5,500.00 #NULL! 38.00 5.70 2.80 246 204.00 65.00 145.00 120.00 30.60
10,200.00 10.96 31.00 3.30 1.40 660 703.00 41.00 530.00 161.00 36.40
4,700.00 #NULL! 42.00 4.10 2.10 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
107.00 9.80 161.00 6.80 4.00 151 153.00 35.00 92.00 124.00 30.60
736.00 1.30 221.00 6.70 3.90 #NULL! #NULL! #NULL! #NULL! 117.00 30.20
1,900.00 3.34 56.00 5.20 3.20 141 65.00 76.00 60.00 81.60 14.60
5,600.00 #NULL! 108.00 5.60 2.90 #NULL! #NULL! #NULL! #NULL! 132.00 31.00
73.00 #NULL! 25.00 7.30 4.50 #NULL! #NULL! #NULL! #NULL! 138.00 54.30
759.00 #NULL! 47.00 8.10 3.90 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
1,700.00 0.97 42.00 7.30 4.10 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
2,700.00 #NULL! 36.00 7.10 3.20 #NULL! #NULL! #NULL! #NULL! 129.00 49.40
3,400.00 #NULL! 61.00 6.50 3.00 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
9,700.00 8.09 35.00 4.90 2.80 #NULL! #NULL! #NULL! #NULL! 129.00 50.20
2,200.00 4.42 41.00 6.20 3.20 180 121.00 52.00 114.00 97.10 27.60
1,100.00 #NULL! 35.00 6.50 3.80 149 187.00 44.00 74.00 101.00 21.20
1,400.00 #NULL! 43.00 6.80 4.50 117 108.00 39.00 70.00 #NULL! #NULL!
3,000.00 4.04 190.00 6.30 4.10 #NULL! #NULL! #NULL! #NULL! 83.40 34.90
354.00 #NULL! 47.00 7.30 4.70 #NULL! #NULL! #NULL! #NULL! 0.00 0.00
100.00 #NULL! 40.00 7.90 4.20 141 102.00 31.00 93.00 159.00 58.00
4,100.00 3.24 95.00 6.10 3.00 109 37.00 62.00 39.00 89.30 17.50
1,100.00 0.78 60.00 5.70 3.30 168 68.00 29.00 152.00 103.00 40.80
6,700.00 33.98 122.00 6.30 2.70 245 164.00 48.00 164.00 31.60 31.40
1,300.00 #NULL! 93.00 6.60 3.60 166 117.00 45.00 99.00 #NULL! #NULL!
17,500.00 17.46 61.00 3.50 1.60 487 618.00 35.00 354.00 44.90 13.50
360.00 #NULL! 35.00 8.40 4.50 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
592.00 #NULL! 119.00 7.20 4.20 #NULL! #NULL! #NULL! #NULL! 126.00 16.10
1,000.00 #NULL! 61.00 6.40 3.70 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
689.00 #NULL! 90.00 5.80 3.60 209 218.00 51.00 126.00 112.00 39.40
800.00 1.20 51.00 7.80 4.60 174 185.00 35.00 120.00 108.00 15.50
5,500.00 10.75 45.00 4.50 1.50 167 87.00 60.00 94.00 106.00 26.90
1,340.00 1.34 45.00 6.10 3.80 226 225.00 34.00 159.00 113.00 36.70
578.00 #NULL! 142.00 7.00 3.70 106 48.00 52.00 56.00 129.00 58.70
342.00 0.32 47.00 8.20 4.60 #NULL! #NULL! #NULL! #NULL! 99.70 29.30
3,400.00 5.11 236.00 5.70 3.00 #NULL! #NULL! #NULL! #NULL! 88.50 42.00
133.00 0.03 23.00 7.60 4.90 157 85.00 46.00 103.00 105.00 19.30
5,300.00 #NULL! 88.00 7.00 4.10 183 5.00 65.00 108.00 136.00 27.70
4,100.00 3.96 55.00 7.50 4.50 #NULL! #NULL! #NULL! #NULL! 75.40 22.00
2,600.00 #NULL! 38.00 6.00 4.00 199 87.00 50.00 139.00 127.00 35.40
610.00 #NULL! 67.00 5.60 2.70 411 130.00 100.00 262.00 102.00 69.80
8,800.00 #NULL! 52.00 6.60 3.70 #NULL! #NULL! #NULL! #NULL! 135.00 45.90
850.00 #NULL! 106.00 7.70 4.30 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
2,100.00 0.97 67.00 7.30 4.00 130 128.00 53.00 60.00 128.00 47.70
12,400.00 #NULL! 74.00 5.80 2.60 206 154.00 33.00 155.00 111.00 47.00
988.00 1.53 31.00 8.40 4.00 #NULL! #NULL! #NULL! #NULL! 86.40 34.40
109.00 0.11 42.00 6.80 4.00 #NULL! #NULL! #NULL! #NULL! #NULL! #NULL!
5,200.00 #NULL! 88.00 5.60 3.00 #NULL! #NULL! #NULL! #NULL! 81.60 31.30
4,800.00 #NULL! 98.00 5.90 2.80 182 126.00 34.00 125.00 105.00 20.30
ANA DsDNA ASO ADNB ANCA CANCA PANCA CIS pred CNIS Endoxan MMF
0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 1.00 1.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 1.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 1.00 0.00 0.00 0.00
2.00 665.00 0.00 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 1.00
1.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 1.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 733.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 1.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 1.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
3.00 225.00 0.00 0.00 0.00 0.00 0.00 1.00 1.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 1.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 300.00 1.00 1.00 0.00 0.00 1.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 1.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 1.00 0.00 0.00 0.00
0.00 0.00 776.00 1,040.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 1.00 1.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
3.00 615.00 0.00 0.00 1.00 0.00 0.00 1.00 1.00 0.00 0.00 1.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
3.00 524.00 0.00 0.00 0.00 0.00 0.00 1.00 1.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 1.00 0.00 0.00 1.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 253.00 898.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 1.00 0.00 0.00 1.00 1.00 1.00 0.00 1.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 1.00 0.00 1.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 1.00 0.00 1.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
1.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 1.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 1.00 0.00 299.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 1.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
1.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 1.00 0.00 1.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 135.00 0.00 0.00 0.00 0.00 0.00 1.00 1.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 1.00 0.00 1.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 1.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.00 1.00 1.00 1.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 205.00 1,420.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 #NULL! 0.00 0.00 0.00 0.00
Levamisole Glomerularcompartment Intcompt Tubucompt Vasccompt IgG IgA IgM ifC3 ifC4
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00 Mesangial prol normal normal normal 0 0 0 0 0
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00 membrane thick normal normal normal 1 0 0 1 0
0.00
0.00
0.00
0.00 MEMBRANOUS NEP
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00 0
0.00
0.00
0.00
0.00 FPGN 0 0 0 0 0
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00 segmental scle interstitial f foci of ta arterioscleros
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00 CLASS IV LUPUS
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00 NORMAL AIN 0 0 0 0 0
0.00 MCD
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
C1Q LC immuno electronmicro histopatho usgrt usglft Echogencity paren
#NULL! #NULL! #NULL! 10.00 10.60 0.00 #NULL!
#NULL! #NULL! #NULL! 9.90 9.00 2.00 #NULL!
#NULL! #NULL! #NULL! 11.70 11.70 2.00 #NULL!
#NULL! #NULL! #NULL! 10.00 9.50 0.00 #NULL!
#NULL! #NULL! #NULL! 11.30 11.00 1.00 #NULL!
#NULL! #NULL! #NULL! 10.40 10.30 1.00 #NULL!
#NULL! #NULL! #NULL! 11.00 10.90 2.00 #NULL!
#NULL! #NULL! #NULL! 8.30 8.60 0.00 #NULL!
#NULL! #NULL! #NULL! 10.20 11.00 0.00 #NULL!
#NULL! #NULL! #NULL! 12.00 12.50 1.00 #NULL!
#NULL! #NULL! #NULL! 9.40 9.50 1.00 #NULL!
#NULL! #NULL! #NULL! 9.85 9.52 0.00 #NULL!
#NULL! #NULL! #NULL! 12.20 11.90 1.00 #NULL!
#NULL! #NULL! #NULL! 10.80 10.00 1.00 #NULL!
#NULL! #NULL! #NULL! 11.50 12.30 0.00 #NULL!
#NULL! #NULL! #NULL! 11.40 11.20 0.00 #NULL!
0 0 0 0 Resolving PIGN 10.00 10.00 2.00 #NULL!
#NULL! #NULL! #NULL! 9.90 10.50 0.00 #NULL!
#NULL! #NULL! #NULL! 10.40 11.40 0.00 #NULL!
#NULL! #NULL! #NULL! 12.00 11.50 1.00 #NULL!
#NULL! #NULL! #NULL! 8.30 9.10 0.00 #NULL!
#NULL! #NULL! #NULL! 9.00 9.00 2.00 #NULL!
#NULL! #NULL! #NULL! 9.90 10.30 0.00 #NULL!
#NULL! #NULL! #NULL! 8.80 9.00 3.00 #NULL!
0 0 0 0 Menmbranous nephropathy 10.00 10.60 0.00 #NULL!
#NULL! #NULL! #NULL! 9.99 10.80 0.00 #NULL!
#NULL! #NULL! #NULL! 10.60 9.80 0.00 #NULL!
#NULL! #NULL! #NULL! 11.00 9.80 1.00 #NULL!
#NULL! #NULL! #NULL! 10.90 10.50 1.00 #NULL!
#NULL! #NULL! #NULL! 8.30 8.40 1.00 #NULL!
#NULL! #NULL! #NULL! 8.00 8.20 1.00 #NULL!
#NULL! #NULL! #NULL! 10.00 11.20 1.00 #NULL!
#NULL! #NULL! #NULL! 9.60 10.00 0.00 #NULL!
#NULL! #NULL! #NULL! 10.30 10.70 2.00 #NULL!
#NULL! #NULL! #NULL! 10.60 10.00 2.00 #NULL!
#NULL! #NULL! #NULL! 9.50 9.70 1.00 #NULL!
#NULL! #NULL! #NULL! 9.40 10.60 2.00 #NULL!
#NULL! #NULL! #NULL! 9.40 10.50 2.00 #NULL!
#NULL! #NULL! #NULL! 9.00 8.60 2.00 #NULL!
#NULL! #NULL! #NULL! 10.60 10.50 0.00 #NULL!
#NULL! #NULL! #NULL! 9.20 9.00 2.00 #NULL!
#NULL! #NULL! #NULL! 10.50 10.70 1.00 #NULL!
#NULL! #NULL! #NULL! 9.00 10.20 3.00 #NULL!
#NULL! #NULL! #NULL! 10.40 9.50 1.00 #NULL!
#NULL! #NULL! #NULL! 10.60 11.50 1.00 #NULL!
#NULL! #NULL! #NULL! 8.20 9.20 2.00 #NULL!
#NULL! #NULL! #NULL! 9.80 10.40 1.00 1.42
#NULL! #NULL! #NULL! 11.30 12.00 2.00 #NULL!
#NULL! #NULL! #NULL! 8.70 8.40 1.00 #NULL!
#NULL! #NULL! #NULL! 11.40 11.70 0.00 #NULL!
#NULL! #NULL! #NULL! 10.90 10.90 0.00 #NULL!
0 0 0 0 FOCAL PROLIFERATIVE GN 9.70 10.20 0.00 #NULL!
#NULL! #NULL! #NULL! FOCAL SEGMENTAL GLOMERULOSCLEROSIS 9.80 10.00 1.00 #NULL!
#NULL! #NULL! #NULL! 11.00 11.60 1.00 #NULL!
#NULL! #NULL! #NULL! 11.50 12.20 0.00 #NULL!
#NULL! #NULL! #NULL! 10.10 12.50 2.00 #NULL!
#NULL! #NULL! #NULL! 9.80 9.80 1.00 #NULL!
#NULL! #NULL! #NULL! 10.90 11.50 0.00 #NULL!
#NULL! #NULL! #NULL! 10.70 12.30 2.00 #NULL!
#NULL! #NULL! #NULL! focal segmental glomeurlosclerosis 9.50 11.30 1.00 #NULL!
#NULL! #NULL! #NULL! 8.90 10.00 3.00 #NULL!
#NULL! #NULL! #NULL! 9.60 9.50 3.00 #NULL!
#NULL! 0 0 DPGN 11.90 12.00 2.00 #NULL!
#NULL! #NULL! #NULL! 11.30 11.90 1.00 #NULL!
#NULL! #NULL! #NULL! 9.00 9.00 1.00 1.12
#NULL! #NULL! #NULL! 11.29 11.77 1.00 #NULL!
#NULL! #NULL! #NULL! 10.00 10.50 2.00 #NULL!
#NULL! #NULL! #NULL! 10.20 10.90 2.00 #NULL!
#NULL! #NULL! #NULL! 8.20 9.00 1.00 #NULL!
#NULL! #NULL! #NULL! 9.80 9.20 0.00 #NULL!
#NULL! #NULL! #NULL! 8.40 9.00 2.00 #NULL!
#NULL! #NULL! #NULL! CLASS IV LN WITH CRESCENT IN ONE GLOMERULUS 9.20 9.00 1.00 #NULL!
#NULL! #NULL! #NULL! 9.00 8.90 0.00 #NULL!
#NULL! #NULL! #NULL! 9.00 9.50 2.00 #NULL!
#NULL! #NULL! #NULL! 10.10 10.70 2.00 1.12
#NULL! #NULL! #NULL! 10.50 9.90 1.00 #NULL!
#NULL! #NULL! #NULL! 9.80 9.80 2.00 #NULL!
#NULL! #NULL! #NULL! 9.10 10.50 1.00 #NULL!
#NULL! #NULL! #NULL! 10.20 9.50 3.00 #NULL!
#NULL! #NULL! #NULL! 9.00 9.70 2.00 #NULL!
#NULL! #NULL! #NULL! 12.00 13.00 0.00 #NULL!
#NULL! #NULL! #NULL! 8.80 8.50 2.00 #NULL!
#NULL! #NULL! #NULL! 9.00 8.90 1.00 #NULL!
#NULL! #NULL! #NULL! 9.00 10.00 1.00 #NULL!
#NULL! #NULL! #NULL! 8.40 8.90 2.00 #NULL!
#NULL! #NULL! #NULL! 8.00 7.60 1.00 0.94
#NULL! #NULL! #NULL! 9.70 9.60 0.00 #NULL!
#NULL! #NULL! #NULL! 10.70 10.40 0.00 #NULL!
#NULL! #NULL! #NULL! 9.10 8.70 2.00 #NULL!
#NULL! #NULL! #NULL! 9.20 9.20 2.00 #NULL!
#NULL! #NULL! #NULL! 10.50 12.00 2.00 #NULL!
#NULL! #NULL! #NULL! 9.00 8.60 0.00 #NULL!
#NULL! #NULL! #NULL! 11.20 9.80 3.00 #NULL!
#NULL! #NULL! #NULL! 9.20 8.50 2.00 #NULL!
0 0 1 0 AIN WITH ILLDEFINED GRANULOMAS /RENAL TB 10.20 9.70 2.00 #NULL!
#NULL! #NULL! #NULL! MINIMAL CHANGE DISESAE 10.70 10.60 1.00 #NULL!
#NULL! #NULL! #NULL! 8.20 10.00 2.00 #NULL!
#NULL! #NULL! #NULL! 9.60 9.10 2.00 #NULL!
#NULL! #NULL! #NULL! 8.30 8.90 2.00 #NULL!
#NULL! #NULL! #NULL! 12.20 13.00 1.00 #NULL!
#NULL! #NULL! #NULL! 12.90 12.90 1.00 #NULL!
#NULL! #NULL! #NULL! 8.30 8.00 1.00 #NULL!
#NULL! #NULL! #NULL! 11.00 11.60 2.00 #NULL!
#NULL! #NULL! #NULL! 10.80 10.70 1.00 #NULL!
ARFIR1 DEPTHR1 ARFIR2 DEPTHR2 ARFIR3 DEPTHR3 ARFIR4 DEPTHR4 ARFIR5 DEPTHR5 MedianR meanR
0.96 5.40 0.83 5.40 1.29 5.10 0.85 5.30 0.98 5.20 0.96 0.98
2.69 5.80 2.03 5.80 2.23 5.80 2.02 5.70 2.66 5.40 2.23 2.33
1.51 3.30 2.28 5.20 1.35 3.20 2.14 2.80 1.82 4.80 1.82 1.82
2.19 4.30 1.39 4.10 1.15 4.10 1.72 4.10 1.91 4.10 1.72 1.67
1.51 4.50 1.43 4.80 0.97 4.30 1.92 4.30 0.84 4.30 1.43 4.33
1.88 4.60 3.03 3.50 2.49 5.20 3.08 4.10 2.53 4.10 2.53 2.60
0.80 6.20 0.55 6.30 2.08 6.50 0.84 6.90 1.05 5.80 0.84 1.06
2.39 2.70 1.39 3.30 2.17 2.70 1.21 2.70 1.94 2.70 1.94 1.82
1.34 6.40 1.54 6.30 0.52 7.40 1.07 7.40 2.04 6.50 1.21 1.18
1.69 6.30 2.35 6.90 1.33 7.40 2.62 6.50 1.07 5.20 1.80 1.83
2.60 4.80 2.05 4.90 1.36 6.30 1.82 4.80 1.25 6.40 1.82 1.82
2.67 2.80 2.94 3.20 1.97 3.60 2.03 2.80 1.57 3.10 2.03 2.24
3.66 2.60 3.70 2.80 3.01 2.80 2.96 2.80 2.19 3.00 3.01 3.10
1.06 3.60 2.74 3.20 3.15 3.20 3.02 3.00 3.01 3.30 3.01 2.60
3.01 7.10 2.02 7.10 2.05 6.60 2.08 6.50 0.56 6.40 2.05 1.94
3.63 4.90 2.10 4.60 3.86 4.40 3.58 4.40 2.86 4.60 3.58 3.21
2.48 4.20 0.86 6.40 1.40 4.20 2.89 5.20 1.54 4.30 1.54 1.83
1.31 5.70 1.42 5.70 2.22 2.50 2.24 5.10 3.85 5.40 2.22 2.21
1.39 7.30 1.87 7.30 1.75 7.30 1.28 7.30 1.57 7.30 1.57 1.57
1.11 4.10 1.12 4.10 1.27 4.10 1.32 4.10 1.34 4.10 1.27 1.23
0.65 6.70 0.96 5.90 0.92 6.70 0.80 6.20 0.84 5.40 0.84 0.83
1.09 5.70 1.02 5.50 0.85 5.50 0.84 5.70 0.83 5.70 0.85 0.93
1.36 2.90 1.20 3.20 1.42 3.10 #NULL! #NULL! #NULL! #NULL! 1.36 1.33
2.18 3.60 2.44 3.70 2.30 3.70 2.03 3.50 2.28 3.60 2.28 2.25
0.96 5.40 0.83 5.40 1.29 5.10 0.85 5.30 0.98 5.20 0.96 0.98
0.79 7.10 0.76 6.80 0.86 6.80 0.81 7.00 1.34 6.50 0.81 0.91
0.79 4.50 0.76 5.80 0.86 5.60 0.81 6.00 1.34 5.60 0.81 0.91
2.10 4.40 2.26 4.40 2.36 4.40 2.26 3.90 2.60 4.10 2.26 2.34
2.16 8.00 1.82 8.00 1.86 7.40 1.51 7.40 1.48 8.00 1.67 1.69
1.96 5.40 2.05 5.50 1.70 5.30 1.64 7.30 2.13 7.70 1.96 1.90
1.01 5.90 1.17 5.90 1.32 6.00 1.41 6.00 1.62 6.00 1.32 1.31
1.63 6.00 1.47 6.10 1.52 5.10 1.92 5.10 1.95 4.60 1.53 1.68
1.60 5.70 1.90 5.90 1.68 5.40 2.15 5.70 1.40 6.50 1.68 1.75
2.17 5.10 2.33 5.70 2.35 5.40 1.50 4.60 2.45 5.10 2.33 2.16
2.17 3.50 2.49 3.50 2.22 3.50 2.68 3.70 1.86 4.20 2.22 2.28
2.32 4.70 1.81 5.10 1.90 3.90 1.56 5.40 1.43 5.10 1.81 1.80
1.41 7.10 1.62 6.00 1.18 6.40 0.54 6.50 1.09 7.30 1.18 1.17
0.74 6.10 1.55 7.40 1.37 6.30 0.69 7.50 0.80 6.60 0.80 1.30
1.79 5.30 1.13 5.20 2.30 5.50 1.49 4.60 1.81 4.40 1.79 1.70
2.37 4.70 2.93 5.60 1.98 5.00 1.79 5.00 2.20 4.30 2.20 2.25
2.37 5.40 1.67 5.70 1.86 5.00 1.37 4.20 1.35 5.20 1.65 1.67
1.42 7.80 1.63 7.80 1.84 6.80 2.43 7.60 1.19 7.90 1.63 1.70
1.95 7.10 1.64 5.80 1.27 6.20 2.14 6.20 2.62 6.20 1.95 1.92
2.16 4.70 2.76 4.70 1.80 4.50 2.88 6.00 1.97 4.90 2.16 2.31
1.41 6.00 2.15 6.70 0.68 6.00 1.12 5.70 1.55 6.10 1.41 1.38
1.54 5.30 1.74 6.70 0.57 6.80 1.17 4.90 2.00 4.30 1.54 1.40
1.16 6.30 0.85 6.00 0.81 6.10 2.36 6.10 2.06 6.10 1.55 1.53
1.94 3.60 1.53 4.30 3.07 3.60 0.92 4.60 1.80 4.70 1.80 1.85
1.89 5.50 2.45 5.70 0.78 6.10 0.86 5.70 1.08 5.20 1.08 1.41
1.19 7.60 0.67 7.20 1.42 7.20 2.22 7.50 2.41 5.90 1.42 1.68
2.96 5.50 2.88 5.30 1.45 7.20 1.74 8.00 1.51 6.80 1.74 2.11
2.88 5.00 2.76 4.00 1.69 3.70 1.19 4.80 1.44 4.90 1.69 1.99
2.67 5.80 0.71 6.90 0.87 5.30 0.87 6.50 2.12 5.60 0.87 1.43
2.33 6.40 0.55 7.60 0.25 6.00 0.84 7.90 1.94 7.50 1.94 1.58
2.17 3.40 2.39 3.00 3.96 2.70 3.84 2.90 3.38 3.10 3.38 3.15
4.77 4.00 3.59 3.50 1.88 5.70 4.00 3.80 3.55 3.60 3.59 3.59
0.77 5.20 2.70 4.40 1.02 5.20 2.55 4.90 1.48 4.30 1.48 1.70
3.21 4.10 2.44 4.00 2.73 3.80 4.53 4.00 4.17 3.80 3.21 3.42
1.63 7.80 1.81 8.00 1.72 8.00 2.29 7.30 2.18 7.50 1.81 1.93
0.65 5.20 0.69 5.20 0.65 4.70 0.64 4.70 0.97 4.70 0.67 0.72
1.36 5.70 1.28 5.20 0.95 6.10 1.03 6.10 1.57 5.90 1.28 1.24
0.81 5.90 1.00 5.70 1.20 5.90 1.04 5.70 1.07 5.70 1.04 1.02
1.74 6.30 1.53 6.40 1.92 5.90 1.64 6.50 1.63 6.00 1.64 1.69
0.59 5.90 0.60 5.00 0.65 6.70 0.52 5.80 1.06 4.60 0.60 0.68
0.77 7.20 0.89 7.30 1.26 6.60 1.20 7.30 0.85 7.00 0.89 0.99
1.96 5.40 2.05 5.50 1.70 5.30 1.64 7.30 2.13 7.70 1.96 1.90
2.57 4.30 2.26 4.20 1.89 4.20 2.40 4.20 2.32 3.90 2.32 2.29
1.47 5.00 2.04 4.20 2.18 5.60 1.85 4.90 2.00 5.40 2.00 1.91
0.58 6.80 0.69 6.60 0.82 6.60 0.51 6.20 1.22 4.70 0.69 0.76
0.80 4.00 1.04 4.80 1.35 4.40 0.57 3.50 0.85 4.00 0.85 0.92
3.08 3.40 2.46 3.40 2.36 3.50 2.77 3.40 2.69 3.40 2.69 2.67
1.10 7.40 1.89 6.90 1.84 7.00 2.06 6.50 1.92 6.80 1.89 1.76
1.61 6.40 1.76 7.40 1.78 7.90 2.24 7.40 2.19 7.30 1.78 1.92
1.88 4.50 1.65 3.90 1.22 6.10 2.09 5.00 1.72 3.40 1.72 1.71
1.91 5.00 1.75 4.90 2.13 4.50 1.39 4.50 2.01 4.70 1.83 1.71
1.07 5.70 1.78 7.00 1.43 7.00 2.76 7.00 2.06 6.40 1.85 1.84
2.12 5.00 2.77 3.10 1.70 3.50 2.38 5.10 2.42 4.30 2.38 2.28
1.33 2.90 1.74 4.40 1.72 5.20 0.91 5.90 1.91 2.70 1.72 1.52
2.20 4.20 2.95 3.60 1.97 5.20 2.54 3.60 2.68 3.80 2.54 2.47
1.60 5.60 1.11 6.10 1.16 5.20 0.58 6.40 0.62 5.20 1.11 1.01
2.11 3.50 1.43 2.90 1.70 3.60 2.46 4.70 1.54 2.90 1.70 1.85
2.12 5.40 1.60 5.70 1.89 5.00 1.21 4.20 1.22 5.20 1.60 1.61
1.08 7.10 1.34 7.70 1.79 6.60 0.69 7.60 1.59 7.30 1.34 1.30
1.05 5.50 2.47 4.50 1.06 4.20 1.03 4.40 1.35 5.30 1.06 1.39
1.47 6.50 2.30 6.20 1.71 7.30 2.09 5.30 1.15 7.00 1.71 1.74
1.87 5.20 2.38 4.60 0.96 5.00 1.14 4.40 1.08 4.80 1.11 1.39
2.04 4.00 1.36 5.00 2.11 4.60 2.88 3.80 1.80 4.40 2.04 2.04
2.50 5.30 2.03 5.30 1.88 5.60 2.78 5.90 2.99 5.80 2.50 2.44
1.63 6.60 2.30 6.00 2.94 6.30 2.87 5.40 2.60 5.70 2.60 2.47
1.07 5.10 0.66 7.30 0.90 6.90 1.68 7.60 1.77 7.00 1.07 1.22
1.41 6.00 2.15 6.70 0.68 6.00 1.12 5.70 1.55 6.10 1.41 1.38
1.87 5.30 2.74 5.30 1.15 6.40 1.76 5.00 1.48 4.80 1.76 1.80
2.83 2.50 2.29 2.50 1.24 3.60 1.82 3.40 2.06 3.10 2.06 2.05
2.06 3.10 2.93 3.90 2.23 2.50 2.58 3.30 3.59 2.40 2.58 2.68
2.44 5.90 1.09 6.40 0.79 4.70 0.80 5.30 1.39 4.50 1.09 1.30
2.69 4.10 4.02 4.10 3.20 4.10 3.86 4.00 4.25 4.00 3.86 3.60
1.05 3.30 1.96 3.30 1.43 3.50 0.81 5.30 2.35 3.30 1.43 1.52
3.32 6.50 1.39 5.90 2.85 5.70 2.30 5.30 2.78 5.30 2.78 2.53
2.30 7.00 1.23 5.90 1.09 5.80 2.67 4.90 1.74 6.30 1.74 1.81
2.56 6.90 1.29 7.30 1.31 6.70 2.28 6.00 0.82 7.60 1.31 1.65
2.68 4.70 1.99 5.90 1.35 4.20 2.29 5.50 3.45 5.20 2.29 2.35
1.36 4.30 0.86 4.80 3.56 4.40 1.71 5.50 1.75 4.90 1.71 1.85
2.50 3.00 0.93 3.50 3.43 2.80 2.94 2.90 2.33 2.90 2.50 2.43
2.28 5.60 2.80 5.40 0.84 7.50 0.77 6.50 1.06 5.10 1.06 1.55
SDR IORR VAR00002 ARFIL1 DEPTHL1 ARFIL2 DEPTHL2 ARFIL3 DEPTHL3 ARFIL4 DEPTHL4 ARFIL5
0.18 0.30 #NULL! 0.64 4.60 0.92 4.80 1.11 4.10 1.40 5.30 0.87
0.33 0.65 #NULL! 1.54 5.20 1.75 4.80 1.87 4.90 1.42 4.80 1.68
0.40 0.78 #NULL! 1.55 3.80 2.56 4.80 2.47 3.90 2.03 3.80 1.15
0.41 0.78 #NULL! 1.90 3.90 2.36 4.00 1.33 4.00 0.53 3.30 1.57
0.44 0.81 #NULL! 1.22 4.90 2.21 4.30 1.39 4.90 2.23 3.50 3.77
0.49 0.87 #NULL! 1.12 5.10 1.34 3.10 2.64 3.80 1.66 4.30 2.34
0.60 0.89 #NULL! 2.74 5.00 0.60 5.70 1.51 4.20 1.01 4.40 2.33
0.50 0.98 #NULL! 2.70 3.80 2.74 2.80 3.08 3.20 3.21 2.20 4.13
0.59 0.99 #NULL! 0.55 4.60 0.85 5.40 1.38 4.00 0.53 4.10 1.01
0.59 1.02 #NULL! 1.90 6.00 1.06 5.60 2.68 5.80 1.94 7.00 2.54
0.55 1.02 #NULL! 2.66 5.30 2.29 4.20 1.64 5.90 1.42 5.40 1.36
0.56 1.04 #NULL! 0.78 3.80 1.45 5.00 0.89 4.60 0.61 3.10 1.91
0.62 1.10 #NULL! 2.36 4.70 2.48 4.50 2.84 4.90 2.76 4.90 1.57
0.87 1.19 #NULL! 1.46 5.10 2.22 5.10 2.00 5.10 1.24 5.10 1.97
0.88 1.26 #NULL! 1.28 7.40 1.24 7.40 2.22 8.00 1.75 7.50 1.51
0.72 1.27 #NULL! 3.84 4.90 3.51 5.20 3.41 4.70 2.29 6.90 3.54
0.83 1.56 #NULL! 1.25 3.90 1.55 3.50 1.74 5.30 3.06 6.20 2.16
1.02 1.68 #NULL! 1.89 5.60 1.22 5.50 1.29 5.40 2.04 5.30 1.70
0.24 0.47 #NULL! 1.80 7.90 2.08 7.90 1.80 8.00 1.53 8.00 1.99
0.11 0.21 #NULL! 1.86 5.00 1.51 5.00 1.83 5.00 1.38 5.30 1.56
0.12 0.21 #NULL! 2.13 6.10 1.07 5.10 1.86 5.30 1.51 5.00 0.92
0.12 0.22 #NULL! 0.74 7.00 1.66 6.90 1.60 6.80 1.74 7.10 1.64
0.11 0.22 #NULL! 1.21 3.30 1.58 3.10 1.06 3.60 #NULL! #NULL! #NULL!
0.15 0.26 #NULL! 1.82 4.90 1.84 5.20 1.70 5.20 1.46 5.50 1.98
0.18 0.30 #NULL! 0.64 4.60 0.92 4.80 1.11 4.10 1.40 5.30 0.87
0.24 0.32 #NULL! 1.13 6.30 1.02 6.30 1.05 6.80 1.64 6.50 1.59
0.24 0.32 #NULL! 1.13 4.50 1.02 5.60 1.05 5.80 1.64 5.60 1.59
0.68 0.35 #NULL! 2.25 3.90 1.45 3.90 2.83 3.90 2.32 3.90 2.54
0.31 0.38 #NULL! 2.03 6.50 1.93 6.50 2.48 6.50 1.51 6.80 1.50
0.22 0.42 #NULL! 1.45 5.90 2.22 6.50 1.57 6.00 2.13 5.50 2.61
0.23 0.43 #NULL! 1.19 4.90 2.24 4.60 1.37 4.90 2.44 5.30 1.10
0.24 0.44 #NULL! 0.95 5.30 0.79 5.00 1.35 5.00 1.35 4.30 2.98
0.29 0.53 #NULL! 1.70 5.00 1.54 5.00 1.72 6.00 1.41 6.10 1.62
0.38 0.56 #NULL! 1.43 6.10 1.38 6.50 1.74 7.50 1.86 5.90 1.89
0.31 0.57 #NULL! 2.54 3.40 2.76 3.50 2.93 3.30 2.56 2.80 2.78
0.34 0.61 #NULL! 1.53 5.00 0.54 5.40 1.74 5.20 1.40 6.20 2.09
0.41 0.70 #NULL! 2.25 5.30 2.07 5.60 2.55 5.40 1.37 5.90 0.58
0.43 0.74 #NULL! 1.86 5.80 0.83 5.80 0.83 6.80 0.81 7.20 0.86
0.43 0.74 #NULL! 0.61 5.70 1.53 5.20 1.08 5.80 1.81 5.10 1.14
0.44 0.76 #NULL! 0.72 4.20 0.61 5.90 2.02 4.50 1.95 5.90 1.74
0.40 0.80 #NULL! 1.25 5.30 0.95 5.40 1.87 5.70 1.37 6.40 0.97
0.47 0.83 #NULL! 1.89 5.40 2.68 5.70 2.02 5.70 2.88 5.50 2.20
0.51 0.92 #NULL! 1.80 5.10 2.55 4.60 2.06 5.60 1.57 6.00 2.94
0.48 0.93 #NULL! 1.96 4.10 1.74 4.80 2.28 3.40 1.78 3.30 1.92
0.54 0.95 #NULL! 1.15 5.30 0.89 5.20 1.13 5.10 1.68 5.50 0.95
0.56 1.00 #NULL! 0.79 6.30 0.91 6.30 2.88 6.80 2.03 7.30 0.66
0.67 1.21 #NULL! 1.95 6.10 1.20 5.90 1.12 5.90 2.56 5.40 1.31
0.79 1.28 #NULL! 1.59 4.40 1.98 3.80 2.54 3.00 1.94 4.00 2.22
0.73 1.35 #NULL! 2.04 5.70 1.81 5.10 1.10 6.20 1.59 4.70 2.51
0.73 1.39 #NULL! 2.78 5.90 0.68 6.90 4.31 7.90 1.50 7.10 3.10
0.75 1.44 #NULL! 1.95 5.10 2.09 5.50 1.06 6.60 2.09 5.10 1.86
0.78 1.50 #NULL! 1.36 3.60 1.53 4.10 2.03 4.20 1.45 3.60 0.63
0.85 1.55 #NULL! 0.63 6.60 1.91 6.30 0.53 5.80 3.75 6.70 3.01
0.83 1.59 #NULL! 3.99 5.60 0.55 6.40 2.28 6.00 0.60 6.40 2.66
0.83 1.62 #NULL! 1.68 5.10 1.95 3.80 2.43 3.80 3.06 3.50 0.96
1.06 1.67 #NULL! 2.72 3.50 3.76 3.40 2.72 4.90 3.77 3.20 3.99
0.88 1.73 #NULL! 0.89 5.20 1.29 4.90 1.76 4.80 1.46 4.80 2.07
0.90 1.76 #NULL! 2.20 3.20 3.03 3.00 3.79 2.90 3.09 2.70 1.45
0.29 0.57 #NULL! 2.41 5.60 2.56 7.20 1.64 7.10 2.60 7.10 1.86
0.13 0.09 #NULL! 0.74 5.50 0.88 5.30 1.30 5.30 0.95 5.20 0.74
0.25 0.18 #NULL! 1.11 6.70 1.54 6.40 1.12 6.60 1.00 6.40 1.49
0.14 0.23 #NULL! 1.07 4.40 2.39 4.20 1.64 3.80 0.75 5.70 1.55
0.15 0.25 #NULL! 2.15 6.80 2.23 6.40 1.90 5.40 1.99 6.30 1.96
0.22 0.31 #NULL! 0.95 6.50 2.53 5.70 2.13 7.20 1.84 6.20 1.41
0.22 0.42 #NULL! 2.61 6.00 1.41 6.30 1.72 6.60 1.84 6.50 2.13
0.22 0.42 #NULL! 1.45 5.90 2.22 6.50 1.57 6.00 2.13 5.50 2.61
0.25 0.42 #NULL! 2.85 3.90 2.69 3.90 3.02 3.90 3.42 3.60 1.60
0.27 0.45 #NULL! 1.19 4.70 2.07 4.30 1.82 3.80 2.70 4.00 2.63
0.28 0.48 #NULL! 0.63 7.60 2.08 4.90 1.64 4.00 2.03 3.40 1.85
0.29 0.51 #NULL! 2.05 4.50 1.71 4.00 1.98 4.00 1.79 5.50 2.09
0.28 0.52 #NULL! 2.65 4.60 2.01 4.60 3.06 4.50 3.36 4.40 3.50
0.38 0.52 #NULL! 1.71 6.40 1.58 6.40 1.52 6.40 1.59 6.40 2.03
0.28 0.53 #NULL! 0.91 5.00 1.23 5.10 0.87 4.70 1.18 4.40 1.88
0.32 0.55 #NULL! 1.88 4.70 1.90 5.00 2.10 3.40 2.25 5.20 1.53
0.40 0.62 #NULL! 1.59 4.60 1.29 4.90 1.87 3.60 2.69 3.10 2.96
0.58 0.63 #NULL! 1.91 7.90 1.88 7.70 0.85 7.60 2.17 7.60 2.33
0.40 0.69 #NULL! 1.25 6.40 0.77 7.60 0.94 8.00 2.31 7.50 1.57
0.40 0.71 #NULL! 1.58 3.40 1.73 3.30 1.23 3.40 1.63 3.40 1.19
0.39 0.73 #NULL! 2.40 3.90 2.77 4.60 3.22 3.60 2.62 3.60 3.83
0.42 0.78 #NULL! 0.70 5.10 0.68 6.00 0.88 5.40 0.79 4.80 1.05
0.43 0.80 #NULL! 3.25 3.00 1.70 4.70 3.35 3.00 2.34 3.30 3.24
0.40 0.80 #NULL! 1.21 5.30 0.95 5.40 1.84 5.70 1.27 6.40 0.93
0.43 0.80 #NULL! 0.55 6.90 1.99 6.50 1.77 4.90 1.23 6.10 1.84
0.62 0.87 #NULL! 1.64 4.40 1.41 5.90 2.28 5.10 2.06 4.60 1.64
0.46 0.88 #NULL! 1.27 6.50 1.61 4.90 1.19 5.40 2.00 6.50 1.68
0.60 0.91 #NULL! 0.90 4.70 1.47 4.40 1.30 4.30 1.72 4.50 1.54
0.55 0.92 #NULL! 2.03 5.40 1.64 4.00 1.10 4.50 0.72 5.40 1.91
0.48 0.94 #NULL! 2.30 5.30 1.79 5.70 1.67 5.20 2.54 4.90 1.96
0.53 0.94 #NULL! 4.36 4.40 3.29 4.20 2.73 4.60 3.74 4.00 4.29
0.49 0.95 #NULL! 2.59 6.40 2.31 6.60 1.82 5.70 1.99 7.70 1.41
0.54 0.95 #NULL! 1.15 5.30 0.89 5.20 1.13 5.10 1.68 5.50 0.95
0.59 0.99 #NULL! 1.43 6.00 3.57 6.00 2.92 5.60 3.90 5.40 1.65
0.59 1.03 #NULL! 1.88 2.90 2.06 4.30 2.27 3.10 2.79 3.90 1.53
0.61 1.11 #NULL! 1.93 3.50 1.47 3.30 1.66 3.60 1.78 3.30 1.74
0.68 1.12 #NULL! 0.57 6.60 2.02 5.30 0.85 6.50 2.31 6.80 2.05
0.64 1.19 #NULL! 3.02 4.00 2.85 4.20 3.65 4.70 3.83 4.70 2.98
0.64 1.23 #NULL! 1.65 4.10 1.21 3.60 1.47 3.20 1.28 3.60 1.22
0.73 1.25 #NULL! 0.69 6.00 1.23 5.60 1.11 5.10 1.15 6.50 1.60
0.68 1.33 #NULL! 0.78 5.80 1.52 5.20 1.83 4.80 1.55 4.60 2.17
0.73 1.36 #NULL! 2.06 6.80 2.32 7.50 3.33 6.10 1.37 7.00 2.29
0.78 1.40 #NULL! 1.23 6.30 1.50 7.70 2.16 6.50 2.25 6.90 1.39
1.02 1.55 #NULL! 0.64 6.50 0.68 5.40 0.84 6.10 0.82 5.80 1.78
0.94 1.56 #NULL! 0.84 3.60 2.15 3.90 2.12 5.60 2.86 3.50 2.35
0.93 1.73 #NULL! 2.66 4.50 1.68 5.40 1.44 4.00 2.07 3.70 2.47
DEPTHL5 MedianL meanL SDL IORL ARFIMedianFVAR00001 MeanF SDF IQRF Cysts Calculi
5.30 0.92 0.99 0.28 0.49 0.94 #NULL! 0.99 0.23 0.26 0.00 0.00
4.80 1.68 1.65 0.18 0.33 1.95 1.00 1.99 0.43 0.55 0.00 0.00
3.40 2.03 1.95 0.60 1.17 1.92 1.00 1.89 0.49 0.77 0.00 0.00
3.40 1.57 1.64 0.68 1.20 1.65 1.00 1.60 0.54 0.68 0.00 0.00
4.60 2.21 2.16 1.01 1.69 1.47 #NULL! 1.75 0.85 0.99 0.00 0.00
4.30 1.66 1.82 0.65 1.26 2.42 #NULL! 2.21 0.68 0.98 0.00 0.00
4.40 1.51 1.64 0.89 1.73 1.03 #NULL! 1.35 0.78 1.28 0.00 0.00
2.30 3.08 3.17 0.58 0.95 2.55 #NULL! 2.50 0.88 1.14 0.00 0.00
5.40 0.85 0.86 0.35 0.65 1.01 #NULL! 1.03 0.50 0.83 0.00 0.00
5.20 1.94 2.02 0.64 1.13 1.90 #NULL! 1.92 0.59 1.21 0.00 0.00
4.20 1.64 1.87 0.57 1.09 1.73 #NULL! 1.85 0.53 0.93 0.00 0.00
3.90 0.89 1.13 0.54 0.98 1.74 1.00 1.68 0.78 1.14 0.00 0.00
4.70 2.48 2.40 0.50 0.83 2.48 1.00 2.80 0.55 0.65 0.00 0.00
4.80 1.97 1.78 0.41 0.76 2.11 #NULL! 2.19 0.77 1.55 0.00 0.00
7.60 1.51 1.60 0.40 0.73 1.89 #NULL! 1.77 0.67 0.80 0.00 0.00
5.10 3.51 3.32 0.60 0.84 3.53 1.00 3.26 0.63 0.77 0.00 0.00
4.10 1.74 1.95 0.70 1.21 1.65 #NULL! 1.89 0.73 1.08 0.00 0.00
5.40 1.70 1.63 0.36 0.72 1.80 1.00 1.92 0.78 0.91 0.00 0.00
8.00 1.80 1.84 0.21 0.37 1.78 1.00 1.71 0.26 0.34 0.00 0.00
5.60 1.56 1.63 0.21 0.40 1.36 #NULL! 1.43 0.26 0.29 0.00 0.00
5.00 1.51 1.50 0.51 1.00 0.94 #NULL! 1.17 0.50 0.67 0.00 0.00
6.90 1.64 1.48 0.41 0.53 1.06 #NULL! 1.20 0.41 0.80 0.00 0.00
#NULL! 1.21 1.28 0.27 0.52 1.29 #NULL! 1.31 0.19 0.22 0.00 0.00
5.40 1.82 1.76 0.19 0.33 2.01 #NULL! 2.00 0.30 0.46 0.00 0.00
5.30 0.92 0.99 0.28 0.49 0.94 #NULL! 0.99 0.23 0.26 0.00 0.00
6.50 1.28 1.31 0.28 0.54 1.05 #NULL! 1.13 0.32 0.62 0.00 0.00
5.60 1.28 1.31 0.28 0.54 1.05 #NULL! 1.13 0.32 0.62 0.00 0.00
3.20 2.32 2.28 0.52 0.83 2.26 #NULL! 2.14 0.60 0.53 0.00 0.00
6.80 1.72 1.78 0.45 0.56 1.67 #NULL! 1.74 0.37 0.50 0.00 0.00
4.20 2.13 2.00 0.48 0.91 2.01 #NULL! 1.96 0.36 0.49 0.00 0.00
5.00 1.98 1.84 0.54 1.06 1.39 #NULL! 1.58 0.49 0.79 0.00 0.00
4.60 1.35 1.48 0.87 1.30 1.50 #NULL! 1.58 0.61 0.57 0.00 0.00
6.20 1.62 1.60 0.13 0.23 1.65 1.00 1.67 0.22 0.18 0.00 0.00
5.90 1.74 1.66 0.24 0.48 1.88 #NULL! 1.91 0.40 0.83 0.00 0.00
3.00 2.76 2.71 0.16 31.00 2.55 #NULL! 2.50 0.33 0.54 0.00 0.00
4.80 1.53 1.46 0.58 0.95 1.65 #NULL! 1.63 0.48 0.47 0.00 0.00
6.50 2.07 1.76 0.79 1.42 1.39 #NULL! 1.47 0.67 0.98 0.00 0.00
6.60 0.83 1.34 0.46 0.54 0.83 #NULL! 1.03 0.41 0.57 0.00 0.00
4.50 1.14 1.23 0.46 0.82 1.51 #NULL! 1.47 0.49 0.68 0.00 0.00
4.40 1.74 1.41 0.69 1.32 1.97 #NULL! 1.83 0.70 0.46 0.00 0.00
5.60 1.32 1.37 0.37 0.62 1.37 #NULL! 1.47 0.41 0.63 0.00 0.00
5.50 2.20 2.33 0.43 0.82 1.96 1.00 2.02 0.54 0.80 0.00 0.00
5.40 2.06 2.18 0.56 1.06 2.01 #NULL! 2.05 0.52 0.91 0.00 0.00
3.80 1.92 1.94 0.21 0.36 1.97 #NULL! 2.13 0.40 0.48 0.00 0.00
5.90 1.13 1.16 0.31 0.50 1.14 #NULL! 1.27 0.43 0.60 #NULL! 0.00
7.40 0.91 1.45 0.97 1.73 1.36 #NULL! 1.43 0.74 1.21 0.00 0.00
5.80 1.31 1.63 0.62 1.10 1.31 #NULL! 1.57 0.62 0.94 0.00 0.00
3.80 1.98 2.05 0.35 0.61 1.94 #NULL! 1.95 0.58 0.63 0.00 0.00
5.50 1.81 1.81 0.52 0.93 1.70 #NULL! 1.61 0.63 0.96 0.00 0.00
4.50 2.78 2.47 1.42 2.62 1.86 #NULL! 2.03 1.16 1.59 0.00 0.00
5.40 1.95 1.97 0.66 1.04 1.91 #NULL! 2.04 0.67 1.37 0.00 0.00
6.30 1.45 1.40 0.50 0.78 1.49 #NULL! 1.70 0.69 0.67 0.00 0.00
5.00 1.91 1.97 1.43 2.80 1.39 #NULL! 1.70 1.14 1.86 0.00 0.00
6.20 2.28 2.02 1.46 2.76 2.09 1.00 1.80 1.14 1.73 0.00 0.00
4.40 1.97 2.01 0.71 0.75 2.39 #NULL! 2.53 0.93 1.43 0.00 0.00
3.40 3.76 3.39 0.62 1.16 3.68 #NULL! 3.47 0.82 1.27 0.00 0.00
4.70 1.46 1.49 0.45 0.83 1.47 #NULL! 1.60 0.67 1.05 0.00 0.00
2.80 3.03 2.71 0.90 1.61 3.06 #NULL! 3.06 0.93 1.35 0.00 0.00
6.60 2.41 2.21 0.44 0.83 2.02 1.00 2.07 0.38 0.69 0.00 0.00
5.50 0.88 0.92 0.23 0.39 0.74 #NULL! 0.81 0.20 0.30 0.00 0.00
6.50 1.12 1.25 0.25 0.46 1.20 #NULL! 1.25 0.23 0.46 0.00 0.00
5.00 1.55 1.48 0.62 1.11 1.07 #NULL! 1.25 0.49 0.55 0.00 0.00
6.00 1.99 2.05 0.14 0.26 1.91 #NULL! 1.87 0.23 0.36 0.00 0.00
6.20 1.84 1.77 0.62 1.15 1.00 #NULL! 1.02 0.72 1.24 0.00 0.00
5.20 1.84 1.94 0.45 0.80 1.34 #NULL! 1.47 0.60 0.95 0.00 0.00
4.20 2.13 2.00 0.48 0.91 2.01 #NULL! 1.96 0.36 0.49 0.00 0.00
4.50 2.85 2.72 0.68 1.07 2.49 #NULL! 2.50 0.53 0.59 0.00 0.00
3.10 2.07 2.08 0.62 1.16 2.02 #NULL! 2.00 0.46 0.36 0.00 0.00
3.90 1.85 1.65 0.59 0.91 1.02 #NULL! 1.20 0.64 1.22 0.00 0.00
3.70 1.98 1.92 0.17 0.32 1.53 #NULL! 1.42 0.57 1.13 0.00 0.00
4.40 3.06 2.92 0.60 1.10 2.73 #NULL! 2.79 0.45 0.62 0.00 0.00
6.30 1.59 1.69 0.20 0.32 1.78 #NULL! 1.70 0.29 0.34 0.00 0.00
4.50 1.18 1.21 0.40 0.67 1.69 #NULL! 1.57 0.49 0.70 0.00 0.00
3.60 1.90 1.93 0.27 0.46 1.88 #NULL! 1.82 0.30 0.44 0.00 0.00
3.00 1.87 2.08 0.72 1.39 1.87 #NULL! 1.88 0.57 0.74 0.00 0.00
7.30 1.91 1.83 0.58 0.88 1.91 #NULL! 1.83 0.55 0.74 0.00 0.00
6.90 1.25 1.37 0.61 1.08 0.91 #NULL! 1.82 0.68 1.13 0.00 0.00
3.50 1.58 1.47 0.25 0.47 1.61 #NULL! 1.60 0.32 0.50 0.00 0.00
4.40 2.77 2.97 0.57 1.02 2.65 #NULL! 2.72 0.53 0.55 0.00 0.00
5.80 0.79 0.82 0.15 0.28 0.84 #NULL! 0.92 0.32 0.43 0.00 0.00
2.60 3.24 2.78 0.73 1.28 2.22 1.00 2.31 0.76 1.54 0.00 0.00
5.60 1.21 1.24 0.37 0.62 1.25 #NULL! 1.42 0.41 0.63 0.00 0.00
6.20 1.77 1.48 0.59 1.03 1.47 #NULL! 1.39 0.50 0.71 0.00 0.00
4.30 1.65 1.81 0.35 0.64 1.53 #NULL! 1.60 0.52 1.00 0.00 0.00
6.00 1.61 1.55 0.33 0.61 1.65 #NULL! 1.65 0.39 0.73 0.00 0.00
4.40 1.47 1.39 0.31 0.53 1.30 #NULL! 1.39 0.47 0.76 0.00 0.00
3.80 1.64 1.49 0.56 1.08 1.86 #NULL! 1.76 0.60 0.70 0.00 0.00
5.20 1.96 2.05 0.36 0.69 2.17 #NULL! 2.24 0.45 0.66 0.00 0.00
3.90 3.74 3.68 0.69 1.32 2.91 #NULL! 3.08 0.86 1.14 0.00 0.00
5.90 1.99 2.02 0.45 0.83 1.73 #NULL! 1.62 0.62 0.92 0.00 0.00
5.90 1.13 1.16 0.31 0.50 1.14 #NULL! 1.27 0.43 0.60 0.00 0.00
5.20 3.15 2.81 1.03 1.92 1.87 #NULL! 2.35 0.98 1.89 0.00 0.00
3.20 2.06 2.11 0.47 0.82 2.06 #NULL! 2.08 0.50 0.47 0.00 0.00
3.30 1.74 1.72 0.17 0.29 2.00 #NULL! 2.20 0.66 0.84 0.00 0.00
5.40 2.02 1.56 0.79 1.47 1.24 #NULL! 1.43 0.71 1.25 0.00 0.00
4.30 3.34 3.51 0.72 0.85 3.65 #NULL! 3.55 0.65 1.04 0.00 0.00
4.70 1.28 1.37 0.19 0.35 1.36 #NULL! 1.44 0.45 0.44 0.00 0.00
5.00 1.15 1.16 0.32 0.52 1.50 #NULL! 1.84 0.90 1.63 0.00 0.00
4.60 1.55 1.57 0.51 0.85 1.65 #NULL! 1.69 0.58 0.94 0.00 0.00
6.80 2.29 2.27 0.70 1.11 2.17 #NULL! 1.96 0.75 1.01 0.00 0.00
6.50 1.50 1.71 0.47 0.90 2.08 #NULL! 2.03 0.70 0.90 0.00 0.00
5.10 0.82 0.95 0.47 0.65 1.11 #NULL! 1.40 0.89 0.93 0.00 0.00
4.60 2.15 2.06 0.75 1.13 2.34 #NULL! 2.25 0.82 0.74 0.00 0.00
5.50 2.07 2.06 0.51 1.01 1.88 #NULL! 1.81 0.76 1.41 0.00 0.00
noofattempt bxdate prebxsbp prebxdbp bloodproduct nopieces postSBP PostDBP majorcomplication PGS Cvascular
10.00 04-Oct-2013 118.00 80.00 0.00 3.00 120.00 80.00 0.00 0.00 2
10.00 ########## 120.00 80.00 0.00 2.00 120.00 80.00 0.00 0.00 2
10.00 21-Jan-2014 110.00 80.00 0.00 3.00 110.00 80.00 0.00 0.00 1
10.00 ########## 130.00 80.00 0.00 2.00 130.00 80.00 0.00 0.00 1
10.00 ########## 130.00 80.00 0.00 2.00 140.00 90.00 0.00 0.00 1
10.00 21-Oct-2013 125.00 72.00 0.00 2.00 130.00 80.00 0.00 0.00 2
10.00 ########## 130.00 80.00 0.00 2.00 130.00 80.00 0.00 #NULL! 2
10.00 06-Jan-2014 130.00 90.00 0.00 3.00 130.00 90.00 0.00 0.00 2
11.00 ########## 130.00 80.00 0.00 2.00 130.00 80.00 0.00 0.00 1
11.00 ########## 140.00 90.00 0.00 2.00 140.00 90.00 0.00 0.00 2
10.00 ########## 150.00 80.00 0.00 2.00 140.00 90.00 0.00 14.20 2
10.00 03-Oct-2013 100.00 80.00 0.00 2.00 100.00 80.00 0.00 9.00 0
10.00 ########## 130.00 80.00 0.00 2.00 130.00 80.00 0.00 0.00 2
10.00 ########## 130.00 90.00 0.00 2.00 135.00 90.00 0.00 9.00 2
10.00 ########## 140.00 88.00 0.00 3.00 140.00 88.00 0.00 0.00 0
10.00 14-Jan-2014 110.00 80.00 0.00 3.00 110.00 80.00 0.00 0.00 1
10.00 23-Oct-2013 110.00 80.00 0.00 3.00 110.00 80.00 0.00 16.00 1
10.00 ########## 110.00 80.00 0.00 2.00 110.00 80.00 0.00 0.00 2
10.00 ########## 130.00 80.00 0.00 2.00 140.00 90.00 0.00 0.00 1
10.00 ########## 130.00 80.00 0.00 2.00 130.00 80.00 0.00 3.80 0
10.00 14-Oct-2013 120.00 80.00 0.00 3.00 130.00 80.00 0.00 33.00 2
10.00 14-Jan-2014 140.00 80.00 0.00 2.00 140.00 90.00 0.00 48.00 1
6.00 ########## 130.00 80.00 0.00 2.00 150.00 90.00 0.00 0.00 2
10.00 ########## 130.00 80.00 0.00 2.00 140.00 90.00 0.00 66.60 2
10.00 ########## 120.00 80.00 0.00 3.00 120.00 80.00 0.00 8.30 2
11.00 ########## 120.00 80.00 0.00 2.00 130.00 80.00 0.00 6.25 2
10.00 ########## 130.00 90.00 0.00 2.00 130.00 90.00 0.00 30.00 2
10.00 17-Oct-2013 120.00 80.00 0.00 3.00 120.00 80.00 0.00 0.00 0
11.00 ########## 130.00 80.00 0.00 3.00 130.00 80.00 0.00 0.00 2
10.00 28-Oct-2013 130.00 80.00 0.00 3.00 140.00 90.00 0.00 11.00 2
10.00 ########## 130.00 80.00 0.00 3.00 140.00 90.00 0.00 69.20 2
10.00 ########## 102.00 72.00 0.00 2.00 102.00 72.00 0.00 0.00 2
10.00 ########## 130.00 80.00 0.00 2.00 140.00 80.00 0.00 0.00 1
10.00 ########## 130.00 90.00 0.00 3.00 130.00 90.00 0.00 66.60 2
10.00 ########## 130.00 80.00 0.00 2.00 130.00 90.00 0.00 0.00 2
10.00 ########## 140.00 90.00 0.00 2.00 140.00 90.00 0.00 25.00 2
10.00 23-Oct-2013 130.00 90.00 0.00 3.00 130.00 90.00 0.00 11.00 1
10.00 ########## 130.00 80.00 0.00 3.00 140.00 80.00 0.00 0.00 1
10.00 ########## 140.00 90.00 0.00 2.00 130.00 80.00 0.00 100.00 2
10.00 10-Oct-2013 110.00 80.00 0.00 2.00 110.00 80.00 0.00 0.00 1
10.00 14-Oct-2013 130.00 80.00 0.00 3.00 140.00 90.00 0.00 50.00 2
10.00 ########## 130.00 80.00 0.00 2.00 130.00 80.00 0.00 0.00 0
10.00 ########## 140.00 90.00 0.00 2.00 140.00 90.00 0.00 50.00 2
10.00 ########## 140.00 90.00 0.00 2.00 140.00 90.00 0.00 24.13 2
10.00 ########## 130.00 90.00 0.00 2.00 130.00 80.00 0.00 11.00 0
10.00 02-Oct-2013 110.00 80.00 0.00 2.00 120.00 80.00 0.00 12.50 2
11.00 ########## 135.00 89.00 0.00 2.00 140.00 90.00 0.00 0.00 2
10.00 ########## 130.00 80.00 0.00 3.00 130.00 80.00 0.00 9.00 2
10.00 ########## 150.00 90.00 0.00 2.00 140.00 90.00 0.00 37.50 2
10.00 ########## 150.00 99.00 0.00 2.00 150.00 90.00 0.00 0.00 1
10.00 16-Jan-2014 130.00 90.00 0.00 2.00 130.00 90.00 0.00 30.70 1
10.00 ########## 130.00 80.00 0.00 2.00 130.00 80.00 0.00 0.00 0
10.00 ########## 133.00 95.00 0.00 3.00 130.00 90.00 0.00 8.30 2
10.00 ########## 130.00 80.00 0.00 2.00 130.00 80.00 0.00 50.00 2
11.00 ########## 130.00 80.00 0.00 2.00 120.00 80.00 0.00 0.00 0
10.00 10-Jan-2014 112.00 80.00 0.00 2.00 112.00 80.00 0.00 0.00 0
10.00 ########## 130.00 80.00 0.00 2.00 140.00 80.00 0.00 0.00 2
10.00 10-Feb-2013 125.00 80.00 0.00 2.00 130.00 80.00 0.00 12.50 2
10.00 ########## 130.00 80.00 0.00 2.00 140.00 90.00 0.00 0.00 0
10.00 ########## 118.00 81.00 0.00 3.00 130.00 85.00 0.00 0.00 1
10.00 02-Oct-2013 140.00 85.00 0.00 2.00 150.00 90.00 0.00 77.70 2
10.00 14-Jan-2014 140.00 90.00 0.00 2.00 140.00 90.00 0.00 85.71 2
10.00 ########## 130.00 80.00 0.00 2.00 140.00 80.00 0.00 25.00 2
10.00 ########## 140.00 80.00 0.00 2.00 140.00 80.00 0.00 0.00 2
10.00 ########## 130.00 80.00 1.00 2.00 130.00 90.00 0.00 50.00 2
10.00 21-Oct-2013 100.00 70.00 0.00 2.00 110.00 80.00 0.00 0.00 2
10.00 ########## 140.00 90.00 0.00 2.00 140.00 90.00 0.00 66.66 2
10.00 ########## 130.00 80.00 0.00 2.00 150.00 90.00 0.00 10.00 2
10.00 09-Oct-2013 160.00 90.00 0.00 2.00 140.00 90.00 0.00 60.00 2
10.00 21-Oct-2013 112.00 80.00 0.00 2.00 10.00 80.00 0.00 44.40 2
10.00 ########## 130.00 80.00 0.00 3.00 140.00 80.00 0.00 64.20 2
10.00 ########## 130.00 80.00 0.00 2.00 130.00 80.00 0.00 33.30 2
10.00 ########## 140.00 90.00 0.00 3.00 140.00 90.00 0.00 60.00 2
10.00 ########## 140.00 90.00 0.00 2.00 140.00 90.00 0.00 63.60 2
11.00 ########## 150.00 90.00 0.00 2.00 150.00 90.00 0.00 25.00 2
11.00 ########## 140.00 90.00 0.00 2.00 130.00 90.00 0.00 0.00 2
10.00 ########## 140.00 90.00 0.00 3.00 140.00 90.00 0.00 60.00 1
10.00 24-Oct-2013 130.00 90.00 0.00 3.00 130.00 90.00 0.00 33.30 1
10.00 15-Jan-2014 140.00 90.00 0.00 2.00 140.00 90.00 0.00 93.30 2
10.00 ########## 150.00 90.00 0.00 2.00 150.00 90.00 0.00 100.00 2
10.00 14-Jan-2014 110.00 80.00 0.00 3.00 110.00 80.00 0.00 0.00 1
10.00 10-Oct-2013 140.00 90.00 0.00 2.00 140.00 90.00 0.00 84.60 2
10.00 ########## 140.00 80.00 0.00 2.00 150.00 90.00 0.00 50.00 2
10.00 10-Oct-2013 140.00 90.00 0.00 2.00 140.00 90.00 0.00 21.40 2
10.00 01-Oct-2013 140.00 80.00 0.00 2.00 140.00 90.00 0.00 20.00 2
11.00 ########## 130.00 90.00 0.00 2.00 135.00 90.00 0.00 90.00 2
10.00 21-Oct-2013 105.00 65.00 0.00 3.00 110.00 80.00 0.00 0.00 2
10.00 ########## 130.00 80.00 0.00 2.00 140.00 80.00 0.00 20.00 1
10.00 ########## 140.00 80.00 0.00 2.00 150.00 90.00 0.00 82.60 2
10.00 ########## 130.00 80.00 0.00 2.00 150.00 93.00 0.00 0.00 2
10.00 22-Jan-2014 140.00 90.00 0.00 3.00 140.00 90.00 0.00 30.00 2
11.00 ########## 140.00 90.00 0.00 2.00 150.00 90.00 0.00 #NULL! 2
10.00 ########## 140.00 90.00 0.00 2.00 140.00 90.00 0.00 #NULL! 2
10.00 03-Jan-2014 140.00 90.00 0.00 3.00 140.00 90.00 0.00 33.33 2
10.00 ########## 140.00 80.00 0.00 3.00 140.00 90.00 0.00 37.50 2
11.00 ########## 130.00 80.00 0.00 3.00 135.00 80.00 0.00 14.20 2
10.00 14-Jan-2014 140.00 90.00 0.00 3.00 140.00 90.00 0.00 81.80 2
10.00 ########## 140.00 90.00 0.00 2.00 140.00 90.00 0.00 68.75 2
10.00 15-Jan-2014 100.00 70.00 0.00 2.00 110.00 80.00 2.00 42.80 1
10.00 ########## 140.00 80.00 0.00 2.00 140.00 90.00 0.00 75.00 2
10.00 02-Oct-2013 138.00 102.00 0.00 2.00 130.00 80.00 0.00 0.00 2
10.00 ########## 130.00 80.00 0.00 3.00 140.00 80.00 0.00 62.50 2
10.00 16-Jan-2014 144.00 100.00 0.00 2.00 144.00 90.00 0.00 36.30 2
10.00 02-Oct-2013 125.00 84.00 0.00 2.00 130.00 90.00 0.00 8.30 2
Ctubular Cinterstitial CIF CIFIGG CIFIGA CIFIGM CIFC3 CIFC4 CIFCIQ CIFI CIFLC
0 0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0 0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0 0 1.00 0.00 2.00 0.00 0.00 0.00 0.00 0.00 0.00
0 0 1.00 2.00 1.00 2.00 3.00 1.00 2.00 1.00 0.00
0 0 1.00 3.00 0.00 1.00 2.00 2.00 2.00 0.00 0.00
0 0 1.00 0.00 2.00 0.00 1.00 0.00 0.00 0.00 0.00
0 0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0 0 1.00 3.00 0.00 0.00 2.00 0.00 0.00 0.00 0.00
0 0 1.00 3.00 0.00 0.00 2.00 0.00 0.00 0.00 0.00
0 0 0.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00
0 0 1.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00
0 0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0 0 1.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00
0 0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0 0 1.00 3.00 0.00 1.00 2.00 0.00 0.00 0.00 0.00
0 0 1.00 2.00 0.00 0.00 2.00 0.00 2.00 0.00 0.00
0 0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0 0 1.00 3.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
1 1 1.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00
0 0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0 0 1.00 0.00 3.00 0.00 2.00 0.00 0.00 0.00 0.00
1 1 1.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00
1 1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
2 2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0 0 1.00 3.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00
0 0 1.00 3.00 0.00 0.00 2.00 0.00 0.00 0.00 0.00
0 0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
2 2 1.00 0.00 0.00 0.00 2.00 0.00 0.00 0.00 0.00
1 1 1.00 3.00 2.00 2.00 1.00 0.00 1.00 0.00 0.00
2 2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
1 1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0 0 1.00 3.00 0.00 0.00 2.00 0.00 0.00 0.00 0.00
1 0 1.00 3.00 3.00 0.00 3.00 3.00 0.00 0.00 0.00
1 1 1.00 0.00 0.00 1.00 1.00 0.00 0.00 0.00 0.00
1 1 1.00 3.00 2.00 1.00 3.00 0.00 0.00 0.00 0.00
1 1 1.00 0.00 3.00 0.00 2.00 0.00 0.00 0.00 0.00
1 1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
1 1 1.00 0.00 2.00 0.00 2.00 0.00 0.00 0.00 0.00
1 1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
1 1 1.00 3.00 0.00 0.00 2.00 0.00 0.00 0.00 0.00
2 2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0 0 1.00 2.00 3.00 2.00 3.00 3.00 2.00 0.00 0.00
1 1 1.00 0.00 2.00 0.00 2.00 0.00 0.00 0.00 0.00
1 1 1.00 2.00 2.00 2.00 2.00 2.00 2.00 0.00 0.00
0 0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0 0 1.00 0.00 2.00 0.00 0.00 0.00 0.00 0.00 0.00
0 0 1.00 0.00 0.00 1.00 1.00 0.00 0.00 0.00 0.00
0 0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.00
1 1 1.00 0.00 3.00 0.00 0.00 0.00 0.00 0.00 0.00
0 0 1.00 3.00 2.00 1.00 3.00 2.00 2.00 0.00 0.00
1 1 1.00 0.00 3.00 0.00 2.00 0.00 0.00 0.00 0.00
1 1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0 0 2.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
1 1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
1 1 1.00 3.00 2.00 1.00 1.00 1.00 2.00 0.00 0.00
0 0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
2 2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
1 1 1.00 3.00 0.00 0.00 2.00 0.00 0.00 0.00 0.00
0 0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
2 2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
2 2 1.00 0.00 2.00 0.00 0.00 0.00 0.00 0.00 0.00
2 2 1.00 0.00 2.00 0.00 2.00 0.00 0.00 0.00 0.00
2 2 1.00 3.00 0.00 2.00 3.00 2.00 0.00 0.00 0.00
2 2 1.00 0.00 3.00 0.00 3.00 0.00 0.00 0.00 0.00
0 1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
2 2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
2 2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
1 1 1.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00 0.00
2 2 1.00 0.00 3.00 0.00 2.00 0.00 0.00 0.00 0.00
2 2 1.00 3.00 0.00 2.00 2.00 1.00 1.00 0.00 0.00
1 2 1.00 0.00 2.00 1.00 1.00 0.00 0.00 0.00 0.00
2 2 1.00 2.00 0.00 0.00 2.00 0.00 0.00 0.00 0.00
2 2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
2 2 1.00 0.00 0.00 1.00 1.00 0.00 0.00 0.00 0.00
0 0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0 0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
2 2 1.00 0.00 0.00 1.00 1.00 0.00 0.00 0.00 0.00
2 2 1.00 2.00 3.00 0.00 2.00 0.00 0.00 0.00 0.00
2 2 0.00 0.00 0.00 1.00 1.00 0.00 0.00 0.00 0.00
0 0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
1 1 0.00 2.00 2.00 1.00 2.00 2.00 2.00 2.00 0.00
2 2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
1 1 1.00 0.00 0.00 1.00 1.00 0.00 0.00 0.00 0.00
1 1 1.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00
2 2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
2 2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
2 2 1.00 3.00 0.00 0.00 2.00 0.00 0.00 0.00 0.00
1 1 1.00 0.00 0.00 2.00 2.00 0.00 0.00 0.00 0.00
2 2 1.00 0.00 0.00 1.00 1.00 0.00 0.00 0.00 0.00
1 1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
2 2 1.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00
0 0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
2 2 1.00 0.00 2.00 1.00 1.00 0.00 0.00 0.00 0.00
2 2 1.00 0.00 3.00 0.00 2.00 0.00 0.00 0.00 0.00
2 2 1.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00
2 2 1.00 0.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00
2 2 1.00 0.00 0.00 1.00 1.00 0.00 0.00 0.00 0.00
2 2 1.00 0.00 0.00 1.00 0.00 0.00 0.00 0.00 0.00
2 2 1.00 0.00 3.00 0.00 2.00 0.00 0.00 0.00 0.00
2 2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
2 2 1.00 0.00 0.00 0.00 2.00 0.00 0.00 0.00 0.00
2 2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
2 1 1.00 0.00 3.00 0.00 2.00 0.00 0.00 0.00 0.00
2 2 1.00 0.00 3.00 2.00 2.00 0.00 1.00 0.00 0.00
tubularatrophy TA TASCO IFSCO fibroscoring CEM biopsyreport
0.00 0.00 0.00 20.00 0.00 0.00 Membrnaous nephropathy
0.00 0.00 0.00 15.00 0.00 0.00 Mesangio proliferative GN
0.00 0.00 0.00 15.00 0.00 0.00 Diffuse proliferative IgA  with FSGS
0.00 0.00 0.00 5.00 0.00 0.00 CLASS IV LN
0.00 0.00 0.00 15.00 0.00 0.00 PROLIFERATIVE GN WITH HYALINE THROMBI
0.00 0.00 0.00 10.00 0.00 0.00 diffuse proliferative  ig A gn with focal mesangial sclerosis
0.00 0.00 0.00 15.00 0.00 0.00 Arteriolonephrosclerosis with focal ischemic glomerular atrophy
0.00 0.00 0.00 20.00 0.00 0.00 Membrnous nephropathy
0.00 0.00 0.00 5.00 0.00 0.00 MEMBRANOUS NEPHROPATHY
0.00 0.00 0.00 5.00 0.00 0.00 ARTERIOLONEPHROSCLEROSIS
0.00 0.00 0.00 10.00 0.00 0.00 ARTERIOLONEPHROSCLEROSIS
0.00 0.00 0.00 15.00 0.00 0.00 MESANGIOPROLIFEARTIVE GLOMERULONEPHRITIS
0.00 0.00 0.00 15.00 0.00 0.00 MESPGN
0.00 0.00 0.00 15.00 0.00 0.00 dIFFUSE PREDOMINANATLY MES PGN
0.00 0.00 0.00 15.00 0.00 0.00 DPGN
0.00 0.00 0.00 5.00 0.00 0.00 Membranous Nephropathy
0.00 0.00 0.00 5.00 0.00 0.00 Mesangioproliferative GN
0.00 0.00 0.00 10.00 0.00 0.00 MEMBRANOUS NEPHROPATHY
0.00 0.00 0.00 20.00 0.00 0.00 FOCAL AND SEGMENTAL PROLIFERATIVE GLOMERULONEPHRITIS WITH SEG SCLEROSIS
0.00 0.00 0.00 35.00 1.00 0.00 MESANGIAL PROLIFERATIVE GN
0.00 0.00 0.00 25.00 1.00 0.00 Mesangial Ig A nephropathy with FSGS
0.00 0.00 0.00 25.00 1.00 0.00 focal segmental glomerulosclerosis
1.00 1.00 1.00 45.00 1.00 0.00 FOCAL SEG PROLI GN WITH INCIPIENT NECROSIS VASCULITIS
1.00 1.00 1.00 45.00 1.00 0.00 ARETIONEPHROSCLEROSI WITH CIN
0.00 1.00 1.00 35.00 1.00 0.00 Membranous nephropathy
0.00 0.00 0.00 35.00 1.00 0.00 dIFFUSE INTERCAPILLARY GS WITH CONCOMITANT MN
1.00 1.00 1.00 30.00 1.00 0.00 Chronic interstitial nephritis
1.00 1.00 1.00 40.00 1.00 0.00 DIFFUSE PROLIFERATIVE GLOMERULONEPHRITIS
1.00 1.00 1.00 50.00 1.00 0.00 CLASS V LN
0.00 0.00 0.00 25.00 1.00 1.00 Arterionephr osclerosis with ischemic atrophy with cin
1.00 1.00 1.00 40.00 1.00 0.00 CIN WITH DIFFUSE GLOBAL GLOMERULOSCLEROSIS
1.00 1.00 1.00 30.00 1.00 0.00 CLASS II LN
1.00 1.00 1.00 35.00 1.00 0.00 DPGN
1.00 1.00 1.00 30.00 1.00 0.00 Arteriolonephrosclerosis with fsgs
1.00 1.00 1.00 45.00 1.00 0.00 dpgn WITH CAP THICKENING CLASS IV LN
1.00 1.00 1.00 40.00 1.00 0.00 PROLIFERATIVVE IGA WITH FSGS
0.00 0.00 0.00 25.00 1.00 0.00 Diffuse intercapillary diabetic glomerulosclerosis
1.00 1.00 1.00 40.00 1.00 0.00 MESANGIAL IGA NEPHROPATHY WITH FSGS
1.00 1.00 1.00 35.00 1.00 0.00 ARTERIONEPHROSCLEROSIS
1.00 1.00 1.00 35.00 1.00 0.00 MEMBRANOUS NEPHROPATHY
1.00 1.00 1.00 45.00 1.00 0.00 CHRONIC INTERSTITIAL NEPHRITIS WITH CONCOMITANT ARTERIONEPHROSCLEROSIS
0.00 0.00 0.00 25.00 1.00 0.00 LN IV
1.00 1.00 1.00 45.00 1.00 0.00 mesangio proliferative igA
1.00 1.00 1.00 30.00 1.00 0.00 MPGN class IV LUPUS NEPHRITIS
0.00 1.00 1.00 25.00 1.00 0.00 SLE class IV LN
1.00 1.00 1.00 30.00 1.00 0.00 Mesangial Ig A with arterionephrosclerosis
1.00 1.00 1.00 45.00 1.00 0.00 mES PGN WITH FSGS
1.00 1.00 1.00 35.00 1.00 0.00 Primary amyloidosis
1.00 1.00 1.00 35.00 1.00 0.00 MESANGIOPROLIFERATIVE IGA GN
1.00 1.00 1.00 50.00 1.00 0.00 Diffuse proliferative glomerulonephritis with focal capillary thickening
1.00 1.00 1.00 50.00 1.00 0.00 Diffuse proliferative IgA GN with seg sclerosis
1.00 1.00 1.00 35.00 1.00 0.00 MILD MESANGIAL HYPERCELLULARITY
1.00 1.00 1.00 40.00 1.00 0.00 MEMBRANOUS NEPHROPATHY WITH FOCI OF SEG SCLORISIS AND HYALINOSIS
1.00 1.00 2.00 45.00 1.00 0.00 dIFFUSE INTERCAPILLARY AND NODUALR GLOMERULOSCLEOSIS
1.00 1.00 1.00 40.00 1.00 0.00 MEMBRANOSU WITH FSGS
1.00 1.00 1.00 30.00 1.00 0.00 diffuse predominantly mesangial proliferative GN
1.00 1.00 1.00 35.00 1.00 0.00 ARTERIONEPHROSCLEROSIS WITH GLOMERULAR ATROPHY AND FSGS
1.00 1.00 1.00 40.00 1.00 0.00 Menbranous Nephropathy
0.00 0.00 0.00 25.00 1.00 0.00 FOCAL SEGMENTAL PROLIFERATIVE GN WITH INCIPIENT TUFT NECROSIS
2.00 1.00 2.00 65.00 2.00 0.00 Mesangioproliferative proliferative glomerulonephritis with focal segmental sclerosis
2.00 1.00 2.00 75.00 2.00 0.00 chronic sclerosing Ig A glomerulonephritis
2.00 1.00 3.00 80.00 2.00 0.00 chronic sclerosing IgA GN with ATN
2.00 1.00 2.00 65.00 2.00 0.00 PROLIFERATIVE GN WITH DIF
2.00 1.00 2.00 65.00 2.00 0.00 dpgnIGA WITH FOCAL INCIPINET NECROSIS
2.00 1.00 2.00 55.00 2.00 0.00 Hypertensive arteriolosclerosis with chronic interstitial nephritis
2.00 1.00 2.00 80.00 2.00 0.00 Acute on chronic tubulointerstitial nephritis with tubular necrosis
2.00 1.00 3.00 80.00 2.00 0.00 Diffuse intercapillary glomerulosclerosis with CIN
2.00 1.00 2.00 72.00 2.00 0.00 ARTERIONEPHROSCLEROSIS WITH FSGS WITH MESAN PROLIFERATION
2.00 1.00 2.00 60.00 2.00 0.00 Mesangial proliferative ig A Gn with segmental sclerosis
2.00 1.00 2.00 65.00 2.00 0.00 MEMBRANOUS NEPHROPATHY
2.00 1.00 2.00 65.00 2.00 1.00 DPAND SCLEROSING GN
2.00 1.00 2.00 75.00 2.00 0.00 DPGN FOCI OF MESANGIAL SCLEROSIS
2.00 1.00 2.00 65.00 2.00 0.00 ARTERIONEPHROSCLEROSIS WITH TUBULOINTERSTITIAL SCARRING
2.00 1.00 2.00 75.00 2.00 0.00 Diffuse intercapillary and focal nodular diabetic glomerulosclerosis
2.00 1.00 2.00 65.00 2.00 0.00 Arterionephrosclerosis with focal glomerular atrophy.
2.00 1.00 2.00 65.00 2.00 0.00 aRTERIONEPHROSCLEROSIS
2.00 1.00 3.00 80.00 2.00 0.00 Diffuse intercapillary and focal nodular glomerulosclerosis
2.00 1.00 2.00 60.00 2.00 0.00 Mes proliferative Ig A GN with FSGS
2.00 1.00 2.00 75.00 2.00 0.00 Diabetic Nephropathy with CIN
2.00 1.00 2.00 65.00 2.00 0.00 ARTERIONEPHROSCLEROSIS
2.00 1.00 2.00 55.00 2.00 0.00 class iv lupus nephritis
2.00 1.00 2.00 55.00 2.00 0.00 ARTERIOLONEPHROSCLEROSIS WITH FOCAL AND SEGMENTAL GLOMERULOSCLEROSIS
2.00 1.00 2.00 55.00 2.00 0.00 FSGS WITH ARTERIONEPHROSCLEROSIS
2.00 1.00 2.00 75.00 2.00 0.00 ARTERIONEPHROSCLEROSIS WITH FSGS AND GLOMERULAR ATROPHY
2.00 1.00 2.00 65.00 2.00 0.00 chronic interstitial nephritis
2.00 1.00 2.00 55.00 2.00 0.00 ARTERIONEPHROSCLEROSIS WITH SEC FSGS
2.00 1.00 2.00 60.00 2.00 0.00 DIFFUSE INTERCAPILLARY GLOMERULOSCLEROSIS WITH MN
2.00 1.00 2.00 65.00 2.00 0.00 PROLIFERATIVE GN  AND SEGMENTAL GLOMERULOSCLEROSIS
2.00 1.00 3.00 90.00 2.00 0.00 DIFFUSE GLOBAL SCLEROSIS
2.00 1.00 2.00 65.00 2.00 0.00 ARTERIONEPHROSCLEROSIS WITH CIN
2.00 1.00 3.00 80.00 2.00 0.00 roliferarive sclerosisng GN with a FSGS with ATN
1.00 1.00 1.00 65.00 2.00 0.00 Arterionephrosclerosis with focal tubular necrosis.
2.00 1.00 2.00 60.00 2.00 0.00 Proliferative Ig A Gn with segments sclerpsis and tubular necrosis
2.00 1.00 2.00 75.00 2.00 0.00 proliferative  and sclerosing Ig A
2.00 1.00 2.00 75.00 2.00 0.00 ARETIONEPHROSCLEROSIS WITH TUBULAR NECROSIS
2.00 1.00 2.00 75.00 2.00 1.00 MESANGIOPROLIFERATIVE GN WITH ACUTE TUBULAR NECROSIS
2.00 1.00 2.00 70.00 2.00 0.00 arterionephrosclerosis
2.00 1.00 2.00 75.00 2.00 0.00 FSGS with ATN
2.00 1.00 2.00 60.00 2.00 0.00 Proliferative and sclerosing Ig A glomeruloneprhitis
2.00 1.00 3.00 85.00 2.00 0.00 nODULAR DIABETIC GLOMERULOSCLEROSIS
2.00 1.00 2.00 60.00 2.00 0.00 DIFFUSE PROLIFRERATIVE GLOMERULONEPHRITIS
2.00 1.00 2.00 72.00 2.00 0.00 dIFFUSE IN FIBROSIS WITH TUBULAR ATROPHY WITH FOCAL MESANGIOLYSIS
2.00 1.00 2.00 70.00 2.00 0.00 proliferative gN with seg sclerosis with cellular to fibroscellular crescents
2.00 1.00 2.00 70.00 2.00 0.00 diffuse proliferative IgA
CGlomer finaldiagnosis agegroup Stage2 FS symphtn depth2
0/4 uniform thickening of capillary walls with pronminMN 46-55 1.00 0.00 0 1
0/9 mesnagial  exp and mes proliferation PGN 26-35 1.00 0.00 0 1
0/16 fsgs with mes matrix exp with endo cap prol IGA 15-25 1.00 0.00 0 1
0/16 ENDOCAPILLARY PROLIFERATION LN 15-25 1.00 1.00 1 1
0/12 PROLIFERATIVE GN WITH HYALINE THROMBILN 26-35 1.00 1.00 0 1
0/14 mild mes expa with mes cellularity with endocap prIGA 15-25 1.00 1.00 0 1
secondary FSGS Hypertensive Nephrosclerosis 56-65 1.00 0.00 1 0
0/16 mild mesangial thick and prolif  thickening of capMN 56-65 2.00 0.00 0 1
0/11 UNIFORM CAPILLARY THICKENING MN 15-25 1.00 1.00 1 0
0/10 MESAN EXPAN HYPERCELLULARITY Hypertensive Nephrosclerosis 26-35 2.00 1.00 1 0
1/7 INTERCAPILLARY MES EXPAN Hypertensive Nephrosclerosis 46-55 2.00 1.00 1 1
2/21 VAR INCREASE IN MES CELLULARITY PGN 15-25 1.00 0.00 0 1
0/7 MESANGIAL PROLIFERATION with variable increase in mesangial cellularityPGN 15-25 1.00 1.00 1 1
1/11 MILD MESANG CELLULARITY  ENDOCAPILLARY PROMINENCEPGN 56-65 2.00 1.00 0 1
0/6 ENDOCAPILLARY PROLIFERATION CAPILLARY WALL THICKENPGN 56-65 1.00 1.00 1 0
0/9mesangial matrix exp and cellularity MN 15-25 1.00 0.00 0 1
1/6 globally sclerosed PGN 36-45 1.00 1.00 0 0
0/14 MILD MES EXPAN WITH CAPILLLARY WAll THICKENINGMN 46-55 1.00 1.00 0 1
0/5 enlarged tufts with matrix expansion PGN 15-25 1.00 1.00 0 0
1/26 MESANGIAL EXPANSION WITH HYPERCELLULARITYPGN 15-25 1.00 1.00 0 1
1/3 globally sclerosed mes expan with fsgs IGA 36-45 2.00 0.00 1 1
2/5 global sclerosis with mesangial hypercellulari FSGS 46-55 2.00 0.00 1 1
0/11 MES EXPAN AND CELLULARITY INCIPIENT NECROSISVAS ULITI 26-35 1.00 1.00 1 1
2/3 SCLEROSED REST DIFF INTERCAP EXPANSIONC N 26-35 2.00 1.00 1 1
1/12 globally sclerosed with uniform thick of cap MN 36-45 1.00 0.00 0 1
1/16 SLCEROSED INTERCAP MATRIX EX WITH MEMBRANOUSMN 56-65 1.00 1.00 1 0
3/10 glom tuft atrophy with mesangial matrix expansion with var incr in cellularityCIN 15-25 1.00 1.00 1 1
0/11 ENDOCAPILLARY PROLIFERATION WITH VAR MES CELLUALARPGN 15-25 2.00 1.00 1 1
0/12 CAPILLARY WALL THICKENING LN 46-55 1.00 1.00 0 0
1/9sclerosed3 show ischemic atrophy intercapmesexHypertensive Nephrosclerosis 56-65 2.00 1.00 1 1
9/13 SCLEROSED WITH MESANGIAL EXPANSIONCIN 46-55 2.00 1.00 0 1
0/12 DIF MES PROLIFERATION LN 36-45 1.00 1.00 0 0
0/5 MESANGIAL MATRIX EXPANSION PGN 15-25 1.00 1.00 0 1
2/3 globally sclerosed mes exp amd mes cell FSGS 46-55 1.00 1.00 1 1
0/22 ENLARGED ENDOCAP PROLI with mesangial expansionLN 15-25 2.00 1.00 1 1
1/4 INCREASE MESANGIAL CELLULARITY WITH FSGSIGA 26-35 2.00 1.00 1 1
1/9 glon\bally sclerosed with remaining mes expansDN 36-45 1.00 1.00 1 1
0/8 MESANGIAL HYPERCELLULARITY WITH FSGSI A 46-55 1.00 1.00 1 0
3/3 GLOBALLY SCLEROSED GLOMERULI Hypertensive Nephrosclerosis 26-35 2.00 1.00 1 1
0/19 VARIABLE INCREASE IN MES CELLULARITY UNIFORM THICKMN 36-45 1.00 1.00 0 1
5/10 GLOBALLY SCLEROSED REST INTERCAP MES EXPASIONCIN 46-55 2.00 1.00 1 1
0/6DIF ENDOCAPILLARY WITH CAP WALL THICKENINGLN 15-25 1.00 0.00 0 0
1/2 glomeruli sclerosed 1 mesan exp with incre celIGA 36-45 2.00 1.00 1 1
7/29 sclerosed accentuation of lobulation LN 56-65 1.00 1.00 1 1
1/9 globally sclerosed diffuse proliferation LN 15-25 1.00 0.00 1 0
1/8 mesangial expansion with prominence of endocapillaIGA 36-45 2.00 1.00 1 0
0/5 MES EXPAN INCRE CELLULARITY fsgs PGN 36-45 1.00 1.00 1 1
1/11 globally sclerosed with rest showing amorphous congophilic materialPrimary amyloidosis 66-75 2.00 1.00 1 1
3/8 MES PROLIFERATIVE GN SEGMENTAL SCLEROSISIGA 26-35 2.00 1.00 1 1
0/12 endocapillary cell proliferation with neutrophiliPGN 26-35 2.00 1.00 0 0
4/13 globally sclerosed mes and eno proliferation IGA 36-45 2.00 1.00 1 1
0/10 MILD MESANGIAL EX WITH VARIA HYPERCELLULARITYPGN 15-25 1.00 1.00 1 1
1/12 UNIFORM CAPILLARY WALL THICKENINGMN 46-55 1.00 1.00 1 0
1/2 SCLEROSED REST INTERCAPILLARY DIFFUSE EXAPNSIDN 46-55 1.00 1.00 0 0
0/13MILD MESANG HYPERCELLULARITY WITH THICKENING OF CAMN 36-45 1.00 1.00 0 1
0/11 mes expansion and mes hypercellularity with prominence of endocapillary cellPGN 26-35 2.00 1.00 1 1
0/8 INTERCAPILLARY MATRIX EXPANSION Hypertensive Nephrosclerosis 36-45 2.00 1.00 1 1
1/8 uniform capillary wall thickening with narrowingMN 56-65 2.00 1.00 1 1
0/15 FOCAL SEGMENTAL PROLIFERATIVE GN PGN 15-25 1.00 1.00 0 0
0/5 matrix mesangial expansion with mesangial hypercelPGN 36-45 2.00 1.00 1 1
7/9 global glomerulosclerosis with cap synechia IGA 15-25 2.00 1.00 1 1
6/7 sclerosed endocapillary prominance with scleroIGA 26-35 2.00 1.00 1 1
2/8 SCLEROSED MES EXAP AND PROMINANCE OF ENDOCAPILPGN 15-25 2.00 1.00 1 0
0/16CIICUMFERENTIAL CELLULAR CRESCENTSIGA 15-25 2.00 1.00 1 1
3/6 glomerulosclerosiss Hypertensive Nephrosclerosis 36-45 2.00 1.00 1 0
0/8 mild mes expan prominence of endocapillary CIN 36-45 2.00 1.00 0 1
4/6 globally sclerosed with intercapillary scleros DN 56-65 2.00 1.00 1 1
1/10 SCLEROSED ENDO CAP PROLI AMD MESA EXPANSIONPGN 56-65 2.00 1.00 1 1
6/10 globally sclerosed remain mesangial sclerosis with cap synechiaeIGA 36-45 2.00 1.00 1 0
4/9 GLOBALLY SCLEROSED PROM ENDOCAPIL CAP THICMN 46-55 1.00 1.00 0 1
9/14 are sclerosed mes expansion and endocap prolPGN 26-35 2.00 1.00 1 1
2/6 SCLEROSED MESAN EXP AND ENDO CAPIL PROLIFERATIN 36-45 2.00 1.00 1 0
6/10 INTERCAPILLARY MATRIX EXPANSION Hypertensive Nephrosclerosis 26-35 2.00 1.00 1 0
7/11globally sclerosed dif mes exp endocapillary cDN 36-45 2.00 1.00 1 1
3/12 globally sclerosed MES EXPAN INCRE CELLULARITYAND ENDOPRO AND ATROPHYHypertensive Nephrosclerosis 36-45 2.00 1.00 1 1
0/4 INTERCAPILLARY MESANGIAL EXPANSIONHypertensive Nephrosclerosis 36-45 2.00 1.00 0 0
3/5 globally sclerosed with nodular expansion inte DN 56-65 2.00 1.00 1 1
1/3 sclerosedmes expan and proliferation IGA 15-25 2.00 1.00 1 1
14/15 globally sclerosed with intercapillary scler DN 46-55 2.00 1.00 1 1
1/1 GLOBAL SCELROSED Hypertensive Nephrosclerosis 46-55 2.00 1.00 1 0
0/10 glomeruli with tuft accentuation and dif prol LN 15-25 1.00 1.00 0 1
11/13 GLOBAL SCLEROSED REST FSGS Hypertensive Nephrosclerosis 56-65 2.00 1.00 1 1
3/6 ARE SCLEROSED WITH REST SHOWING FSGSFSGS 46-55 2.00 1.00 1 0
3/14 FOAL AND SEGMENTAL SCLEROSIS WITH MESANGIAL EXPANSHypertensive Nephrosclerosis 36-45 2.00 1.00 1 1
1/5 intercapillary mesangial expansion CIN 36-45 2.00 1.00 1 0
9/10 DIFFUSE GLOBAL SCLEROSIS Hypertensive Nephrosclerosis 36-45 2.00 1.00 1 1
0/13 DIFFUSE MESAN EXPAN CAPILLARY WALL THICKENINGDN 56-65 2.00 1.00 1 1
1/5 SCLEROSED WITH REST ENDOCAP PROLIFERATIONPGN 36-45 2.00 1.00 0 1
19/23 GLOBALLLY SCLEROSED WITH REST SHOWING FSGSCGN 46-55 2.00 1.00 1 1
0/5 DIFFUSE INTERCAPILLARY MATRIX EXPANSIONHypertensive Nephrosclerosis 46-55 2.00 1.00 1 0
3/10 scle endo capi prolmesexp amd mes cellul endoFSGS 56-65 2.00 1.00 1 0
MES EXPAN WITH MILD INCREASE IN CELLULARITYHypertensive Nephrosclerosis 46-55 2.00 1.00 1 1
mesangio proliferative IGA 36-45 2.00 1.00 1 1
2/6 sclerosed endo cap proliferation mes exp& celIGA 15-25 2.00 1.00 1 1
3/8 SCLEROSSED WITH REST FSGS Hypertensive Nephrosclerosis 26-35 2.00 1.00 1 0
1/7 VARIABLE INCREASE IM MES CELLULARITYprominence of endocapillary cellsPGN 15-25 2.00 1.00 1 1
9/11 globally sclerosed remain mes exp and Hypertensive Nephrosclerosis 56-65 2.00 1.00 1 1
11/16sclerosed prom endocapillary cells with seg sFSGS 15-25 2.00 1.00 1 1
3/7 globally sclerosed remaining showing mes exp and endocapillar proliferIGA 46-55 2.00 1.00 1 1
6/8 GLOBALLY SCLEROSEDREST DIFFUSE INTERCAPILLARYDN 46-55 2.00 1.00 1 0
0/8 INCREASED MESangial  AND ENDOCAPILLARY CELLULARITYPGN 36-45 2.00 1.00 1 1
5/8 GLOBAL SCLEROSED WITH INCRE CELLULARITY OF REMAINICGN 26-35 2.00 1.00 1 1
4/11sclerosed mes expansion with proliferation VASCULITIS 26-35 2.00 1.00 1 1
1/12 endocapillary prolif and mesangial matrix expansioIGA 36-45 2.00 1.00 1 1
depth1 depth3 depth4 depth5 dll1 dll2 dll3 dll4 dll5 FDL FDR stage3
1 1 1 1 1 1 1 1 1 1 1 1.00
1 1 1 1 1 1 1 1 1 1 1 1.00
1 1 1 1 1 1 1 1 1 1 1 1.00
1 1 1 1 1 1 1 1 1 1 1 1.00
1 1 1 1 1 1 1 1 1 1 1 1.00
1 1 1 1 1 1 1 1 1 1 1 1.00
0 0 0 1 1 1 1 1 1 1 0 1.00
1 1 1 1 1 1 1 1 1 1 1 1.00
0 0 0 0 1 1 1 1 1 1 0 1.00
0 0 0 1 1 1 1 0 1 0 0 1.00
1 0 1 0 1 1 1 1 1 1 0 1.00
1 1 1 1 1 1 1 1 1 1 1 1.00
1 1 1 1 1 1 1 1 1 1 1 1.00
1 1 1 1 1 1 1 1 1 1 1 1.00
0 0 0 0 0 0 0 0 0 0 0 1.00
1 1 1 1 1 1 1 0 1 0 1 1.00
1 1 1 1 1 1 1 0 1 0 0 1.00
1 1 1 1 1 1 1 1 1 1 1 1.00
0 0 0 0 0 0 0 0 0 0 0 1.00
1 1 1 1 1 1 1 1 1 1 1 1.00
0 0 0 1 0 1 1 1 1 0 0 1.00
1 1 1 1 0 0 0 0 0 0 1 1.00
1 1 #NULL! #NULL! 1 1 1 #NULL! #NULL! #NULL! #NULL! 1.00
1 1 1 1 1 1 1 1 1 1 1 2.00
1 1 1 1 1 1 1 1 1 1 1 1.00
0 0 0 0 0 0 0 0 0 0 0 1.00
1 1 1 1 1 1 1 1 1 1 1 1.00
1 1 1 1 1 1 1 1 1 1 1 1.00
0 0 0 0 0 0 0 0 0 0 0 1.00
1 1 0 0 1 0 1 1 1 0 0 1.00
1 1 1 1 1 1 1 1 1 1 1 1.00
1 1 1 1 1 1 1 1 1 1 0 1.00
1 1 1 0 1 1 1 0 0 0 0 1.00
1 1 1 1 0 0 0 1 1 0 1 1.00
1 1 1 1 1 1 1 1 1 1 1 1.00
1 1 1 1 1 1 1 0 1 0 1 2.00
0 0 0 0 1 1 1 1 0 0 0 1.00
0 0 0 0 1 1 0 0 0 0 0 1.00
1 1 1 1 1 1 1 1 1 1 1 2.00
1 1 1 1 1 1 1 1 1 1 1 1.00
1 1 1 1 1 1 1 0 1 0 1 2.00
0 0 0 0 1 1 1 1 1 1 0 1.00
0 0 0 0 1 1 1 1 1 1 0 1.00
1 1 1 1 1 1 1 1 1 1 1 1.00
1 1 1 0 1 1 1 1 1 1 0 1.00
1 0 1 1 0 0 0 0 0 0 0 1.00
0 0 0 0 0 1 1 1 1 0 0 1.00
1 1 1 1 1 1 1 1 1 1 1 1.00
1 0 1 1 1 1 0 1 1 0 0 1.00
0 0 0 1 1 0 0 0 1 0 0 2.00
1 0 0 0 1 1 0 1 1 0 0 1.00
1 1 1 1 1 1 1 1 0 0 1 1.00
1 1 0 1 0 0 1 0 1 0 0 1.00
0 1 0 0 1 0 1 0 0 0 0 1.00
1 1 1 1 1 1 1 1 1 1 1 1.00
1 1 1 1 1 1 1 1 1 1 1 2.00
1 1 1 1 1 1 1 1 1 1 1 1.00
1 1 1 1 1 1 1 1 1 1 1 1.00
0 0 0 0 1 0 0 0 0 0 0 1.00
1 1 1 1 1 1 1 1 1 1 1 1.00
1 0 0 1 0 0 0 0 0 0 0 2.00
1 1 1 1 1 1 1 1 1 1 1 2.00
0 1 0 1 0 0 1 0 1 0 0 1.00
1 0 1 1 0 1 0 0 0 0 0 2.00
0 0 0 0 1 0 0 0 1 0 0 1.00
1 1 0 0 1 0 1 1 1 0 0 1.00
1 1 1 1 1 1 1 1 1 1 1 2.00
1 1 1 1 1 1 1 1 1 1 1 1.00
0 0 0 1 0 1 1 1 1 0 0 1.00
1 1 1 1 1 1 1 1 1 1 1 1.00
1 1 1 1 1 1 1 1 1 1 1 1.00
0 0 0 0 0 0 0 0 0 0 0 1.00
0 0 0 0 1 1 1 1 1 1 0 2.00
1 0 1 1 1 1 1 1 1 1 0 2.00
1 1 1 1 1 1 1 1 1 1 1 1.00
1 0 0 0 0 0 0 0 0 0 0 2.00
1 1 1 1 0 0 0 0 0 0 1 2.00
1 1 1 1 1 1 1 1 1 1 1 1.00
1 1 1 1 1 1 1 1 1 1 1 2.00
1 1 0 1 1 1 1 1 1 1 0 2.00
1 1 1 1 1 1 1 1 1 1 1 1.00
1 1 1 1 1 1 1 0 1 0 1 1.00
0 0 0 0 0 0 1 0 0 0 0 2.00
1 1 1 1 1 1 1 1 1 1 1 2.00
0 0 1 0 0 1 1 0 1 0 0 2.00
1 1 1 1 1 1 1 1 1 1 1 2.00
1 1 1 1 1 1 1 1 1 1 1 1.00
1 1 1 1 1 1 1 1 1 1 1 1.00
0 0 1 1 1 1 1 1 1 1 0 2.00
1 0 0 0 0 0 1 0 1 0 0 2.00
1 1 1 0 1 1 1 1 1 1 0 2.00
1 0 1 1 1 1 1 1 1 1 0 1.00
1 1 1 1 1 1 1 1 1 1 1 2.00
1 1 1 1 1 1 1 1 1 1 1 2.00
1 1 1 1 0 1 0 0 1 0 0 1.00
1 1 1 1 1 1 1 1 1 1 1 2.00
1 1 1 1 1 1 1 1 1 1 1 1.00
0 1 1 1 1 1 1 0 1 0 0 2.00
0 1 1 0 1 1 1 1 1 1 0 2.00
0 0 1 0 0 0 0 0 0 0 0 2.00
1 1 1 1 0 0 0 0 0 0 1 1.00
1 1 1 1 0 1 0 1 1 0 1 1.00
1 1 1 1 1 1 1 1 1 1 1 2.00
1 0 0 1 1 1 1 1 1 1 0 2.00
newFS newfibrosissco echo2 echo1
0.00 0.00 0.00 0.00
0.00 0.00 1.00 1.00
0.00 0.00 1.00 1.00
0.00 0.00 0.00 0.00
0.00 0.00 0.00 1.00
0.00 0.00 0.00 1.00
0.00 0.00 1.00 1.00
0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00
0.00 0.00 0.00 1.00
0.00 0.00 0.00 1.00
0.00 0.00 0.00 0.00
0.00 0.00 0.00 1.00
0.00 0.00 0.00 1.00
0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00
0.00 0.00 1.00 1.00
0.00 0.00 0.00 0.00
0.00 0.00 0.00 0.00
0.00 1.00 0.00 1.00
0.00 1.00 0.00 0.00
0.00 1.00 1.00 1.00
0.00 1.00 0.00 0.00
0.00 1.00 1.00 1.00
0.00 1.00 0.00 0.00
0.00 1.00 0.00 0.00
0.00 1.00 0.00 0.00
0.00 1.00 0.00 1.00
0.00 1.00 0.00 1.00
0.00 1.00 0.00 1.00
0.00 1.00 0.00 1.00
0.00 1.00 0.00 1.00
0.00 1.00 0.00 0.00
0.00 1.00 1.00 1.00
0.00 1.00 1.00 1.00
0.00 1.00 0.00 1.00
0.00 1.00 1.00 1.00
0.00 1.00 1.00 1.00
0.00 1.00 1.00 1.00
0.00 1.00 0.00 0.00
0.00 1.00 1.00 1.00
0.00 1.00 0.00 1.00
0.00 1.00 1.00 1.00
0.00 1.00 0.00 1.00
0.00 1.00 0.00 1.00
0.00 1.00 1.00 1.00
0.00 1.00 0.00 1.00
0.00 1.00 1.00 1.00
0.00 1.00 0.00 1.00
0.00 1.00 0.00 0.00
0.00 1.00 0.00 0.00
0.00 1.00 0.00 0.00
0.00 1.00 0.00 1.00
0.00 1.00 0.00 1.00
0.00 1.00 0.00 0.00
0.00 1.00 1.00 1.00
0.00 1.00 0.00 1.00
0.00 1.00 0.00 0.00
1.00 1.00 1.00 1.00
1.00 2.00 0.00 1.00
1.00 2.00 1.00 1.00
1.00 2.00 1.00 1.00
1.00 2.00 1.00 1.00
1.00 2.00 0.00 1.00
1.00 2.00 0.00 1.00
1.00 2.00 0.00 1.00
1.00 2.00 1.00 1.00
1.00 2.00 1.00 1.00
1.00 2.00 0.00 1.00
1.00 2.00 0.00 0.00
1.00 2.00 1.00 1.00
1.00 2.00 0.00 1.00
1.00 2.00 0.00 0.00
1.00 2.00 1.00 1.00
1.00 2.00 1.00 1.00
1.00 2.00 0.00 1.00
1.00 2.00 1.00 1.00
1.00 2.00 0.00 1.00
1.00 2.00 1.00 1.00
1.00 2.00 1.00 1.00
1.00 2.00 0.00 0.00
1.00 2.00 1.00 1.00
1.00 2.00 0.00 1.00
1.00 2.00 0.00 1.00
1.00 2.00 1.00 1.00
1.00 2.00 0.00 1.00
1.00 2.00 0.00 0.00
1.00 2.00 0.00 0.00
1.00 2.00 1.00 1.00
1.00 2.00 1.00 1.00
1.00 2.00 1.00 1.00
1.00 2.00 0.00 0.00
1.00 2.00 1.00 1.00
1.00 2.00 1.00 1.00
1.00 2.00 1.00 1.00
1.00 2.00 0.00 1.00
1.00 2.00 1.00 1.00
1.00 2.00 1.00 1.00
1.00 2.00 1.00 1.00
1.00 2.00 0.00 1.00
1.00 2.00 0.00 1.00
1.00 2.00 0.00 1.00
1.00 2.00 1.00 1.00
1.00 2.00 0.00 1.00
Proforma 
 
Serial number: 
Hospital No:    
 
                                                                                                               
 
 
 
 
 
 
 
 
7.Presenting Complaints: 
 
 
 
 
 
 
 
Comorbidities:    
 
TYPE YES NO Duration (If Yes) 
DM    
HTN    
CAD    
Malignancy    
Prior Kidney 
disease 
   
 
Pre-biopsy Diagnosis: 
 
Glomerulonephritis  Non Diabetic   Diabetic  
Interstitial Nephritis  
Others  
 
 
 
 
 
 
 
   
1 Name  
2 Age  
3 Sex M F 
4 Height  
5 Weight  
6 BMI  
7 eGFR(MDRD)  Stage: 
 yes NO Duration(If 
YES) 
1.Edema    
2.Hypertension    
3.Renal dysfunction    
4.Hematuria    
    
Brief  History 
 
 
 
 
H/o Smoking /Drug abuse 
(NSAIDS) 
 
Family H/o Renal 
disease/DM/HTN/Others 
 
No. of  Antihypertensives 
 
Antiplatelet drugs : yes/No 
 
 
Non Diabetic Glomerulonephritis: 
 
Prebiopsy Lab Parameters 
 
Past H/o use of immunosuppression (pred/CNIs/Endoxan/MMF) 
Drug YES NO Duration ofimmunosuppresion 
Prednisolone    
CNIs    
Endoxan    
MMF    
Levamisole    
 
 
Hemoglobin  
Platelet count  
PT with INR  
APTT  
Bleeding time  
HIV  
HBsAg  
HCV  
Urine analysis  
WBC    
RBC   
CASTS    
CRYSTALS  
Protein  
Blood  
24 Hr Urine Protien  
UP/UC  
Urea  
Creatinine  
Albumin  
Total protein  
Lipid profile TC TG HDL LDL 
C3  
C4  
ANA  
Ds DNA  
ASO  
ADNB  
ANCA CANCA P ANCA 
Serum Electrophoresis  
κ:λ  
Details of previous biopsy 
 
 
Histo-pathological Diagnosis: 
 
Pre biopsy  
Ultrasound Right Kidney Left Kidney 
Size   
Echogencity   
Parenchymal thickness   
ARFI scan   
Cysts   
Calculi   
 
Lower pole values values of ARFI: 
Right Kidney Left Kidney 
  
  
  
  
  
 
Number of attempts : 
 
Biopsy date: 
 
Prebiopsy BP: 
 
Prebiopsy medication (DDVAP) 
 
Blood product infused (FFP/Platelets) 
 
Radiologist : 
 
Biopsy Done by: 
 
Place of biopsy: 
 
No. of Attempts: 
 
Underguidance: yes  no 
 
Glomerular compartment  
Interstitial compartment  
Tubular compartment  
Vascular compartment  
Immunofluroscence  
Electron Micrscopy  
No. of  pieces obtained: 
 
Post Biopsy screening(Immediate): yes/No 
 
Post Biopsy : BP                Immediate                  At 6 Hours.                
  
 
Hb base line 
 
18-24 hours : 
 
24 hr USG Screening : Yes/No  
 
If Yes : Findings 
 
Any major complication 
Gross Hematuria  
Blood transfusion  
Catheterisation and irrigation  
Intervention  
  
 
 
Biopsy report: 
 
 
 
Fibrosis Scoring 
<25%  
25-50  
>50%  
 
 
 
Review biopsy report (in nephrology Department)- 
 
 
Final diagnosis made 
 
 
 
Glomerular compartment  
Interstitial compartment  
Tubular compartment  
Vascular compartment  
Immunofluroscence  
Electron Micrscopy  
 
       INFORMED CONSENT FORM  
     
Study: Correlation of fibrosis in renal biopsy with ARFI 
estimated pre biopsy shear wave velocity 
PATIENTS’S  NAME:  
    
I confirm that I have read the information sheet or information sheet was read to me 
and understood the information sheet dated …………….   for the above study 
document and had its contents explained to me and understand the purpose of this 
study and what my participation in it will involve.  
 
I do freely give my consent to participate in this study, as described to me in this 
document. 
 
I am aware that I may, at any stage, withdraw participation from the study without 
prejudice, giving any reason without my medical care and legal rights being affected. 
 
I understand the primary investigator; others working on the primary investigator’s 
behalf, the Ethics committee and the regulatory authorities will not need my 
permission to look at my health records both in respect of the current study and any 
further research that may be conducted in relation to it, even if I withdraw from the 
trial. I agree to this access. I understand that my identity will not be revealed in any 
information released to third parties or published. 
 
I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose. 
 
I agree to take part in the above study. 
 
________________   _________________  _______________ 
(Patient)   Signature/Thumb Impression   Date 
 
 
______________   _________________  _______________ 
Impartial Witness   Signature   Date 
(If patient is illiterate or gives oral and not signed consent) 
 
 
_________________   __________________ _______________ 
Investigator    Signature   Date 
 
 
 
 
 
 
 
 
 
 
 
स ूचत सहम त 
 
अ ययन: ARFI बायो सी पूव  कतरनी (shear wave)लहर वेग का अनुमान के 
साथ गुद  क  बायो सी म  फाइ ो सस के सहसंबंध  
 
रो गय  का नाम:   
 
ऊपर अ ययन सूचना प क को पढ़ या सुन कर और उस म  मेर  भागीदार   क समझ   क पु    
ऊपर अ ययन का उ े य को  और उस म  शा मल होगी मेर  द तावेज़ और इसक  साम ी मुझ े
समझाया गया था. 
 
म   वतं   प से इस द तावेज़ म  मुझ ेबताए अनुसार, इस अ ययन म  भाग लेन ेके  लए अपनी 
सहम त देत ेह . 
 
मुझ,े  कसी भी  तर पर, मेरे  च क सा, देखभाल के ऊपर   तकूल  भाव डाले  बना,  बना कोई 
कारण बताए और कानूनी अ धकार  भा वत  कया  बना अ ययन स े भागीदार  वापस ल े
सकने  क जानकार  है. 
 
म  समझ थ हँू  क म  पर  ण से भागीदार  वापस लेने पर भी,  ाथ मक अ वेषक,  ाथ मक 
अ वेषक क  ओर से काम कर रहे अ य लोग, आचार स म त और  नयामक अ धका रय  
,वत मान अ ययन के संबंध म  और  कसी भी आग ेके संबंध आयोिजत अनुसंधान के  े  म  
अपने  वा  य  रकॉड  को देखन ेके  लए मेर  अनुम त क  ज रत नह ं होगी. म  इस का उपयोग 
करने के  लए सहमत ह . म  समझ थ हँू  क अपनी पहचान तीसरे प  को जार  या  का शत 
 कसी भी जानकार  म  नह ं  य   क जाएगा. 
 
म  इस तरह के एक  योग को उपल ध कराई गई इस अ ययन से उ प न होने वाले  कसी भी 
डटेा या प रणाम को केवल वै ा नक उ े य के  लए ह ं इ तेमाल करन ेके  लए  कसी   तबंध 
डाले  बना सहम त देते ह .  
म  उपरो  अ ययन म  भाग लेन ेके  लए सहमत ह . 
________________________________________________ 
(रोगी) ह ता र/अगंूठा छाप  तार ख 
______________________________________________ 
 न प  गवाह ह ता र तार ख 
(रोगी अनपढ़ है या तो मौ खक सहम त देता है और ह ता र नह ं  कये) 
__________________________________________________ 
अ वेषक  ह ता र    तार ख 
  
 
సమ త పత మ  
 
అధ యనం: బయ  ీ  మ ందు ultrasound ARFI    త       గం(shear wave velocity) 
అంచ      మ త  ిండ బయ  ీ  ల    ౖబ    ి   క  పరస ర సంబంధం  
 
  ర : 
 
  ౖన అధ యన సంబం  త సమ   రం పత మ    ను చ    ల       మ  య  అర ం 
 ేసుక న     ా    సు  న ను . అధ యనం  క  ఉప గం మ  య  అందుల     
  గ ా మ ం ఎంత క    ఉంట ం     ను  అర ం  ేసుక న ను. 
 
  ను స తంత ం ా ఈ పత ంల    క   వ  ం నట   , ఈ అధ యనంల   ాల     ందుక     
సమ తమ  వ క పరసు  న ను. 
 
  ను, ఏ ై    ారణంగ, ఏ దశల   ౖ  ,      ౖద  సంర ణ  మ  య  చట పర   న హక  లను 
ప    తమ  ాక ండ అధ యనం నుం    ఉపసంహ  ంచు  గలను. 
 
  ా ధ క ప    ధక    మ  య    ా ధ క ప    ధక     తరఫ న ప  ేసు  న  వ క   ల , ఎ     
క ట  మ  య   యంత ణ అ   ార ల  చూడట     సంబం  ం  మ  య  సంబం  త తదుప   
అధ యనంల     ఆ  గ     ార   లను చూడట       ను అధ యనం నుం   ఉపసంహ  ంచుకన  
క   ,    అనుమ  అవసరం ల ద    ను అం  క  సు     ను.    గ    ంప ను మ డవ 
ప ంనక    డ దల ల    ప చు  ంచబ  న ఏ సమ   రoల  బ  ర తం  ెయ బడదు అ  అర ం 
 ేనుక న ను. 
 
ఈ అధ యనం నుం   ఉత న మ    సమ    ా   ల    ఫ   ల ఉప గం  ా ీ   య 
ప  జనం   సం మ త    ప   త   న  , అల ంట  ఉప గమ    ను వ      ంచను. 
 
 ________________________________________________ 
(    ) సంతకం/బ  టన     క  మ ద       ే   
 
______________________________________________ 
  ా   క  ా   సంతకం     ే   
(      ర  ాసు ల  ా ఉంట  ల    మ  క అనుమ ) 
 
__________________________________________________ 
ప    ధక     సంతకం     ే   
 
 
 
                                                      INFORMATION SHEET 
 
 
Study: Correlation of ARFI estimated pre biopsy shear wave velocity 
measured in Native kidneys with fibrosis in renal biopsy  
The Departments of Nephrology, Pathology and Radiology is conducting a study to find a 
correlation of pre biopsy ARFI shear wave velocity in native kidneys with a fibrosis in renal 
biopsy  
  
Renal biopsy is done as part of evaluation of many renal diseases for diagnosis and assessing 
the progression, prognosticating of the disease and outcome of the therapeutic 
intervention. One of the reasons to do a renal biopsy is to know the extent of Tubulo-
interstitial fibrosis which is the final common pathway for all renal disease. This estimate 
will help to prognosticate and modulate the therapeutic intervention. 
 
 We are doing this study to find out whether a pre biopsy non invasive test which is ARFI 
scan will be able to predict significant fibrosis in the kidneys by looking at the prebiopsy 
shear wave velocity and finding the correlation with renal biopsy specimen fibrosis scoring.  
 
The subjects will be individuals in which the treating nephrologist has advised for a renal 
biopsy.If they give consent for the biopsy they will be enrolled in the study. We plan to 
document patients relevant history will include height, weight and follow up renal function 
tests as available with us from existing hospital records. Patient need to undergo a 
prebiopsy ARFI ultrasound scan which is non invasive and painless. No additional charges 
will be attributed in addition to the regular treatment requirement.  
 
Think about it. Discuss it with your family and friends. If you have any doubts or questions 
you can ask any of us (Dr. Sudhakar). You can call nephrology office (228-2053) and mention 
about this study and they will direct you to one of us. 
 
If you decide to participate please meet Dr. Sudhakar.  He will give you the consent form. 
Read it and if you agree, sign it. He will take care of your participation after that. 
 
In future, if you decide not to be involved in this study, inform us. We will remove your 
name from the study. 
 
 
 
 
 
 
 
 
సమ   రం పత ం 
 
మ త  ిండ, ా  ల  మ  య      య ల      ాల   ా   క మ త  ిం  ల ల  ARFI   త     
  గం    మ త  ిండ మ క (biopsy) ప    ల    ౖబ    ి  (Fibrosis) పరస ర సంబంధం 
కను    ందుక  ఒక అధ యనం  ర   సు     మ . 
  
మ త  ిండ మ క (biopsy) ప    అ  క మ త  ిండ  ా ధుల   ా  రణ   సం ప    ధనల    గం ా 
ప     మ  య   ా     వ త మ  య  ప   గ  ఫ తం అంచ     యట     ఉప గపడ 
పడ త ం  . మ క (biopsy) ప    వలన ఒక ఉప గకరం ా  షయం ఏ టంట  మ త  ిండ 
ల    ౖబ    ి  (Fibrosis) ఏ   రక  ఉం ొ   ెల సు  వటం . ఈ అంచ      త క  స యం  ేసు  ం  . 
. 
మ త  ిం  ల ల  ARFI   త       గం    మ త  ిండ మ క (biopsy) ప    ల    ౖబ    ి  
(Fibrosis) పరస ర సంబంధం క   ట డం     ా మ త  ిం  ల  గణ య   న   ౖబ    ి  అంచ   
  య ట   ఇ   ఒక   కరo  ా  ప    అ   ెల సు  వ      ఈ అధ యనం  ేసు     ర . 
 
మ త   ిండ జబ   ఉన  ా       ౖదు డ  మ క (biopsy) ప    సూ ం న త ా త  ార  
సమ       అధ యనం  ేర    వ      ఉంట ం  .   మ    గ ల సంబం  త చ  త  న దు , 
బర వ  ఎత    మ  య  ఇప ట    ఉన  ఆసుప      ార   ల మ  య  మ    అందుబ ట ల  
మ త  ిం  ల ప  ర  ప   ల  అనుస   ా  మ  .          కరo  ా  ఇ   ఒక ARFI 
అల       ం   ా    ే ంచు  వల ి ఉంట ం  .  ా  రణ    త  అవస ాల   అదనం ా అదనప  
     ల  ఆ ా  ంచబడప . 
 
    గ   ం  ఆల  ంచం   .   క ట ంబం మ  య       త ల   చ   ం చం  .  ర  ఏ 
సం ే ల  ల    ప శ ల  ఉంట  మమ    (   క   సు  క  ) అడగవచు  .  ర  మ త  ిండ 
 ా ా లయం (228-2053) సంప   ంచవచు . 
 
 ర   ాల     ందుక   ర  ంచుక ంట    క   సు  క  క       క  సమ త  పత ం ఇ ా  ర . అ   
చ     ర  అం  క  సు   ఉంట , అ   సంతకo  ేయం  .  
 
 ర  ఈ అధ యనంల  ప   యం ల ద  భ ష త   ల   ర  ంచుక ంట ,  ె య ేసు      . 
  మ  అధ యనం నుం       ర    ల  సు  ం   . 
 
 
 
 
 
 सचूना शीट 
अ ययन: गुद  म  ARFI कतरनी लहर वेग मापा अनमुान के साथ गदु  क  बायो सी म  
फाइ ो सस के सहसंबंध  
 
ने ोलोजी , पैथोलॉजी और रे डयोलॉजी  वभाग के एक बायो सी पूव  ARFI कतरनी लहर वेग के साथ 
गुद  क  बायो सी म  फाइ ो सस का एक संबंध खोजने के  लए एक अ ययन होर है 
  
रोग क  गंभीरता और  ग त के प रणाम क  जांच और मू यांकन के पूरा होने के  ह स े के  प म  
 व भ न गुदा  रोग  के  नदान के  लए पर  ण करने के  लए गुद  टुकड़ा ( बायो सी ) परोसा जाएगा . 
पर  ण का टुकड़ा ( बायो सी ) एक  ात सीमा है जो गुद  फाइ ो सस ( फाइ ो सस ) म  एक उपयोगी 
चीज है . यह आकलन के इलाज म  मदद  मलेगी. 
 
 हम ARFI  कैन कतरनी लहर वेग को देख और बायो सी नमूना म  फाइ ो सस के साथ संबंध खोजन े
के  ारा गुद  म  मह वपूण  फाइ ो सस क  भ व यवाणी करने म  स म हो जाएगा. 
 
अ ययन म  नामांकन के बाद, हम  ासं गक इ तहास रो गय  ऊंचाई , वजन और गुद   पर  ण मौजूदा 
अ पताल के  रकॉड  से ह  उपल ध हमारे साथ अनुवत  शा मल ह गे द तावेज़ क  योजना है. रोगी और 
कोई जो खम के साथ जुड़ा नह ं है. prebiopsy  लए अ  ासाउंड  कैन कराने क  ज रत है .  नय मत 
उपचार अलावा कोई अ त र  शु क आव यकता न ह होगा . 
 
इसके बारे म  सोचो . अपने प रवार और दो त  के साथ चचा  कर . आप  कसी भी संदेह या    ह , तो आप 
हम  (डॉ. सुधाकर ) से पूछ सकते ह . आप ने ोलॉजी काया लय (228-2053) कॉल और इस अ ययन के 
बारे म  उ लेख है और वे तुम हम म  से एक के  लए  नद  शत कर गे . 
 
आप भाग लेने के  लए त र् है तो डा. सुधाकर  सहम त प  पर दे द गे . इसे पढ़   और अगर आप सहमत 
ह  , इस पर ह ता र . म  उसके बाद अपनी भागीदार  का  याल रखना होगा . 
 
आप इस अ ययन म  शा मल  कया जाना तय नह ं है अगर भ व य म  , हम  सू चत कर . हम अ ययन 
से अपना नाम हटा देगा . 
 
 
 
 

